
<html lang="en"     class="pb-page"  data-request-id="7168b98e-e6b2-4c8b-afc4-20ae0de05ab5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-8;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b02129;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads" /></meta><meta name="dc.Creator" content="Gemma E.  Mudd" /></meta><meta name="dc.Creator" content="Amy  Brown" /></meta><meta name="dc.Creator" content="Liuhong  Chen" /></meta><meta name="dc.Creator" content="Katerine  van Rietschoten" /></meta><meta name="dc.Creator" content="Sophie  Watcham" /></meta><meta name="dc.Creator" content="Daniel P.  Teufel" /></meta><meta name="dc.Creator" content="Silvia  Pavan" /></meta><meta name="dc.Creator" content="Rachid  Lani" /></meta><meta name="dc.Creator" content="Philip  Huxley" /></meta><meta name="dc.Creator" content="Gavin S.  Bennett" /></meta><meta name="dc.Description" content="Bicycles are constrained bicyclic peptides that represent a promising binding modality for use in targeted drug conjugates. A phage display screen against EphA2, a receptor tyrosine kinase highly e..." /></meta><meta name="Description" content="Bicycles are constrained bicyclic peptides that represent a promising binding modality for use in targeted drug conjugates. A phage display screen against EphA2, a receptor tyrosine kinase highly e..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 23, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02129" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02129" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02129" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02129" /></link>
        
    
    

<title>Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02129" /></meta><meta property="og:title" content="Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0008.jpeg" /></meta><meta property="og:description" content="Bicycles are constrained bicyclic peptides that represent a promising binding modality for use in targeted drug conjugates. A phage display screen against EphA2, a receptor tyrosine kinase highly expressed in a number of solid tumors, identified a number of Bicycle families with low nanomolar affinity. A Bicycle toxin conjugate (BTC) was generated by derivatization of one of these Bicycles with the potent cytotoxin DM1 via a cleavable linker. This BTC demonstrated potent antitumor activity in vivo but was poorly tolerated, which was hypothesized to be the result of undesired liver uptake caused by poor physicochemical properties. Chemical optimization of a second Bicycle, guided by structural biology, provided a high affinity, metabolically stable Bicycle with improved physicochemical properties. A BTC incorporating this Bicycle also demonstrated potent antitumor activity and was very well tolerated when compared to the initial BTC. Phage display selection followed by chemical optimization of Bicycles can deliver potent drug conjugates with favorable pharmaceutical properties." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02129"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02129">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02129&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02129&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02129&amp;href=/doi/10.1021/acs.jmedchem.9b02129" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4107-4116</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02107" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b02128" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Gemma E. Mudd</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gemma E. Mudd</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3b5c5e56565a15564e5f5f7b5952584258575e4f4315585456"><span class="__cf_email__" data-cfemail="1b7c7e76767a35766e7f7f5b7972786278777e6f6335787476">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gemma+E.++Mudd">Gemma E. Mudd</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5075-1625" title="Orcid link">http://orcid.org/0000-0002-5075-1625</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy++Brown">Amy Brown</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liuhong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liuhong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liuhong++Chen">Liuhong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katerine van Rietschoten</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katerine van Rietschoten</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katerine++van+Rietschoten">Katerine van Rietschoten</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sophie Watcham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sophie Watcham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sophie++Watcham">Sophie Watcham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel P. Teufel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel P. Teufel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+P.++Teufel">Daniel P. Teufel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Silvia Pavan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Silvia Pavan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Pavan">Silvia Pavan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachid Lani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachid Lani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachid++Lani">Rachid Lani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip Huxley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Huxley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Huxley">Philip Huxley</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Gavin S. Bennett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gavin S. Bennett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gavin+S.++Bennett">Gavin S. Bennett</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02129&amp;href=/doi/10.1021%2Facs.jmedchem.9b02129" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4107–4116</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 23, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 December 2019</li><li><span class="item_label"><b>Published</b> online</span>23 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 April 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02129" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02129</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4107%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGemma%2BE.%2BMudd%252C%2BAmy%2BBrown%252C%2BLiuhong%2BChen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D8%26contentID%3Dacs.jmedchem.9b02129%26title%3DIdentification%2Band%2BOptimization%2Bof%2BEphA2-Selective%2BBicycles%2Bfor%2Bthe%2BDelivery%2Bof%2BCytotoxic%2BPayloads%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4116%26publicationDate%3DApril%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02129"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1580</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02129" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gemma&quot;,&quot;last_name&quot;:&quot;E. Mudd&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Brown&quot;},{&quot;first_name&quot;:&quot;Liuhong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Katerine&quot;,&quot;last_name&quot;:&quot;van Rietschoten&quot;},{&quot;first_name&quot;:&quot;Sophie&quot;,&quot;last_name&quot;:&quot;Watcham&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;P. Teufel&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Pavan&quot;},{&quot;first_name&quot;:&quot;Rachid&quot;,&quot;last_name&quot;:&quot;Lani&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Huxley&quot;},{&quot;first_name&quot;:&quot;Gavin&quot;,&quot;last_name&quot;:&quot;S. Bennett&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4107-4116&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02129&quot;},&quot;abstract&quot;:&quot;Bicycles are constrained bicyclic peptides that represent a promising binding modality for use in targeted drug conjugates. A phage display screen against EphA2, a receptor tyrosine kinase highly expressed in a number of solid tumors, identified a number of Bicycle families with low nanomolar affinity. A Bicycle toxin conjugate (BTC) was generated by derivatization of one of these Bicycles with the potent cytotoxin DM1 via a cleavable linker. This BTC demonstrated potent antitumor activity in vivo but was poorly tolerated, which was hypothesized to be the result of undesired liver uptake caused by poor physicochemical properties. Chemical optimization of a second Bicycle, guided by structural biology, provided a high affinity, metabolically stable Bicycle with improved physicochemical properties. A BTC incorporating this Bicycle also demonstrated potent antitumor activity and was very well tolerated when compared to the initial BTC. Phage display selection followed by chemical optimization of Bicycles can del&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02129&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02129" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02129&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02129" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02129&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02129" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02129&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02129&amp;href=/doi/10.1021/acs.jmedchem.9b02129" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02129" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02129" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02129%26sid%3Dliteratum%253Aachs%26pmid%3D32202781%26genre%3Darticle%26aulast%3DMudd%26date%3D2020%26atitle%3DIdentification%2Band%2BOptimization%2Bof%2BEphA2-Selective%2BBicycles%2Bfor%2Bthe%2BDelivery%2Bof%2BCytotoxic%2BPayloads%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D8%26spage%3D4107%26epage%3D4116%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=291735" title="Toxins">Toxins</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/jmcmar.2020.63.issue-8/20200423/jmcmar.2020.63.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bicycles are constrained bicyclic peptides that represent a promising binding modality for use in targeted drug conjugates. A phage display screen against EphA2, a receptor tyrosine kinase highly expressed in a number of solid tumors, identified a number of Bicycle families with low nanomolar affinity. A Bicycle toxin conjugate (BTC) was generated by derivatization of one of these Bicycles with the potent cytotoxin DM1 via a cleavable linker. This BTC demonstrated potent antitumor activity <i>in vivo</i> but was poorly tolerated, which was hypothesized to be the result of undesired liver uptake caused by poor physicochemical properties. Chemical optimization of a second Bicycle, guided by structural biology, provided a high affinity, metabolically stable Bicycle with improved physicochemical properties. A BTC incorporating this Bicycle also demonstrated potent antitumor activity and was very well tolerated when compared to the initial BTC. Phage display selection followed by chemical optimization of Bicycles can deliver potent drug conjugates with favorable pharmaceutical properties.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bicycle peptides are novel therapeutic agents formed from peptides, typically 9–20 amino acids in length, with three strategically placed cysteine residues within the sequence. The thiol-containing amino acids react selectively with a C<sub>3</sub> symmetrical small-molecule scaffold under mild aqueous conditions, compatible with peptide phage display.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> This transformation forms three stable thioether bonds between the peptide and the scaffold (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), constraining the peptide into a bicyclic structure. The constrained structure gives rise to peptides with high binding affinity and selectivity, comparable to that of antibodies.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The small size of Bicycles (1.5–3 kDa) can lead to rapid and deep tissue penetration,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> a short duration of systemic exposure, and rapid renal elimination.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Schematic representation of a Bicycle with a generic small-molecule scaffold linked via three cysteine residues (orange). N- and C-terminal extensions outside the Bicycle loops can be incorporated (gray). (b) Examples of scaffolds that can be used to generate Bicycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Phage display screening of Bicycles allows the rapid identification of binders from large libraries of diverse sequences (>10<sup>15</sup>). Bicycles are selected for binding to their target while attached to a large (90 nm × 7 nm) bacteriophage particle. As a consequence, Bicycles can be readily conjugated to a variety of payloads without disrupting binding to their target receptor (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Bicycles have a tolerance to conjugation as they are identified while attached to a large phage particle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Bicycle toxin conjugates (BTCs) are generated by conjugating a potent cytotoxic compound to a Bicycle via a cleavable linker, designed to release the payload selectively in the tumor microenvironment.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The relatively small size of BTCs offers potential advantages over other targeted cytotoxic approaches such as antibody–drug conjugates (ADCs), as it allows rapid extravasation, improved tumor penetration, and renal elimination. The short <i>in vivo</i> circulating half-life of Bicycles results in the rapid elimination of any nontumor-bound conjugate, therefore sparing healthy tissue from prolonged exposure to the toxin.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Erythropoietin-producing hepatocellular receptor A2 (EphA2) is a member of the receptor tyrosine kinase family that regulates cell–cell interactions such as differentiation, adhesion, migration, and death.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> EphA2 has low expression in healthy tissue in adults<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> but is overexpressed in a variety of solid tumors and is associated with poor prognosis in patients.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> This expression pattern is ideal for targeted drug conjugates, and for this reason, it has generated considerable interest from a number of groups.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16">(11−16)</a> The antibody–drug conjugate MEDI547 showed preclinical efficacy in EphA2 expressing solid tumors; however, in Phase 1 studies, a poor safety profile precluded further clinical investigation.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Therefore, the development of an alternative therapeutic that can selectively and safely deliver toxic payloads via an EphA2 binding moiety is of high interest.</div><div class="NLM_p last">We have recently described the profile of BT5528, an EphA2 targeting BTC, which has demonstrated rapid tumor shrinkage even in large, heterogeneous patient-derived xenograft models.<a onclick="showRef(event, 'ref6 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref6 ref19 ref20 ref21">(6,19−21)</a> Although the pharmacological activity of BT5528 was clearly demonstrated in these reports, details of the identification and optimization of the targeting Bicycle was not described. Herein we detail the process of selecting and optimizing the EphA2 targeting Bicycle that was incorporated into BT5528.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56248" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56248" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Identification of First-Generation EphA2 Binding Bicycles</h3><div class="NLM_p">In order to identify an EphA2 binding Bicycle, five naïve phage libraries with completely randomized residues between the three Bicycle-forming cysteine residues were panned against the soluble ectodomain of EphA2. Each library presented Bicycles with different loop sizes when cyclized using the scaffold 1,3,5-tris(bromomethyl)benzene (TBMB). Five distinct families of Bicycles, grouped by their conserved binding motifs, were identified and are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The conserved motif of family 1 shares homology with the natural EphA2 ligands, the ephrin-A family members (G-H loop, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>), whereas family 5 has a binding motif similar to previously reported EphA2 binding linear peptides.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The remaining three families identified contain novel motifs not previously reported. Representative sequences from the 5 naïve Bicycle families were synthesized by solid-phase peptide synthesis (SPPS) and their affinities for EphA2 determined by fluorescence polarization competition. These were in the range of <i>K</i><sub>i</sub> = 83 nM to 1 μM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Conserved Motifs and Binding Affinities of Bicycle Families Identified through Phage Display Panning against Epha2 Using Bicycles Formed with a TBMB Scaffold<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">family</th><th class="colsep0 rowsep0" align="center">conserved binding motif</th><th class="colsep0 rowsep0" align="center">loop format</th><th class="colsep0 rowsep0" align="center">naïve Bicycle affinity <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center">affinity matured Bicycle affinity <i>K</i><sub>i</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">“SLG”, motif in common with ephrin-A ligands G-H loop consensus</td><td class="colsep0 rowsep0" align="left">5 × 5</td><td class="colsep0 rowsep0" align="left">101</td><td class="colsep0 rowsep0" align="left">56.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2a</td><td class="colsep0 rowsep0" align="left">P(F/W)GPXW (second loop)</td><td class="colsep0 rowsep0" align="left">6 × 6</td><td class="colsep0 rowsep0" align="left">83.4</td><td class="colsep0 rowsep0" align="left">26.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2b</td><td class="colsep0 rowsep0" align="left">P(F/W)GPXW (first loop)</td><td class="colsep0 rowsep0" align="left">6 × 6</td><td class="colsep0 rowsep0" align="left">263</td><td class="colsep0 rowsep0" align="left">0.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">QGXWXAXXZ(E/D)</td><td class="colsep0 rowsep0" align="left">6 × 6</td><td class="colsep0 rowsep0" align="left">not tested</td><td class="colsep0 rowsep0" align="left">82.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">ACLVNDDCFYMGLCA (enriched singleton)</td><td class="colsep0 rowsep0" align="left">5 × 5</td><td class="colsep0 rowsep0" align="left">931</td><td class="colsep0 rowsep0" align="left">no improvement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">ACGQCWSAWVYDCA “WSA”, a motif similar to previously reported EphA2 binding linear peptides with the YSA motif<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td><td class="colsep0 rowsep0" align="left">2 × 7</td><td class="colsep0 rowsep0" align="left">268</td><td class="colsep0 rowsep0" align="left">no improvement</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Affinities were measured using fluorescence polarization competition. Full sequences and assay details, including the number of replicates, errors, and competing tracer molecules, are in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>. X = random residue, Z = aromatic residue.</p></div></div></div><div class="NLM_p">Families 2–4 were subjected to affinity maturation, a process where further rounds of panning are carried out using bespoke phage libraries, where key binding residues within the motif are fixed, while other residues were randomized in order to find the optimal binding sequence. Short 2–4 amino acid N- and C-terminal extensions outside the Bicycle loops are also added, which may increase affinity further by making new binding contacts. This process identified Bicycles with a significantly improved affinity for EphA2. Full sequences of example Bicycles from each family are detailed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Table S3</a>.</div><div class="NLM_p last">Following affinity maturation, family 2b (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entry 3) provided lead Bicycle BCY0048 (amino acid sequence A<sub>nt5</sub>H<sub>nt4</sub>D<sub>nt3</sub>V<sub>nt2</sub>P<sub>nt1</sub>C<sub>i</sub>P<sub>1</sub>W<sub>2</sub>G<sub>3</sub>P<sub>4</sub>F<sub>5</sub>W<sub>6</sub>C<sub>ii</sub>P<sub>7</sub>V<sub>8</sub>N<sub>9</sub>R<sub>10</sub>P<sub>11</sub>G<sub>12</sub>C<sub>iii</sub>A<sub>ct1</sub>), which binds to EphA2 with a <i>K</i><sub>i</sub> of 0.54 nM, representing a >480-fold increase from its parent peptide. As such, BCY0048 was selected as the binding moiety for a prototype BTC.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Synthesis of Prototype Bicycle Toxin Conjugates Using the First-Generation EphA2 Binding Bicycle</h3><div class="NLM_p">Following identification of a lead Bicycle, our next aim was to stabilize BCY0048 to plasma proteases. Amino acids identified as potential points of metabolism were replaced with noncoded amino acids, and the C-terminal alanine was removed (data not shown). A BTC precursor was synthesized from the resultant sequence by the introduction of a molecular spacer to minimize any interference in binding caused by the addition of a payload and to reduce steric hindrance around the cleavable linker. The 10-unit sarcosine spacer, terminating with a β-alanine residue for the ease of future conjugation is chemically inert and conformationally semirigid and has a positive impact on aqueous solubility.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Incorporation of the spacer at the N-terminus was chosen for synthetic ease and to protect the N-terminal amino acid extension from proteolytic degradation <i>in vivo</i>. These modifications resulted in BCY6044 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which maintained high affinity for EphA2 with a measured <i>K</i><sub>i</sub> of 2.83 nM.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of the chemically stabilized, TBMB cyclized EphA2 binding Bicycle BCY6044 and prototype Bicycle toxin conjugate BCY6046.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A potent microtubule inhibitor, the cytotoxin mertansine (DM1), was conjugated to BCY6044 via a disulfide linker to give toxin conjugate BCY6046 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This combination of reducible linker and toxin payload has been widely described in ADC literature.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The addition of the linker and DM1 did not perturb the ability of the Bicycle to bind EphA2, and BCY6046 demonstrated a <i>K</i><sub>i</sub> of 1.72 nM for binding EphA2. <i>In vitro</i> DMPK analysis revealed that both precursor BCY6044 and final conjugate BCY6046 exhibited very high plasma protein binding (PPB), with the unbound fraction being below the limit of detection in the assay.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> <i>In Vivo</i> Assessment of First-Generation BTC</h3><div class="NLM_p">The antitumor efficacy of BCY6046 was assessed in a cell-derived xenograft (CDX) model using HT-1080 cells, known to express high levels of EphA2.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Dosing at 1 mg/kg once weekly did not produce antitumor activity. However, weekly dosing at 3 mg/kg resulted in robust efficacy, with the BTC producing complete regression of tumors within 14 days (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a, animal body weights shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>). Due to these encouraging results, BCY6046 was progressed to toxicology assessment. Toxicology responses were investigated in a single ascending dose study following IV bolus injection to eight female rats at 1, 2, and 3 mg/kg. Following dosing BCY6046, animals were observed for up to 5 days, and quantitation of circulating liver enzyme levels was carried out on day 5. Elevation of aspartate transaminase (AST) and alanine transaminase (ALT) was observed, indicating a negative effect of this BTC on the liver when dosed at 2 and 3 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Efficacy study using Bicycle toxin conjugate BCY6046. Full regression of the CDX tumor (HT-1080 cells) was observed within 14 days when BCY6046 was dosed at 3 mg/kg qw. (b) BCY6046 toxicology responses were evaluated in a single ascending dose study via IV bolus injection to eight female rats at 1, 2, and 3 mg/kg. ALT and AST levels were measured on day 5. Elevated levels were observed at 2 mg/kg and at the minimum efficacious dose, 3 mg/kg. (c) Bicycle toxin conjugate BCY6135 shows good efficacy in a CDX model using HT-1080 cells when dosed at 3 mg/kg qw, leading to full regression of the tumor. (d) BCY6135 toxicology responses were monitored in a 14 day repeat dose study following IV bolus injection to six female rats at 3, 5, and 7.5 mg/kg on days 1 and 8, with ALT and AST levels measured on day 15. ALT and AST levels were low at the efficacious dose (3 mg/kg) and close to levels recorded for reference laboratory animals at 5 mg/kg. ALT and AST levels exceeded the normal range at 2.5 times the efficacious dose (7.5 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We suspected that these effects might be caused by an undesired uptake of the conjugate into the liver. Liver uptake leading to toxicity is reported for ADCs and has often been linked to hydrophobicity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> We were surprised to see evidence of this effect for a BTC, as previously reported DOTA-conjugated Bicycles have been shown to be predominantly renally eliminated, with minimal liver uptake.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> We hypothesized that liver accumulation was being caused by the combination of a hydrophobic Bicycle sequence and a hydrophobic scaffold. This undesirable physicochemical profile is also reflected by the very high PPB observed. A key objective for the program was, therefore, to develop a more hydrophilic Bicycle exhibiting minimal liver uptake and predominantly renal elimination <i>in vivo</i>.</div><div class="NLM_p last">It has been previously demonstrated that, for a particular target, Bicycles with completely different consensus sequences can be identified from the same linear peptide library by changing the small-molecule scaffold around which the Bicycles are formed.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, rather than undertake a potentially lengthy chemical optimization campaign to modify the physicochemical properties of this Bicycle family, a second phage screen was initiated. This time, a more hydrophilic scaffold, 1,3,5-triacryoyl-1,3,5-triazinane (TATA), was used to generate the Bicycle libraries in order to allow identification of a more hydrophilic starting point for chemical optimization.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Identification of Second-Generation EphA2 Binding Bicycles</h3><div class="NLM_p">For the second screen, a larger panel of nine Bicycle-presenting phage libraries was employed, each containing Bicycles of different loop sizes. Four distinct chemical families were identified with similar motifs to those seen in the TBMB phage panning outputs (derivatives with “AYPD” and “YSA” motifs, families 1–4, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). However, two novel enriched sequences, unique to the TATA scaffold, were identified (families 5 and 6, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Full sequences of example Bicycles from each family are detailed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Table S4</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Conserved Motifs and Binding Affinities of Bicycle Families Identified through Phage Display Panning against EphA2 Using Bicycles Formed with a TATA Scaffold<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">family</th><th class="colsep0 rowsep0" align="center">motif</th><th class="colsep0 rowsep0" align="center">loop format</th><th class="colsep0 rowsep0" align="center" char=".">naïve Bicycle affinity, <i>K</i><sub><b>i</b></sub> (nM)</th><th class="colsep0 rowsep0" align="center">affinity matured Bicycleaffinity, <i>K</i><sub><b>i</b></sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">AZX(D/N)</td><td class="colsep0 rowsep0" align="left">5 × 5</td><td class="colsep0 rowsep0" align="char" char=".">210</td><td class="colsep0 rowsep0" align="left">39.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">AVXN</td><td class="colsep0 rowsep0" align="left">5 × 5</td><td class="colsep0 rowsep0" align="char" char=".">223</td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">AYPX</td><td class="colsep0 rowsep0" align="left">2 × 7, 6 × 6, 2 × 6</td><td class="colsep0 rowsep0" align="char" char=".">815</td><td class="colsep0 rowsep0" align="left">160</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">YSA</td><td class="colsep0 rowsep0" align="left">2 × 7</td><td class="colsep0 rowsep0" align="char" char=".">2618</td><td class="colsep0 rowsep0" align="left">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">GZMGLXP</td><td class="colsep0 rowsep0" align="left">7 × 3</td><td class="colsep0 rowsep0" align="char" char=".">3102</td><td class="colsep0 rowsep0" align="left">81.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">P(L/M)VNPL</td><td class="colsep0 rowsep0" align="left">6 × 6</td><td class="colsep0 rowsep0" align="char" char=".">115</td><td class="colsep0 rowsep0" align="left">5.78</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Affinities were measured using fluorescence polarization. Full sequences and assay details, including the number of replicates, errors, and competing tracer molecules, are in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>. X = random residue, Z = aromatic residue.</p></div></div></div><div class="NLM_p last">Following affinity maturation, BCY6065 was selected from family 6 as the lead Bicycle (amino acid sequence A<sub>nt3</sub>R<sub>nt2</sub>D<sub>nt1</sub>C<sub>i</sub>P<sub>1</sub>L<sub>2</sub>V<sub>3</sub>N<sub>4</sub>P<sub>5</sub>L<sub>6</sub>C<sub>ii</sub>L<sub>7</sub>H<sub>8</sub>P<sub>9</sub>G<sub>10</sub>W<sub>11</sub>T<sub>12</sub>C<sub>iii</sub>A<sub>ct1</sub>), as it exhibited high affinity for EphA2 (<i>K</i><sub>i</sub> = 5.78 nM). In order to assess the plasma protein binding and stability of this sequence, BCY0745, an analogue of BCY6065, was synthesized, whereby the termini were stabilized (the C-terminal alanine was removed, and the N<i>-</i>terminus was acetylated). Following PPB analysis, the percentage of unbound BCY0745 was determined to be 64.6% (human plasma), which was much lower than that of the first-generation Bicycle BCY0048. The <i>in vitro</i> half-life of the acetylated Bicycle upon incubation with mouse and human plasma was found to be only 3.6 and 3.7 h, respectively. However, we anticipated this to be readily addressable during chemical optimization.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Bicycle-EphA2 Cocrystal Structure</h3><div class="NLM_p">An X-ray structure of BCY6065 cocrystallized with the human EphA2 ligand-binding domain was obtained, and the structure of the Bicycle–EphA2 complex was determined at a resolution of 2.3 Å (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) EphA2 (gray ribbon) interacts with its cognate ligands via the ligand-binding domain (LBD); ephrin A5 (blue ribbon) inserts a large unstructured loop into a hydrophobic channel on EphA2 (PDB accession number <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X11">2X11</a><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>). (b) BCY6065 (orange sticks and surface) binds EphA2 LBD (gray ribbon). The Bicycle backbone forms an open turn structure with a central short 3<sub>10</sub> helix stabilized by the TATA scaffold (PDB accession number <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RW2">6RW2</a>). (c) BCY6065 (orange sticks) sits closely over the surface of EphA2 (gray ribbon and surface), burying around 1650 Å<sup>2</sup>; two conformers were observed for His8 of the Bicycle (alternate conformer shown in purple).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">BCY6065 binds to the ligand-binding domain of EphA2 with a footprint that overlaps the binding site reported for endogenous ephrin ligands (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> The peptide presents an open conformation, with the amino acid backbone forming a large turn structure constrained by the central TATA scaffold (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c). As is the case with the ephrin ligands, the Bicycle loop that inserts into the EphA2 ligand-binding channel contributes most of the binding interaction. Interestingly, six amino acids in the middle of the Bicycle sequence, including one of the scaffold-tethered cysteines, form a short 3<sub>10</sub> helix, which is broken at both ends by proline residues.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Chemical Optimization of Second-Generation Bicycle Binders</h3><div class="NLM_p">BCY6065 presented a good starting point for chemical optimization due to its high affinity for EphA2 and low plasma protein binding. In order to avoid biodistribution to the liver upon conjugation of a hydrophobic toxin payload, the optimization was focused on further increasing the hydrophilic character of the Bicycle through the introduction of polar or charged non-natural amino acids, while at the same time increasing the stability to plasma proteases and maintaining low nanomolar binding affinity.</div><div class="NLM_p">Guided by the cocrystal structure, a series of analogues of the parent sequence were synthesized, whereby single amino acids within the Bicycle were substituted for non-natural residues and the binding affinity determined (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The CHIlogP, a chromatographic measure of hydrophobicity, was also determined to allow selection of substitutions that maintain or increase overall hydrophilicity.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Sequences, Affinities, and CHIlogP Values of BCY6065 and Analogues Containing Non-Natural Amino Acids<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide no.</th><th class="colsep0 rowsep0" align="center">substituted amino acid</th><th class="colsep0 rowsep0" align="center">sequence</th><th class="colsep0 rowsep0" align="center" char="±">EphA2 <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">CHIlogP</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6065</td><td class="colsep0 rowsep0" align="left">none (parent)</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCLHPGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 3.04</td><td class="colsep0 rowsep0" align="char" char=".">1.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6067</td><td class="colsep0 rowsep0" align="left">Pro1</td><td class="colsep0 rowsep0" align="left">ARDC<b>[</b><i>trans</i><b>-Hyp]</b>LVNPLCLHPGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 1.18</td><td class="colsep0 rowsep0" align="char" char=".">1.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6085</td><td class="colsep0 rowsep0" rowspan="3" align="left">Leu2</td><td class="colsep0 rowsep0" align="left">ARDCP<b>[hPhe]</b>VNPLCLHPGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">14.5 ± 0.49</td><td class="colsep0 rowsep0" align="char" char=".">1.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6114</td><td class="colsep0 rowsep0" align="left">ARDCP<b>[C5g]</b>VNPLCLHPGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">34.5 ± 4.9</td><td class="colsep0 rowsep0" align="char" char=".">1.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6115</td><td class="colsep0 rowsep0" align="left">ARDCP<b>[Cba]</b>VNPLCLHPGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.35</td><td class="colsep0 rowsep0" align="char" char=".">1.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6121</td><td class="colsep0 rowsep0" rowspan="2" align="left">His8</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCL<b>[3,3-Dpa]</b>PGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.05</td><td class="colsep0 rowsep0" align="char" char=".">2.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6072</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCL<b>E</b>PGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">12.9 ± 3.14</td><td class="colsep0 rowsep0" align="char" char=".">1.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6074</td><td class="colsep0 rowsep0" rowspan="2" align="left">Gly10</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCLHP<b>[</b><span class="smallcaps smallerCapital">d</span><b>-Ala]</b>WTCA</td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 0.69</td><td class="colsep0 rowsep0" align="char" char=".">1.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6075</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCLHP<b>[</b><span class="smallcaps smallerCapital">d</span><b>-Asp]</b>WTCA</td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 3.33</td><td class="colsep0 rowsep0" align="char" char=".">1.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY0756</td><td class="colsep0 rowsep0" rowspan="2" align="left">Trp11</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCLHPG<b>[1Nal]</b>TCA</td><td class="colsep0 rowsep0" align="char" char="±">2439 ± 157</td><td class="colsep0 rowsep0" align="char" char=".">1.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY0757</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCLHPG<b>[2Nal]</b>TCA</td><td class="colsep0 rowsep0" align="char" char="±">539 ± 110</td><td class="colsep0 rowsep0" align="char" char=".">1.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6076</td><td class="colsep0 rowsep0" align="left">Thr12</td><td class="colsep0 rowsep0" align="left">ARDCPLVNPLCLHPGW<b>[HArg]</b>CA</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 3.23</td><td class="colsep0 rowsep0" align="char" char=".">2.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6066</td><td class="colsep0 rowsep0" align="left">Arg(nt2)</td><td class="colsep0 rowsep0" align="left">A<b>[HArg]</b>DCPLVNPLCLHPGWTCA</td><td class="colsep0 rowsep0" align="char" char="±">9.0 ± 5.88</td><td class="colsep0 rowsep0" align="char" char=".">1.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BCY6088</td><td class="colsep0 rowsep0" align="left">multiple</td><td class="colsep0 rowsep0" align="left">A<b>[HArg]</b>DC<b>[Hyp]</b>LVNPLCLHP<b>[</b><span class="smallcaps smallerCapital">d</span><b>-Asp]</b>W<b>[HArg]</b>CA</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.78</td><td class="colsep0 rowsep0" align="char" char=".">1.34</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Affinities were measured by FP competition (details in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>). Each compound was tested at least <i>n</i> = 2. Amino acids that differ from the parent sequence are highlighted in bold text. All amino acids are <span class="smallcaps smallerCapital">l</span>-configuration unless otherwise stated. <i>trans</i>-Hyp = <i>trans</i>-hydroxyproline, hPhe = homophenylalanine, C5g = cyclopentylglycine, Cba = cyclobutylalanine, 3,3-Dpa = 3,3-diphenylalanine, <span class="smallcaps smallerCapital">d</span>-Ala = <span class="smallcaps smallerCapital">d</span>-alanine, <span class="smallcaps smallerCapital">d</span>-Asp = <span class="smallcaps smallerCapital">d</span>-aspartic acid, 1Nal = 1-naphthylalanine, 2Nal = 2-naphthylalanine, HArg = homoarginine. Peptides were synthesized with amidated C-terminus.</p></div></div></div><div class="NLM_p">Incorporation of <i>trans-</i>hydroxyproline in place of Pro<sub>1</sub> in BCY6065 was well tolerated (BCY6067, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and allowed the introduction of a polar hydroxyl group, which increased the overall hydrophilicity of the Bicycle, evidenced by a lower CHIlogP value compared to the parent (1.57 vs 1.67, respectively).</div><div class="NLM_p">Leu<sub>2</sub> was replaced with various hydrophobic substituents in an attempt to increase affinity through improved hydrophobic interactions. The best tolerated was cyclobutylalanine (Cba, BCY6115). However, this substitution resulted in a significant increase in CHIlogP and so was deprioritized.</div><div class="NLM_p">Residues Asn<sub>4</sub>, Pro<sub>5</sub>, Leu<sub>6</sub>, Cys<sub>ii</sub>, Leu<sub>7</sub>, and His<sub>8</sub> are involved in the formation of a 3<sub>10</sub> helix in the middle of the Bicycle sequence. Binding of this helical segment to the protein is driven mainly by a series of hydrophobic interactions between the peptide side chains and EphA2; therefore, this portion of the Bicycle was not considered a good place to introduce additional hydrophilic substitutions.</div><div class="NLM_p">Interestingly, the electron density of His<sub>8</sub> in the crystallographic data suggested that this residue can adopt two different poses and consequently will form two different sets of contacts with the EphA2 receptor (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c). One is a π-cation interaction with Arg159 and the other a hydrophobic interaction with Met59. We hypothesized that the incorporation of a bivalent amino acid might enable the engagement of EphA2 through both interactions simultaneously and result in a higher affinity. Indeed, the introduction of 3,3-diphenylalanine (3,3-DPA) in this position resulted in a 4-fold increase in binding affinity (BCY6121, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Unfortunately, this substitution also substantially increased the overall hydrophobicity of the Bicycle and was therefore not progressed further.</div><div class="NLM_p">Glycine can form backbone conformations that are not possible with <span class="smallcaps smallerCapital">l</span>-amino acids and is often found at positions in loops to enable novel structures to form. The observed dihedral angles of Gly<sub>10</sub> (Φ = +107, Ψ = +14) suggest that substitutions to this residue would be more compatible with <span class="smallcaps smallerCapital">d</span>- rather than <span class="smallcaps smallerCapital">l</span>-amino acid side chains.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a><span class="smallcaps smallerCapital">d</span>-Alanine and <span class="smallcaps smallerCapital">d</span>-aspartic acid were therefore incorporated into this position, resulting in affinities of <i>K</i><sub>i</sub> = 4.8 nM and 6.8 nM, respectively (BCY6074, BCY6075). <span class="smallcaps smallerCapital">d</span>-Aspartic acid was favored due to the introduction of a charged group, which significantly lowered the CHIlogP. <span class="smallcaps smallerCapital">d</span>-Amino acids have the added benefit of constraining an otherwise flexible loop structure and may increase the stability of peptidic species toward proteases.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">Trp<sub>11</sub> was identified as a key binding residue, which inserts into a hydrophobic pocket within the protein, consequently making hydrophobic interactions with Ile64 and Met66 of EphA2. This residue was substituted with non-natural aromatic amino acids, 1-naphthylalanine (1Nal) and 2-naphthylalanine (2Nal); however, both substitutions resulted in a significant decrease in binding affinity (BCY0756, BCY0757).</div><div class="NLM_p">It is known that a number of proteases cleave peptides following the recognition of positively charged amino acids.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> Therefore, we suspected that Arg<sub>nt2</sub> could be a major cleavage site contributing to the poor plasma stability exhibited by BCY6065. Replacement of arginine with non-natural analogue homoarginine (HArg) resulted in only a slight loss of binding affinity compared to the parent peptide (BCY6066, <i>K</i><sub>i</sub> = 9.0 nM) and therefore presenting a viable option for stabilization of the Bicycle. It was additionally observed, in multiple phage clones closely related to BCY6065, that Thr<sub>12</sub> was replaced by an arginine residue. We took inspiration from this and inserted homoarginine into position 12, generating BCY6076. Homoarginine (hArg) maintained the binding affinity (5.2 nM) and allowed the introduction of an additional charged residue.</div><div class="NLM_p last">The final optimized Bicycle, BCY6088, was generated by combining four non-natural amino acids that individually imparted improved physicochemical, stability, or affinity enhancing properties over parent BCY6065 (<i>trans</i>-HyP<sub>1</sub>, <span class="smallcaps smallerCapital">d</span>-Asp<sub>10</sub>, hArg<sub>12</sub>, and hArg<sub>nt2</sub>). BCY6088 was found to fulfill the target criteria set out for chemical optimization: increased hydrophilicity (CHIlogP = 1.34 vs 1.67 for parent BCY6065) and maintenance of high affinity for EphA2 (<i>K</i><sub>i</sub> = 2.0 nM). This Bicycle was therefore utilized as a starting point for the construction of new BTCs.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthesis of Prototype Bicycle Toxin Conjugates Using a Second-Generation EphA2 Binding Bicycle</h3><div class="NLM_p">BTC precursor BCY6099 was synthesized in the same way as previously described, by incorporation of a polysarcosine spacer at the N<i>-</i>terminus of Bicycle binder BCY6088 and removal of the C-terminal alanine (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of TATA-cyclized BTC precursor BCY6099, DOTA conjugate BCY6164, and Bicycle toxin conjugates BCY6135.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Chemical stabilization of this Bicycle series was proven to be successful as the <i>in vitro</i> half-life of BCY6099 in mouse and human plasma was determined to be 33 h and >55 h, respectively, greatly improved over the parent sequence. High binding affinity for EphA2 was maintained (<i>K</i><sub>i</sub> = 5.74 nM), and upon analysis of human plasma protein binding, the fraction unbound was determined to be 41%, greatly reduced compared to the first-generation, TBMB-based BTC precursor BCY6044.</div><div class="NLM_p last">Bicycle toxin conjugate BCY6135 was prepared by linking the cytotoxin DM1 to BCY6099 via a disulfide linker. As expected, binding affinity to EphA2 was maintained (<i>K</i><sub>i</sub> = 3.10 nM), and analysis of the human plasma protein binding revealed that the percentage of unbound final conjugate was 44%, again greatly improved over BTC BCY6046 that contained the TBMB scaffold.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> Assessment of a Second-Generation BTC</h3><div class="NLM_p">A micro-positron emission tomography (μPET) imaging experiment was carried out in order to ascertain whether this improved physicochemical profile gave rise to favorable biodistribution. Chelating agent DOTA was conjugated to BCY6099 to give BCY6164 (<i>K</i><sub>i</sub> = 5.07 nM), which was loaded with <sup>68</sup>Ga and used to assess the <i>in vivo</i> distribution of the Bicycle.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> shows a μPET image taken 60 min after dosing BCY6164. High levels of labeled Bicycle are evident in the EphA2 expressing tumor, with minimal uptake in the liver. There is a very high signal to background, indicating that the unbound Bicycle is rapidly cleared from the systemic circulation. A high signal in the kidneys and bladder suggests that this is the primary route of elimination.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. μPET image of an HT-1080 tumor-bearing mouse 60 min after dosing Ga<sup>68</sup>-BCY6164 (scaled at 4–20% ID/g). High levels of Bicycle can be seen in the tumor. A high signal in the kidneys and bladder show this to be the main route of elimination, whereas the signal in the liver is minimal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Bicycle toxin conjugate BCY6135 was evaluated in an HT-1080 xenograft model, and tumor volume was measured over time (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c, animal body weights shown in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>). BCY6135 shows comparable efficacy to BCY6046, also producing complete regression of the tumor within 14 days when dosed at 3 mg/kg. BCY6135 toxicology responses were monitored in a 14 day repeat dose study following IV bolus injection to six female rats at 3, 5, and 7.5 mg/kg on days 1 and 8, with ALT and AST levels measured on day 15 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>d). In contrast to BCY6046, BCY6135 is very well tolerated at the efficacious dose (3 mg/kg), indicated by low levels of ALT and AST. Even at 5 mg/kg, levels are low and close to those recorded for reference laboratory animals (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a> for reference animal levels). ALT and AST levels did exceed the normal range at 2.5 times the efficacious dose (7.5 mg/kg). This result is compatible with the hypothesis that faster renal elimination and low biodistribution to the liver gives rise to Bicycle toxin conjugates with reduced liver toxicology and an improved therapeutic index.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Bicycle screening platform, with large compound numbers and high diversity of sequences and structures, successfully delivered multiple sequence families of novel EphA2 Bicycle binders from screens that incorporated two chemically distinct scaffolds. By forming three covalent bonds to the cysteine residues, the scaffold imparts chemical constraint to the Bicycle, which nucleates the folded structures for each peptide. Beyond an architectural role, the scaffold can also significantly impact physicochemical properties. Given their small overall size, each chemical component of the Bicycle should be expected to have a significant role in the overall properties of the molecules.</div><div class="NLM_p">The lead series from both screens were successfully affinity matured to give binders with low to subnanomolar affinities, and each binder was chemically optimized using non-natural amino acids to give equivalent stability to plasma. Phage screens initiated with the more rigid and hydrophobic TBMB scaffold delivered lead Bicycles with lower solubility and higher plasma protein binding. The TBMB scaffolded Bicycle demonstrated strong antitumor activity as a DM1–cytotoxin conjugate; however, the physicochemical properties of the conjugate lead to undesirable liver toxicities at and below the efficacious dose. By contrast, a Bicycle DM1–toxin conjugate derived from the more hydrophilic TATA scaffold demonstrated equally strong antitumor effects without marked liver toxicity at the efficacious dose. A biodistribution study with a PET imaging conjugate showed that the more hydrophilic Bicycle has a low propensity to distribute to liver tissues.</div><div class="NLM_p last">The diversity of chemical equity afforded by the Bicycle platform enabled the rapid development of differentiated Bicycle toxin conjugate prototypes, which could be evaluated <i>in vivo</i> to identify the ideal properties for the delivery of toxin payload to tumor while sparing healthy tissues. Access to diverse starting points of low molecular weight tumor targeting molecules enables a degree of chemical control over the construction of Bicycle toxin conjugates that is not accessible to recombinant protein platforms. Combining structure-guided and rational drug design principles, a potent and stable lead Bicycle, BCY6099, was generated that enabled delivery of DM1 selectively to EphA2 expressing tumors in a conjugate that demonstrated good tolerability in rat toxicology studies. BCY6099 is the Bicycle binder in BT5528, a BTC which is currently under clinical evaluation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthetic schemes and analytical traces can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>. Compounds were isolated at >95% purity by HPLC (apart from screening peptides, which were >90% purity, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Peptide Synthesis</h3><div class="NLM_p last">Bicycle peptides were synthesized on Rink amide resin using standard Fmoc (9-fluorenylmethyloxycarbonyl) solid-phase peptide synthesis, either by manual coupling (for large scale) or using a Biotage SyroII automated peptide synthesizer (for small scale). Following TFA-based cleavage from the resin, peptides were precipitated with diethyl ether and dissolved in 50:50 acetonitrile/water. The crude peptides (at ∼1 mM concentration) were then cyclized with 1.3 equiv of the scaffold, using ammonium bicarbonate (100 mM) as a base. Completion of cyclization was determined by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) or LC–MS. Once complete, the cyclization reaction was quenched using <i>N</i>-acetyl cysteine (10 equiv with respect to the peptide), and the solutions were lyophilized. The residue was dissolved in an appropriate solvent and purified by RP-HPLC. Peptide fractions of sufficient purity and the correct molecular weight (verified by either MALDI-TOF and HPLC or LC–MS) were pooled and lyophilized. Concentrations were determined by UV absorption using the extinction coefficient at 280 nm, which was based on Trp/Tyr content. Standard Fmoc amino acids, as well as nonproteinogenic Fmoc amino acids, were obtained from Sigma-Aldrich, Iris Biotech GmbH, Apollo Scientific, ChemImpex, and Fluorochem.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> BCY6044</h3><div class="NLM_p last">Rink resin (1.0 g, 0.4–0.45 mmol/g) was used to generate 110 mg of BCY6044 using the general methods outlined above (24.7% yield). MS (ESI): exact mass calcd, 3146.64; found, <i>m</i>/<i>z</i> 1049.3 ([M + 3H]<sup>3+</sup>), 787.0 ([M + 4H]<sup>4+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> BCY0416</h3><div class="NLM_p last">To a solution of BCY6044 in DMF (117 mg, 37 μmol, 20 mM) were added SPP linker (CAS: 341498-08-6) (37 mg, 3 equiv, 111 μmol) and DIPEA (385 μL, 20 equiv, 2.2 mmol). The mixture was stirred for 1 h and then diluted and purified using RP-HPLC. Fractions with the desired purity were lyophilized to give BCY0416 (108 mg, 32 μmol, 86%). MS (ESI): exact mass calcd, 3372.94; found, <i>m</i>/<i>z</i> 1686.9 ([M + 2H]<sup>2+</sup>), 1124.9 ([M + 3H]<sup>3+</sup>), 844.1 ([M + 4H]<sup>4+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec-1446-E8CCAAF4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> BCY6046</h3><div class="NLM_p last">BCY0416 (438 mg, 130 μmol) was dissolved to a concentration of 30 mM in anhydrous DMF with DIPEA (125 mM). DM1 (80 mg, 108 μmol, 0.8 equiv) was also dissolved in anhydrous DMF to a concentration of 25 mM. The DM1 solution was added to the peptide solution and mixed. The reaction progress was analyzed after 1 h by HPLC and MS. The reaction mixture was diluted into a solution of 20% acetonitrile in water to a final DMF concentration of 2%. The reaction mixture was filtered before purification by RP-HPLC. Purified peptide BCY6064 was obtained (250 mg, 61.4 μmol, 47%). MS (ESI): exact mass calcd, 3999.11; found, <i>m</i>/<i>z</i> 3998.8 ([M + H]<sup>+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> BCY6099</h3><div class="NLM_p last">Rink resin (8.0 g, 0.4–0.45 mmol/g) was used to generate 2.1 g of BCY6099 using the general methods outlined above (16.3% yield). MS (ESI): exact mass calcd, 3183.68; found, <i>m</i>/<i>z</i> 1061.8 ([M + 3H]<sup>3+</sup>), 796.5 ([M + 4H]<sup>4+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> DM1-SPDB</h3><div class="NLM_p last">DM1 (250 mg, 338.62 μmol, 1 equiv) and 4-(2-pyridyldisulfanyl)butanoic acid (SPDB-CAS 250266-79-6) (100.95 mg, 440.21 μmol, 1.3 equiv) were added under nitrogen to a 50 mL flask containing DMF (10 mL). The mixture was stirred at room temperature for 1 h. LC–MS showed that the DM1 was consumed completely, and one main peak with the desired mass was detected. The residue was purified by flash C18 gel chromatography (ISCO; 120 g SepaFlash C18 Flash Column, eluent of 0–60% MeCN/H<sub>2</sub>O at 85 mL/min). DM1-SPDB (120.0 mg, 140.11 μmol, 41% yield) was obtained as a white solid. MS (ESI) Exact mass calcd: 856.44, found: <i>m</i>/<i>z</i> 838.0 ([M + H – H<sub>2</sub>O]<sup>+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> DM1-SPDB-TFP</h3><div class="NLM_p last">To a solution of DM1-SPDB (120 mg, 140.11 μmol, 1 equiv) and 2,3,5,6-tetrafluorophenol (69.81 mg, 420.34 μmol, 3 equiv) in DCM (1.00 mL) and DMA (3.00 mL) was added EDCI (80.58 mg, 420.34 μmol, 3 equiv). The mixture was stirred at 15 °C for 4 h. LC–MS showed DM1-SPDB was consumed completely, and one main peak with the desired mass was detected. The DCM was removed, and the residue was diluted with water and directly purified by preparative HPLC. Compound DM1-SPDB-TFP (60.00 mg, 59.73 μmol, 42.63% yield) was obtained as a white solid. MS (ESI): exact mass calcd, 1004.5; found, <i>m</i>/<i>z</i> 985.9 ([M + H – H<sub>2</sub>O]<sup>+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> BCY6135</h3><div class="NLM_p last">To a solution of BCY6099 (114.1 mg, 35.84 μmol, 1.2 equiv) in DMA (5 mL) was added DIEA (11.6 mg, 89.61 μmol, 15.6 μL, 3 equiv) and DM1-SPDB-TFP (0.03 g, 29.87 μmol, 1 equiv). The mixture was stirred at 25 °C for 18 h. LC–MS showed DM1-SPDB-TFP was consumed completely, and one main peak with the desired mass was detected. The mixture was diluted with water and directly purified by prep-HPLC. Compound BCY6135 (22.4 mg, 5.30 μmol, 17.74% yield) was obtained as a white solid. MS (ESI): exact mass calcd, 4021.08; found, <i>m</i>/<i>z</i> 1341.5 ([M + 3H]<sup>3+</sup>), 805.0 ([M + 5H]<sup>5+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> BCY6164</h3><div class="NLM_p last">To a solution of BCY6099 (4.9 mg, 1.54 μmol, 1 equiv) in DMF (150 μL) were added DIEA (5.4 μL, 31 μmol, 20 equiv) and DOTA-NHS (7.1 mg, 9.33 μmol, 6 equiv). The mixture was stirred at rt for 2 h. The reaction mixture was diluted with water and purified by preparative HPLC to give BCY6164 (4.17 mg, 1.17 μmol, 76% yield) as a white solid. MS (ESI): exact mass calcd, 3569.06; found, <i>m</i>/<i>z</i> 1190.3 ([M + 3H]<sup>3+</sup>), 893.0 ([M + 4H]<sup>4+</sup>). Purity >95% by HPLC (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02129" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86714" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86714" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02129?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02129</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">General procedures; compound analytics; sequences of representative EphA2 binding Bicycles from phage screens, human Ephrin-A1 to -A5 G-H loop sequence alignment; additional PET images; additional toxicology data; body weights of CDX animals (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf">jm9b02129_si_001.pdf (1.3 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_002.csv">jm9b02129_si_002.csv (17.16 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the EphA2 LBD-BCY6065 cocrystal structure have been deposited in the Protein Data Bank under accession number <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RW2">6RW2</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b02129" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06231" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06231" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gemma E. Mudd</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5075-1625" title="Orcid link">http://orcid.org/0000-0002-5075-1625</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0265676f6f632c6f77666642606b617b616e67767a2c616d6f"><span class="__cf_email__" data-cfemail="5a3d3f37373b74372f3e3e1a3833392339363f2e2274393537">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Brown</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liuhong Chen</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katerine van Rietschoten</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sophie Watcham</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel P. Teufel</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Pavan</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachid Lani</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Huxley</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gavin S. Bennett</span> - <span class="hlFld-Affiliation affiliation">BicycleTx Limited, Building 900, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): G.M., A.B., L.C., K.v.R., S.W., D.T., S.P., R.L., and G.B. are shareholders in BicycleTx Ltd.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Paul Beswick and Kevin McDonnell for the critical review of this manuscript, as well as Helen Harrison, Gabriella Ivanova Berndt, and Heather Allen for experimental support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">EphA2</td><td class="NLM_def"><p class="first last">erythropoietin-producing hepatocellular receptor A2</p></td></tr><tr><td class="NLM_term">BTC</td><td class="NLM_def"><p class="first last">Bicycle toxin conjugate</p></td></tr><tr><td class="NLM_term">DOTA</td><td class="NLM_def"><p class="first last">1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid</p></td></tr><tr><td class="NLM_term">TBMB</td><td class="NLM_def"><p class="first last">1,3,5-tris(bromomethyl)benzene</p></td></tr><tr><td class="NLM_term">TATA</td><td class="NLM_def"><p class="first last">1,3,5-triacryloyl-1,3,5-triazinane</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′,<i>N</i>″-(benzene-1,3,5-triyl)tris(2-bromoacetamide)</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate transaminase</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine transaminase</p></td></tr><tr><td class="NLM_term">68Ga</td><td class="NLM_def"><p class="first last">Gallium-68</p></td></tr><tr><td class="NLM_term">μPET</td><td class="NLM_def"><p class="first last">micro-positron emission tomography</p></td></tr><tr><td class="NLM_term">CDX</td><td class="NLM_def"><p class="first last">cell-derived xenograft</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">LBD</td><td class="NLM_def"><p class="first last">ligand binding domain</p></td></tr><tr><td class="NLM_term">DM1</td><td class="NLM_def"><p class="first last">mertansine.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">Phage-Encoded Combinatorial Chemical Libraries Based on Bicyclic Peptides</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">502</span>, <span class="refDoi"> DOI: 10.1038/nchembio.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-Encoded+Combinatorial+Chemical+Libraries+Based+on+Bicyclic+Peptides&doi=10.1038%2Fnchembio.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0lgbAqZE4XlYuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-Encoded%2520Combinatorial%2520Chemical%2520Libraries%2520Based%2520on%2520Bicyclic%2520Peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26doi%3D10.1038%2Fnchembio.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeriswyl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stace, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tite, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and Its Orthologues While Sparing Paralogous Proteases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fcmdc.201200071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=22492508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1173-1176&issue=7&author=V.+Baeriswylauthor=H.+Rapleyauthor=L.+Pollaroauthor=C.+Staceauthor=D.+Teufelauthor=E.+Walkerauthor=S.+Chenauthor=G.+Winterauthor=J.+Titeauthor=C.+Heinis&title=Bicyclic+Peptides+with+Optimized+Ring+Size+Inhibit+Human+Plasma+Kallikrein+and+Its+Orthologues+While+Sparing+Paralogous+Proteases&doi=10.1002%2Fcmdc.201200071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases</span></div><div class="casAuthors">Baeriswyl, Vanessa; Rapley, Helen; Pollaro, Lisa; Stace, Catherine; Teufel, Dan; Walker, Edward; Chen, Shiyu; Winter, Greg; Tite, John; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1173-1176, S1173/1-S1173/5</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In this work, we aimed at generating bicyclic peptides inhibiting both human and murine plasma kallikrein (PK) but not any paralogous proteases.  We speculated that inhibitors with the desired specificity profile could be obtained by generating binders to a surface region that is identical in PK orthologues but different in paralogues.  By comparing structural models of target and related nontarget proteases to identify conserved regions in the vicinity of the active site and by modulating the loop size of our libraries of peptide macrocycles accordingly, we succeeded in identifying potent inhibitors of human, rat and monkey plasma kallikrein that do not also inhibit related human serum proteases.  Our strategy should facilitate the evaluation of this type of peptide macrocycles in animal models, and furthermore, avoid unwanted off-target activities that would be detrimental to their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTYMUG-b7ubVg90H21EOLACvtfcHk0ljo0q_k46C9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D&md5=5a3177403617ce635c46b0a759a110ab</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200071%26sid%3Dliteratum%253Aachs%26aulast%3DBaeriswyl%26aufirst%3DV.%26aulast%3DRapley%26aufirst%3DH.%26aulast%3DPollaro%26aufirst%3DL.%26aulast%3DStace%26aufirst%3DC.%26aulast%3DTeufel%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DTite%26aufirst%3DJ.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DBicyclic%2520Peptides%2520with%2520Optimized%2520Ring%2520Size%2520Inhibit%2520Human%2520Plasma%2520Kallikrein%2520and%2520Its%2520Orthologues%2520While%2520Sparing%2520Paralogous%2520Proteases%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D7%26spage%3D1173%26epage%3D1176%26doi%3D10.1002%2Fcmdc.201200071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittrup, K. D.</span></span> <span> </span><span class="NLM_article-title">A Modeling Analysis of the Effects of Molecular Size and Binding Affinity on Tumor Targeting</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2861</span>– <span class="NLM_lpage">2871</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1535-7163.MCT-09-0195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19825804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2861-2871&issue=10&author=M.+M.+Schmidtauthor=K.+D.+Wittrup&title=A+Modeling+Analysis+of+the+Effects+of+Molecular+Size+and+Binding+Affinity+on+Tumor+Targeting&doi=10.1158%2F1535-7163.MCT-09-0195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A modeling analysis of the effects of molecular size and binding affinity on tumor targeting</span></div><div class="casAuthors">Schmidt, Michael M.; Wittrup, K. Dane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2861-2871</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and therapy.  However, it remains largely unclear how size differences among these mols. influence their targeting properties.  Here, we develop a simple, mechanistic model that can be used to understand and predict the complex interplay between mol. size, affinity, and tumor uptake.  Empirical relationships between mol. radius and capillary permeability, interstitial diffusivity, available vol. fraction, and plasma clearance were obtained using data in the literature.  These relationships were incorporated into a compartmental model of tumor targeting using MATLAB to predict the magnitude, specificity, time dependence, and affinity dependence of tumor uptake for mols. across a broad size spectrum.  In the typical size range for proteins, the model uncovers a complex trend in which intermediate-sized targeting agents (MW, ∼25 kDa) have the lowest tumor uptake, whereas higher tumor uptake levels are achieved by smaller and larger agents.  Small peptides accumulate rapidly in the tumor but require high affinity to be retained, whereas larger proteins can achieve similar retention with >100-fold weaker binding.  For mols. in the size range of liposomes, the model predicts that antigen targeting will not significantly increase tumor uptake relative to untargeted mols.  All model predictions are shown to be consistent with exptl. observations from published targeting studies.  The results and techniques have implications for drug development, imaging, and therapeutic dosing. [Mol Cancer Ther 2009;8(10):2861-71].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIy-sqAvgserVg90H21EOLACvtfcHk0ljo0q_k46C9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K&md5=da1ea6be17fad4873d808e883eacbf78</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0195%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DM.%2BM.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DA%2520Modeling%2520Analysis%2520of%2520the%2520Effects%2520of%2520Molecular%2520Size%2520and%2520Binding%2520Affinity%2520on%2520Tumor%2520Targeting%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D10%26spage%3D2861%26epage%3D2871%26doi%3D10.1158%2F1535-7163.MCT-09-0195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wüst, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rietschoten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranski, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stace, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schierbaum, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F0008-5472.CAN-18-0238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=30606721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFCns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=841-852&issue=4&author=M.+Ederauthor=S.+Pavanauthor=U.+Bauder-W%C3%BCstauthor=K.+van+Rietschotenauthor=A.-C.+Baranskiauthor=H.+Harrisonauthor=S.+Campbellauthor=C.+L.+Staceauthor=E.+H.+Walkerauthor=L.+Chenauthor=G.+Bennettauthor=G.+Muddauthor=U.+Schierbaumauthor=K.+Leottaauthor=U.+Haberkornauthor=K.+Kopkaauthor=D.+P.+Teufel&title=Bicyclic+Peptides+as+a+New+Modality+for+Imaging+and+Targeting+of+Proteins+Overexpressed+by+Tumors&doi=10.1158%2F0008-5472.CAN-18-0238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic peptides as a new modality for imaging and targeting of proteins overexpressed by tumors</span></div><div class="casAuthors">Eder, Matthias; Pavan, Silvia; Bauder-Wuest, Ulrike; Van Rietschoten, Katerine; Baranski, Ann-Christin; Harrison, Helen; Campbell, Spencer; Stace, Catherine L.; Walker, Edward H.; Chen, Liuhong; Bennett, Gavin; Mudd, Gemma; Schierbaum, Ursula; Leotta, Karin; Haberkorn, Uwe; Kopka, Klaus; Teufel, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">841-852</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. imaging of cancers using probes specific for tumor-assocd. target proteins offers a powerful soln. for providing information regarding selection of targeted therapy, patient stratification, and response to therapy.  Here we demonstrate the power of bicyclic peptides as targeting probes, exemplified with the tumor-overexpressed matrix metalloproteinase MT1-MMP as a target.  A bicyclic peptide with subnanomolar affinity towards MT1-MMP was identified, and its radioconjugate showed selective tumor uptake in an HT1080 xenograft mouse model.  Proteolytic stabilization of the peptide by chem. modification significantly enhanced the in vivo tumor signal [from 2.5%ID/g to 12%ID/g at 1 h post injection (p.i.)].  Studies using mouse xenograft models with different cell lines show a robust correlation between tumor signals and in vivo MT1-MMP expression levels.  Fatty acid modification of the bicyclic peptide extended its circulating half-life, resulting in increased tumor signals (36%ID/g at 6 h p.i.).  Comparative work with an equipotent radiolabeled MT1-MMP targeting antibody demonstrated starkly differential biodistribution and tumor accumulation properties, with the tumor signal slowly increasing to 6.2%ID/g within 48 h.  The rapid tumor penetration characteristics of bicyclic peptides, coupled with high potency and chem. versatility, thus offer high-contrast imaging probes for clin. diagnostics with compelling addnl. potential in targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxf56_J7cP7bVg90H21EOLACvtfcHk0ljo0q_k46C9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFCns7Y%253D&md5=a9b2d0b6494baa6bd8da2acccd4435b9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0238%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DM.%26aulast%3DPavan%26aufirst%3DS.%26aulast%3DBauder-W%25C3%25BCst%26aufirst%3DU.%26aulast%3Dvan%2BRietschoten%26aufirst%3DK.%26aulast%3DBaranski%26aufirst%3DA.-C.%26aulast%3DHarrison%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DStace%26aufirst%3DC.%2BL.%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DSchierbaum%26aufirst%3DU.%26aulast%3DLeotta%26aufirst%3DK.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26atitle%3DBicyclic%2520Peptides%2520as%2520a%2520New%2520Modality%2520for%2520Imaging%2520and%2520Targeting%2520of%2520Proteins%2520Overexpressed%2520by%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D4%26spage%3D841%26epage%3D852%26doi%3D10.1158%2F0008-5472.CAN-18-0238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno
Candilejo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roxburgh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabaratnam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katugampola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremayne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langford, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symeonides, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, M.</span></span> <span> </span><span class="NLM_article-title">A Cancer Research UK Phase I/IIa Trial of BT1718 (a First in Class Bicycle Drug Conjugate) given Intravenously in Patients with Advanced Solid Tumours</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2610</span>– <span class="NLM_lpage">2610</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.TPS2610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1200%2FJCO.2018.36.15_suppl.TPS2610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2610-2610&issue=15&author=U.+Banerjiauthor=N.+Cookauthor=T.+R.+J.+Evansauthor=I.+Moreno%0ACandilejoauthor=P.+Roxburghauthor=C.+L.+S.+Kellyauthor=N.+Sabaratnamauthor=R.+Passiauthor=S.+Leslieauthor=S.+Katugampolaauthor=L.+Godfreyauthor=N.+Tremayneauthor=G.+Bennettauthor=M.+Koehlerauthor=G.+Langfordauthor=S.+N.+Symeonidesauthor=M.+Pittman&title=A+Cancer+Research+UK+Phase+I%2FIIa+Trial+of+BT1718+%28a+First+in+Class+Bicycle+Drug+Conjugate%29+given+Intravenously+in+Patients+with+Advanced+Solid+Tumours&doi=10.1200%2FJCO.2018.36.15_suppl.TPS2610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.TPS2610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.TPS2610%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DCook%26aufirst%3DN.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DMoreno%2BCandilejo%26aufirst%3DI.%26aulast%3DRoxburgh%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DC.%2BL.%2BS.%26aulast%3DSabaratnam%26aufirst%3DN.%26aulast%3DPassi%26aufirst%3DR.%26aulast%3DLeslie%26aufirst%3DS.%26aulast%3DKatugampola%26aufirst%3DS.%26aulast%3DGodfrey%26aufirst%3DL.%26aulast%3DTremayne%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DLangford%26aufirst%3DG.%26aulast%3DSymeonides%26aufirst%3DS.%2BN.%26aulast%3DPittman%26aufirst%3DM.%26atitle%3DA%2520Cancer%2520Research%2520UK%2520Phase%2520I%252FIIa%2520Trial%2520of%2520BT1718%2520%2528a%2520First%2520in%2520Class%2520Bicycle%2520Drug%2520Conjugate%2529%2520given%2520Intravenously%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumours%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15%26spage%3D2610%26epage%3D2610%26doi%3D10.1200%2FJCO.2018.36.15_suppl.TPS2610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span>; <span class="NLM_string-name">Bennett, G. S.</span>; <span class="NLM_string-name">Brown, A.</span>; <span class="NLM_string-name">Mudd, G.</span>; <span class="NLM_string-name">Van Reitschoten, K.</span>; <span class="NLM_string-name">Pavan, S.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Watcham, S.</span>; <span class="NLM_string-name">Lahdenranta, J.</span>; <span class="NLM_string-name">Keen, N.</span></span> <i>Unpubl. Results</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Huxley%2C+P.%3B+Bennett%2C+G.+S.%3B+Brown%2C+A.%3B+Mudd%2C+G.%3B+Van+Reitschoten%2C+K.%3B+Pavan%2C+S.%3B+Chen%2C+L.%3B+Watcham%2C+S.%3B+Lahdenranta%2C+J.%3B+Keen%2C+N.+Unpubl.+Results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuxley%26aufirst%3DP.%26jtitle%3DUnpubl.%2520Results" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">Eph-Ephrin Bidirectional Signaling in Physiology and Disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1016%2Fj.cell.2008.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=18394988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=38-52&issue=1&author=E.+B.+Pasquale&title=Eph-Ephrin+Bidirectional+Signaling+in+Physiology+and+Disease&doi=10.1016%2Fj.cell.2008.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Eph-ephrin bidirectional signaling in physiology and disease</span></div><div class="casAuthors">Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-52</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases of the Eph family bind to cell surface-assocd. ephrin ligands on neighboring cells.  The ensuing bidirectional signals have emerged as a major form of contact-dependent communication between cells.  New findings reveal that Eph receptors and ephrins coordinate not only developmental processes but also the normal physiol. and homeostasis of many adult organs.  Imbalance of Eph/ephrin function may therefore contribute to a variety of diseases.  The challenge now is to better understand the complex and seemingly paradoxical signaling mechanisms of Eph receptors and ephrins, which will enable effective strategies to target these proteins in the treatment of diseases such as diabetes and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwi9x94COQ7Vg90H21EOLACvtfcHk0li9AyXgnRr5og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslOlu7o%253D&md5=67d6b24808f5d0672aad39dca99d3c8f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DEph-Ephrin%2520Bidirectional%2520Signaling%2520in%2520Physiology%2520and%2520Disease%26jtitle%3DCell%26date%3D2008%26volume%3D133%26issue%3D1%26spage%3D38%26epage%3D52%26doi%3D10.1016%2Fj.cell.2008.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">CDNA Cloning and Characterization of Eck, an Epithelial Cell Receptor Protein-Tyrosine Kinase in the Eph/Elk Family of Protein Kinases</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">6316</span>– <span class="NLM_lpage">6324</span>, <span class="refDoi"> DOI: 10.1128/MCB.10.12.6316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1128%2FMCB.10.12.6316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=2174105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADyaK3MXisVWmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=6316-6324&issue=12&author=R.+A.+Lindbergauthor=T.+Hunter&title=CDNA+Cloning+and+Characterization+of+Eck%2C+an+Epithelial+Cell+Receptor+Protein-Tyrosine+Kinase+in+the+Eph%2FElk+Family+of+Protein+Kinases&doi=10.1128%2FMCB.10.12.6316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases</span></div><div class="casAuthors">Lindberg, Richard A.; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6316-24</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A human epithelial (HeLa) cDNA library was screened with degenerate oligonucleotides designed to hybridize to highly conserved regions of protein-tyrosine kinases.  One cDNA from this screen was shown to contain a putative protein-tyrosine kinase catalytic domain and subsequently used to isolate another cDNA from a human keratinocyte library that encompasses the entire coding region of a 976-amino-acid polypeptide.  The predicted protein has an external domain of 534 amino acids with a presumptive N-terminal signal peptide, a transmembrane domain, and a cytoplasmic domain of 418 amino acids that includes a canonical protein-tyrosine kinase catalytic domain.  Mol. phylogeny indicates that this protein kinase is closely related to eph and elk and that this receptor family is more closely related to the non-receptor protein-tyrosine kinase families than to other receptor protein-tyrosine kinases.  Antibodies raised against a TrpE fusion protein immunopptd. a 130-kDa protein that became phosphorylated on tyrosine in immune complex kinase assays, indicating that this protein is a bona fide protein-tyrosine kinase.  Anal. of RNA from 13 adult rat organs showed that the eck gene is expressed most highly in tissues that contain a high proportion of epithelial cells, e.g., skin, intestine, lung, and ovary.  Several cell lines of epithelial origin were found to express the eck protein kinase at the protein and RNA levels.  Immunohistochem. anal. of several rat organs also showed staining in epithelial cells.  These observations lead to the naming of this protein kinase eck, for epithelial cell kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqPiqFHu0RxrVg90H21EOLACvtfcHk0li9AyXgnRr5og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVWmu7c%253D&md5=75d34ab8db9b752fbf1888ac5e58663a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FMCB.10.12.6316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.10.12.6316%26sid%3Dliteratum%253Aachs%26aulast%3DLindberg%26aufirst%3DR.%2BA.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DCDNA%2520Cloning%2520and%2520Characterization%2520of%2520Eck%252C%2520an%2520Epithelial%2520Cell%2520Receptor%2520Protein-Tyrosine%2520Kinase%2520in%2520the%2520Eph%252FElk%2520Family%2520of%2520Protein%2520Kinases%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1990%26volume%3D10%26issue%3D12%26spage%3D6316%26epage%3D6324%26doi%3D10.1128%2FMCB.10.12.6316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker-Daniels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Differential Regulation of EphA2 in Normal and Malignant Cells</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)63899-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1016%2FS0002-9440%2810%2963899-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=12651595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2003&pages=1037-1042&issue=4&author=J.+Walker-Danielsauthor=A.+R.+Hessauthor=M.+J.+C.+Hendrixauthor=M.+S.+Kinch&title=Differential+Regulation+of+EphA2+in+Normal+and+Malignant+Cells&doi=10.1016%2FS0002-9440%2810%2963899-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of EphA2 in normal and malignant cells</span></div><div class="casAuthors">Walker-Daniels, Jennifer; Hess, Angela R.; Hendrix, Mary J. C.; Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1042</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">A review on the biochem. and cellular consequences of EphA2 stimulation, esp. in malignant cells.  The mechanisms that may explain the overexpression and functional alterations of EphA2 in cancer are discussed.  A hypothetical model representing a potential signaling pathway initiated by EphA2 and crit. for vasculogenic mimicry is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOCiDKgpnOxrVg90H21EOLACvtfcHk0li9AyXgnRr5og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D&md5=e6298e47af35ad4815d6ba053df0931c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963899-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963899-0%26sid%3Dliteratum%253Aachs%26aulast%3DWalker-Daniels%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DA.%2BR.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520Regulation%2520of%2520EphA2%2520in%2520Normal%2520and%2520Malignant%2520Cells%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2003%26volume%3D162%26issue%3D4%26spage%3D1037%26epage%3D1042%26doi%3D10.1016%2FS0002-9440%2810%2963899-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ireton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.2174/1568009053765780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&issue=3&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+Receptor+Tyrosine+Kinase+as+a+Promising+Target+for+Cancer+Therapeutics&doi=10.2174%2F1568009053765780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0li1BV4uyuKAVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520Receptor%2520Tyrosine%2520Kinase%2520as%2520a%2520Promising%2520Target%2520for%2520Cancer%2520Therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D157%26doi%3D10.2174%2F1568009053765780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1078-0432.CCR-12-2654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=23155185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=128-137&issue=1&author=S.+Wangauthor=R.+Noberiniauthor=J.+L.+Stebbinsauthor=S.+Dasauthor=Z.+Zhangauthor=B.+Wuauthor=S.+Mitraauthor=S.+Billetauthor=A.+Fernandezauthor=N.+A.+Bhowmickauthor=S.+Kitadaauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Targeted+Delivery+of+Paclitaxel+to+EphA2-Expressing+Cancer+Cells&doi=10.1158%2F1078-0432.CCR-12-2654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Noberini, Roberta; Stebbins, John L.; Das, Swadesh; Zhang, Ziming; Wu, Bainan; Mitra, Sayantan; Billet, Sandrine; Fernandez, Ana; Bhowmick, Neil A.; Kitada, Shinichi; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: YSA is an EphA2-targeting peptide that effectively delivers anticancer agents to prostate cancer tumors.  Here, we report on how we increased the drug-like properties of this delivery system.  Exptl. Design: By introducing non-natural amino acids, we have designed two new EphA2 targeting peptides: YNH, where norleucine and homoserine replace the two methionine residues of YSA, and dYNH, where a D-tyrosine replaces the L-tyrosine at the first position of the YNH peptide.  We describe the details of the synthesis of YNH and dYNH paclitaxel conjugates (YNH-PTX and dYNH-PTX) and their characterization in cells and in vivo.  Results: dYNH-PTX showed improved stability in mouse serum and significantly reduced tumor size in a prostate cancer xenograft model and also reduced tumor vasculature in a syngeneic orthotopic allograft mouse model of renal cancer compared with vehicle or paclitaxel treatments.  Conclusion: This study reveals that targeting EphA2 with dYNH drug conjugates could represent an effective way to deliver anticancer agents to a variety of tumor types.  Clin Cancer Res; 19(1); 128-37. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM9wK1ey90VLVg90H21EOLACvtfcHk0li1BV4uyuKAVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D&md5=9d11d8f57028d5245b0d344652ef311e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2654%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTargeted%2520Delivery%2520of%2520Paclitaxel%2520to%2520EphA2-Expressing%2520Cancer%2520Cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D1%26spage%3D128%26epage%3D137%26doi%3D10.1158%2F1078-0432.CCR-12-2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzad, M. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangala, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2562</span>– <span class="NLM_lpage">2570</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1078-0432.CCR-10-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20388851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlegtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2562-2570&issue=9&author=J.-W.+Leeauthor=R.+L.+Stoneauthor=S.+J.+Leeauthor=E.+J.+Namauthor=J.-W.+Rohauthor=A.+M.+Nickauthor=H.-D.+Hanauthor=M.+M.+K.+Shahzadauthor=H.-S.+Kimauthor=L.+S.+Mangalaauthor=N.+B.+Jenningsauthor=S.+Maoauthor=J.+Gooyaauthor=D.+Jacksonauthor=R.+L.+Colemanauthor=A.+K.+Sood&title=EphA2+Targeted+Chemotherapy+Using+an+Antibody+Drug+Conjugate+in+Endometrial+Carcinoma&doi=10.1158%2F1078-0432.CCR-10-0017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma</span></div><div class="casAuthors">Lee, Jeong-Won; Stone, Rebecca L.; Lee, Sun Joo; Nam, Eun Ji; Roh, Ju-Won; Nick, Alpa M.; Han, Hee-Dong; Shahzad, Mian M. K.; Kim, Hye-Sun; Mangala, Lingegowda S.; Jennings, Nicholas B.; Mao, Shenlan; Gooya, John; Jackson, Dowdy; Coleman, Robert L.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2562-2570</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: EphA2 overexpression is frequently obsd. in endometrial cancers and is predictive of poor clin. outcome.  Here, we use an antibody drug conjugate (MEDI-547) composed of a fully human monoclonal antibody against both human and murine EphA2 (1C1) and the tubulin polymn. inhibitor monomethylauristatin F. Exptl. Design: EphA2 expression was examd. in endometrial cancer cell lines by Western blot.  Specificity of MEDI-547 was examd. by antibody degrdn. and internalization assays.  Viability and apoptosis were investigated in endometrial cancer cell lines and orthotopic tumor models.  RESULTS: EphA2 was expressed in the Hec-1A and Ishikawa cells but was absent in the SPEC-2 cells.  Antibody degrdn. and internalization assays showed that the antibody drug conjugate decreased EphA2 protein levels and was internalized in EphA2-pos. cells (Hec-1A and Ishikawa).  Moreover, in vitro cytotoxicity and apoptosis assays showed that the antibody drug conjugate decreased viability and increased apoptosis of Hec-1A and Ishikawa cells.  In vivo therapy expts. in mouse orthotopic models with this antibody drug conjugate resulted in 86% to 88% growth inhibition (P < 0.001) in the orthotopic Hec-1A and Ishikawa models compared with controls.  Moreover, the mice treated with this antibody drug conjugate had a lower incidence of distant metastasis compared with controls.  The antitumor effects of the therapy were related to decreased proliferation and increased apoptosis of tumor and assocd. endothelial cells.  CONCLUSIONS: The preclin. data for endometrial cancer treatment using MEDI-547 show substantial antitumor activity.  Clin Cancer Res; 16(9); 2562-70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7BtEP1K3EebVg90H21EOLACvtfcHk0li1BV4uyuKAVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlegtrY%253D&md5=3c104d9d0abbcc1240ea66eeb08bf558</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0017%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.-W.%26aulast%3DStone%26aufirst%3DR.%2BL.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DNam%26aufirst%3DE.%2BJ.%26aulast%3DRoh%26aufirst%3DJ.-W.%26aulast%3DNick%26aufirst%3DA.%2BM.%26aulast%3DHan%26aufirst%3DH.-D.%26aulast%3DShahzad%26aufirst%3DM.%2BM.%2BK.%26aulast%3DKim%26aufirst%3DH.-S.%26aulast%3DMangala%26aufirst%3DL.%2BS.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DEphA2%2520Targeted%2520Chemotherapy%2520Using%2520an%2520Antibody%2520Drug%2520Conjugate%2520in%2520Endometrial%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D9%26spage%3D2562%26epage%3D2570%26doi%3D10.1158%2F1078-0432.CCR-10-0017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1403</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fcmdc.201400067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=24677792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1403-1412&issue=7&author=E.+Barileauthor=S.+Wangauthor=S.+K.+Dasauthor=R.+Noberiniauthor=R.+Dahlauthor=J.+L.+Stebbinsauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design%2C+Synthesis+and+Bioevaluation+of+an+EphA2+Receptor-Based+Targeted+Delivery+System&doi=10.1002%2Fcmdc.201400067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System</span></div><div class="casAuthors">Barile, Elisa; Wang, Si; Das, Swadesh K.; Noberini, Roberta; Dahl, Russell; Stebbins, John L.; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1403-1412</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Because of its overexpression in a range of solid tumors, the EphA2 receptor is a validated target for cancer therapeutics.  The authors recently described a new targeted delivery system based on specific EphA2-targeting peptides conjugated with the chemotherapeutic agent paclitaxel.  Here, the chem. determinants responsible for the stability and degrdn. of these agents in plasma were investigated.  Introducing modifications in both the peptide and the linker between the peptide and paclitaxel resulted in drug conjugates that are both long-lived in rat plasma and that markedly decrease tumor size in a prostate cancer xenograft model compared with paclitaxel alone treatment.  These studies identify crit. rate-limiting degrdn. sites on the peptide-drug conjugates, enabling the design of agents with increased stability and efficacy.  These results provide support for the central hypothesis that peptide-drug conjugates targeting EphA2 represent an innovative and potentially effective strategy to selectively deliver cytotoxic drugs to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0PtVZMIpXmrVg90H21EOLACvtfcHk0liPBzzUuNXXCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D&md5=4b83eea1d0ea2ee884f003e7565eb65f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400067%26sid%3Dliteratum%253Aachs%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Bioevaluation%2520of%2520an%2520EphA2%2520Receptor-Based%2520Targeted%2520Delivery%2520System%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D7%26spage%3D1403%26epage%3D1412%26doi%3D10.1002%2Fcmdc.201400067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morvaridi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Therapy of Pancreatic Cancer via an EphA2 Receptor-Targeted Delivery of Gemcitabine</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">17103</span>– <span class="NLM_lpage">17110</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.18632%2Foncotarget.7931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=26959746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17103-17110&issue=13&author=B.+A.+Quinnauthor=S.+Wangauthor=E.+Barileauthor=S.+K.+Dasauthor=L.+Emdadauthor=D.+Sarkarauthor=S.+K.+Deauthor=S.+K.+Morvaridiauthor=J.+L.+Stebbinsauthor=S.+J.+Pandolauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Therapy+of+Pancreatic+Cancer+via+an+EphA2+Receptor-Targeted+Delivery+of+Gemcitabine&doi=10.18632%2Foncotarget.7931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span></div><div class="casAuthors">Quinn Bridget A; Das Swadesh K; Emdad Luni; Sarkar Devanand; Fisher Paul B; Wang Si; Barile Elisa; De Surya K; Stebbins John L; Fisher Paul B; Pellecchia Maurizio; Barile Elisa; De Surya K; Pellecchia Maurizio; Morvaridi Susan Kharagh; Pandol Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">17103-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.  In some patients, an active transport mechanism allows gemcitabine to enter efficiently into the tumor cells, resulting in a significant clinical benefit.  However, in most patients, low expression of gemcitabine transporters limits the efficacy of the drug to marginal levels, and patients need frequent administration of the drug at high doses, significantly increasing systemic drug toxicity.  In this article we focus on a novel targeted delivery approach for gemcitabine consisting of conjugating the drug with an EphA2 targeting agent.  We show that the EphA2 receptor is highly expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective than gemcitabine alone in targeting pancreatic tumors.  Our preliminary observations suggest that this approach may provide a general benefit to pancreatic cancer patients and offers a comprehensive strategy for enhancing delivery of diverse therapeutic agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing toxicity while enhancing therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkle74R4yp-ekdrW1FkXG-fW6udTcc2ebX56hjKvcdzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D&md5=0b5e311729fc3517d90882844ab3d3f2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7931%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMorvaridi%26aufirst%3DS.%2BK.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTherapy%2520of%2520Pancreatic%2520Cancer%2520via%2520an%2520EphA2%2520Receptor-Targeted%2520Delivery%2520of%2520Gemcitabine%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D13%26spage%3D17103%26epage%3D17110%26doi%3D10.18632%2Foncotarget.7931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udompholkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2052-2061&issue=5&author=A.+F.+Salemauthor=S.+Wangauthor=S.+Billetauthor=J.-F.+Chenauthor=P.+Udompholkulauthor=L.+Gambiniauthor=C.+Baggioauthor=H.-R.+Tsengauthor=E.+M.+Posadasauthor=N.+A.+Bhowmickauthor=M.+Pellecchia&title=Reduction+of+Circulating+Cancer+Cells+and+Metastases+in+Breast-Cancer+Models+by+a+Potent+EphA2-Agonistic+Peptide%E2%80%93Drug+Conjugate&doi=10.1021%2Facs.jmedchem.7b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate</span></div><div class="casAuthors">Salem, Ahmed F.; Wang, Si; Billet, Sandrine; Chen, Jie-Fu; Udompholkul, Parima; Gambini, Luca; Baggio, Carlo; Tseng, Hsian-Rong; Posadas, Edwin M.; Bhowmick, Neil A.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EphA2 overexpression has been assocd. with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers.  We have recently proposed the development of peptide-drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YSA peptide or its optimized version, 123B9.  Although our studies indicated that YSA- and 123B9-drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concns. required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic.  Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concns.  Furthermore, we demonstrated that the conjugation of dimeric 123B9 with paclitaxel is very effective at targeting circulating tumor cells and inhibiting lung metastasis in breast-cancer models.  These studies represent an important step toward the development of effective EphA2-targeting PDCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBQLb1QD1aSrVg90H21EOLACvtfcHk0liPBzzUuNXXCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D&md5=a03f5dbbc9030174487353d42332b3ab</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01837%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DA.%2BF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DUdompholkul%26aufirst%3DP.%26aulast%3DGambini%26aufirst%3DL.%26aulast%3DBaggio%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DH.-R.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DReduction%2520of%2520Circulating%2520Cancer%2520Cells%2520and%2520Metastases%2520in%2520Breast-Cancer%2520Models%2520by%2520a%2520Potent%2520EphA2-Agonistic%2520Peptide%25E2%2580%2593Drug%2520Conjugate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2052%26epage%3D2061%26doi%3D10.1021%2Facs.jmedchem.7b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1021/jm201743s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201743s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2427-2436&issue=5&author=S.+Wangauthor=W.+J.+Placzekauthor=J.+L.+Stebbinsauthor=S.+Mitraauthor=R.+Noberiniauthor=M.+Koolpeauthor=Z.+Zhangauthor=R.+Dahlauthor=E.+B.+Pasqualeauthor=M.+Pellecchia&title=Novel+Targeted+System+To+Deliver+Chemotherapeutic+Drugs+to+EphA2-Expressing+Cancer+Cells&doi=10.1021%2Fjm201743s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Placzek, William J.; Stebbins, John L.; Mitra, Sayantan; Noberini, Roberta; Koolpe, Mitchell; Zhang, Ziming; Dahl, Russell; Pasquale, Elena B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2427-2436</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects.  We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors.  Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel.  We found that the peptide-drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site.  We believe these studies open the way to the development of a new class of therapeutic compds. that exploit the EphA2 receptor for drug delivery to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pu5ES26uUrVg90H21EOLACvtfcHk0ljmLOnjRv-Yeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D&md5=3835d4051c60b26e126da69b9b7510ca</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201743s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201743s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPlaczek%26aufirst%3DW.%2BJ.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DNovel%2520Targeted%2520System%2520To%2520Deliver%2520Chemotherapeutic%2520Drugs%2520to%2520EphA2-Expressing%2520Cancer%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D5%26spage%3D2427%26epage%3D2436%26doi%3D10.1021%2Fjm201743s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazenbaker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamynathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiener, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In Vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9367</span>– <span class="NLM_lpage">9374</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F0008-5472.CAN-08-1933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19010911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9367-9374&issue=22&author=D.+Jacksonauthor=J.+Gooyaauthor=S.+Maoauthor=K.+Kinneerauthor=L.+Xuauthor=M.+Camaraauthor=C.+Fazenbakerauthor=R.+Flemingauthor=S.+Swamynathanauthor=D.+Meyerauthor=P.+D.+Senterauthor=C.+Gaoauthor=H.+Wuauthor=M.+Kinchauthor=S.+Coatsauthor=P.+A.+Kienerauthor=D.+A.+Tice&title=A+Human+Antibody%E2%80%93Drug+Conjugate+Targeting+EphA2+Inhibits+Tumor+Growth+In+Vivo&doi=10.1158%2F0008-5472.CAN-08-1933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo</span></div><div class="casAuthors">Jackson, Dowdy; Gooya, John; Mao, Shenlan; Kinneer, Krista; Xu, Linda; Camara, Margarita; Fazenbaker, Christine; Fleming, Ryan; Swamynathan, Sudha; Meyer, Damon; Senter, Peter D.; Gao, Changshou; Wu, Herren; Kinch, Michael; Coats, Steven; Kiener, Peter A.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9367-9374</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase is selectively expressed on the surface of many different human tumors.  We have previously shown that tumor cells can be targeted by EphA2 monoclonal antibodies and that these antibodies function, in part, by inducing EphA2 internalization and degrdn.  In this report, we describe the isolation and characterization of a fully human monoclonal antibody (1C1) that selectively binds both the human and rodent EphA2 receptor.  After cell binding, the antibody induces rapid tyrosine phosphorylation, internalization, and degrdn. of the EphA2 receptor.  Because monoclonal antibodies that selectively bind tumor cells and internalize provide a vehicle for targeted delivery of cytotoxics, 1C1 was conjugated to the microtubule inhibitor monomethylauristatin phenylalanine using a stable maleimidocaproyl linker.  The anti-EphA2 antibody-drug conjugate [1C1-maleimidocaproyl-MMAF (mcMMAF)] stimulated the activation of caspase-3/caspase-7 and the death of EphA2-expressing cells with IC50 values as low as 3 ng/mL.  Similarly, the conjugate induced degrdn. of the EphA2 receptor and inhibited tumor growth in vivo.  Administration of 1C1-mcMMAF at doses as low as 1 mg/kg once weekly resulted in significant growth inhibition of EphA2-expressing tumors without any observable adverse effects in mouse xenograft and rat syngeneic tumor models.  Our data support the use of an antibody-drug conjugate approach to selectively target and inhibit the growth of EphA2-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC1fbfPqDzS7Vg90H21EOLACvtfcHk0ljmLOnjRv-Yeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK&md5=1e17e48422e5fc318773fd1de578ac16</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1933%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCamara%26aufirst%3DM.%26aulast%3DFazenbaker%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DR.%26aulast%3DSwamynathan%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DCoats%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DA%2520Human%2520Antibody%25E2%2580%2593Drug%2520Conjugate%2520Targeting%2520EphA2%2520Inhibits%2520Tumor%2520Growth%2520In%2520Vivo%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9367%26epage%3D9374%26doi%3D10.1158%2F0008-5472.CAN-08-1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziata, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzoianu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechleider, R.</span></span> <span> </span><span class="NLM_article-title">Phase 1, Open-Label Study of MEDI-547 in Patients with Relapsed or Refractory Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9801-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1007%2Fs10637-012-9801-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=22370972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=77-84&issue=1&author=C.+M.+Annunziataauthor=E.+C.+Kohnauthor=P.+LoRussoauthor=N.+D.+Houstonauthor=R.+L.+Colemanauthor=M.+Buzoianuauthor=G.+Robbieauthor=R.+Lechleider&title=Phase+1%2C+Open-Label+Study+of+MEDI-547+in+Patients+with+Relapsed+or+Refractory+Solid+Tumors&doi=10.1007%2Fs10637-012-9801-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors</span></div><div class="casAuthors">Annunziata, Christina M.; Kohn, Elise C.; LoRusso, Patricia; Houston, Nicole D.; Coleman, Robert L.; Buzoianu, Manuela; Robbie, Gabriel; Lechleider, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy.  We aimed to evaluate the safety profile, max. tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate composed of the cytotoxic drug auristatin (toxin) linked to a human anti-EphA2 monoclonal antibody (1C1), in patients with solid tumors relapsed/refractory to std. therapy.  Methods: In this phase 1, open-label study with planned dose-escalation and dose-expansion cohorts, patients received a 1-h i.v. infusion of MEDI-547 (0.08 mg/kg) every 3 wk.  Results: Six patients received 0.08 mg/kg; all discontinued treatment.  Dose escalation was not pursued.  The study was stopped before cohort 2 enrollment due to treatment-related bleeding and coagulation events (hemorrhage-related, n = 3; epistaxis, n = 2).  Therefore, lower doses were not explored and an MTD could not be selected.  The most frequently reported treatment-related adverse events (AEs) were increased liver enzymes, decreased Hb, decreased appetite, and epistaxis.  Three patients (50%) experienced treatment-related serious AEs, including conjunctival hemorrhage, pain (led to study drug discontinuation), liver disorder, and hemorrhage.  Best response included progressive disease (n = 5; 83.3%) and stable disease (n = 1; 16.7%).  Minimal or no dissocn. of toxin from 1C1 conjugate occurred in the blood.  Serum MEDI-547 concns. decreased rapidly, ∼70% by 3 days post-dose.  No accumulation of MEDI-547 was obsd. at 0.08 mg/kg upon administration of a second dose 3 wk following dose 1.  Conclusions: The safety profile of MEDI-547 does not support further clin. investigation in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRCw89EUGfabVg90H21EOLACvtfcHk0lh1rPKPcJk7zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D&md5=9af486f7c7287d8c150dade6baaf45b6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9801-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9801-2%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziata%26aufirst%3DC.%2BM.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DHouston%26aufirst%3DN.%2BD.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DBuzoianu%26aufirst%3DM.%26aulast%3DRobbie%26aufirst%3DG.%26aulast%3DLechleider%26aufirst%3DR.%26atitle%3DPhase%25201%252C%2520Open-Label%2520Study%2520of%2520MEDI-547%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26issue%3D1%26spage%3D77%26epage%3D84%26doi%3D10.1007%2Fs10637-012-9801-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span> <span> </span><span class="NLM_article-title">Abstract 5854: BT5528, a Bicycle Toxin Conjugate Targeting EphA2 Has Potent Anti-Tumor Activity without Bleeding or Coagulation Abnormalities in Preclinical Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">13 Supplement</span>),  <span class="NLM_fpage">5854</span>– <span class="NLM_lpage">5854</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-5854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1538-7445.AM2018-5854" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5854-5854&issue=13+Supplement&author=G.+Bennettauthor=P.+Huxleyauthor=A.+Brownauthor=G.+Muddauthor=P.+U.+Parkauthor=N.+Keen&title=Abstract+5854%3A+BT5528%2C+a+Bicycle+Toxin+Conjugate+Targeting+EphA2+Has+Potent+Anti-Tumor+Activity+without+Bleeding+or+Coagulation+Abnormalities+in+Preclinical+Models&doi=10.1158%2F1538-7445.AM2018-5854"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-5854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-5854%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DKeen%26aufirst%3DN.%26atitle%3DAbstract%25205854%253A%2520BT5528%252C%2520a%2520Bicycle%2520Toxin%2520Conjugate%2520Targeting%2520EphA2%2520Has%2520Potent%2520Anti-Tumor%2520Activity%2520without%2520Bleeding%2520or%2520Coagulation%2520Abnormalities%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D13%2520Supplement%26spage%3D5854%26epage%3D5854%26doi%3D10.1158%2F1538-7445.AM2018-5854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahdenranta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span> <span> </span><span class="NLM_article-title">Abstract 4481: BT5528, an EphA2-Targeting Bicycle Toxin Conjugate (BTC): Profound Efficacy without Bleeding and Coagulation Abnormalities in Animal Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13 Supplement</span>),  <span class="NLM_fpage">4481</span>– <span class="NLM_lpage">4481</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1538-7445.AM2019-4481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4481-4481&issue=13+Supplement&author=G.+S.+Bennettauthor=A.+Brownauthor=G.+Muddauthor=J.+Lahdenrantaauthor=N.+Keen&title=Abstract+4481%3A+BT5528%2C+an+EphA2-Targeting+Bicycle+Toxin+Conjugate+%28BTC%29%3A+Profound+Efficacy+without+Bleeding+and+Coagulation+Abnormalities+in+Animal+Models&doi=10.1158%2F1538-7445.AM2019-4481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4481%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%2BS.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DLahdenranta%26aufirst%3DJ.%26aulast%3DKeen%26aufirst%3DN.%26atitle%3DAbstract%25204481%253A%2520BT5528%252C%2520an%2520EphA2-Targeting%2520Bicycle%2520Toxin%2520Conjugate%2520%2528BTC%2529%253A%2520Profound%2520Efficacy%2520without%2520Bleeding%2520and%2520Coagulation%2520Abnormalities%2520in%2520Animal%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%2520Supplement%26spage%3D4481%26epage%3D4481%26doi%3D10.1158%2F1538-7445.AM2019-4481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahdenranta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span> <span> </span><span class="NLM_article-title">Abstract C066: BT5528, a Bicycle Toxin Conjugate Targeting EphA2: Mechanism of Action and Clinical Translation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12 Supplement</span>),  <span class="NLM_fpage">C066</span>– <span class="NLM_lpage">C066</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1538-7445.AM2019-4481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=C066-C066&issue=12+Supplement&author=G.+Bennettauthor=A.+Brownauthor=G.+Muddauthor=J.+Lahdenrantaauthor=N.+Keen&title=Abstract+C066%3A+BT5528%2C+a+Bicycle+Toxin+Conjugate+Targeting+EphA2%3A+Mechanism+of+Action+and+Clinical+Translation&doi=10.1158%2F1538-7445.AM2019-4481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4481%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DLahdenranta%26aufirst%3DJ.%26aulast%3DKeen%26aufirst%3DN.%26atitle%3DAbstract%2520C066%253A%2520BT5528%252C%2520a%2520Bicycle%2520Toxin%2520Conjugate%2520Targeting%2520EphA2%253A%2520Mechanism%2520of%2520Action%2520and%2520Clinical%2520Translation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26issue%3D12%2520Supplement%26spage%3DC066%26epage%3DC066%26doi%3D10.1158%2F1538-7445.AM2019-4481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dail, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">46974</span>– <span class="NLM_lpage">46979</span>, <span class="refDoi"> DOI: 10.1074/jbc.M208495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1074%2Fjbc.M208495200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=12351647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFSksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46974-46979&issue=49&author=M.+Koolpeauthor=M.+Dailauthor=E.+B.+Pasquale&title=An+Ephrin+Mimetic+Peptide+That+Selectively+Targets+the+EphA2+Receptor&doi=10.1074%2Fjbc.M208495200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor</span></div><div class="casAuthors">Koolpe, Mitchell; Dail, Monique; Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">46974-46979</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases represent promising disease targets because they are differentially expressed in pathol. vs. normal tissues.  The EphA2 receptor is up-regulated in transformed cells and tumor vasculature where it likely contributes to cancer pathogenesis.  To exploit EphA2 as a therapeutic target, the authors used phage display to identify two related peptides that bind selectively to EphA2 with high affinity (submicromolar KD values).  The peptides target the ligand-binding domain of EphA2 and compete with ephrin ligands for binding.  Remarkably, one of the peptides has ephrin-like activity in that it stimulates EphA2 tyrosine phosphorylation and signaling.  Furthermore, this peptide can deliver phage particles to endothelial and tumor cells expressing EphA2.  In contrast, peptides corresponding to receptor-interacting portions of ephrin ligands bind weakly and promiscuously to many Eph receptors.  Bioactive ephrin mimetic peptides could be used to selectively deliver agents to Eph receptor-expressing tissues and modify Eph signaling in therapies for cancer, pathol. angiogenesis, and nerve regeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7htYrrvzjzbVg90H21EOLACvtfcHk0lh1rPKPcJk7zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFSksLc%253D&md5=edc49f9be61235b27420735e3697f5d7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M208495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M208495200%26sid%3Dliteratum%253Aachs%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DDail%26aufirst%3DM.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DAn%2520Ephrin%2520Mimetic%2520Peptide%2520That%2520Selectively%2520Targets%2520the%2520EphA2%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D49%26spage%3D46974%26epage%3D46979%26doi%3D10.1074%2Fjbc.M208495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuweiler, H.</span></span> <span> </span><span class="NLM_article-title">Backbone-Driven Collapse in Unfolded Protein Chains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>409</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2011.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1016%2Fj.jmb.2011.03.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=21497607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2011&pages=250-262&issue=2&author=D.+P.+Teufelauthor=C.+M.+Johnsonauthor=J.+K.+Lumauthor=H.+Neuweiler&title=Backbone-Driven+Collapse+in+Unfolded+Protein+Chains&doi=10.1016%2Fj.jmb.2011.03.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Backbone-Driven Collapse in Unfolded Protein Chains</span></div><div class="casAuthors">Teufel, Daniel P.; Johnson, Christopher M.; Lum, Jenifer K.; Neuweiler, Hannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-262</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Collapse of unfolded protein chains is an early event in folding.  It affects structural properties of intrinsically disordered proteins (IDPs), which take up a considerable fraction of the human proteome.  Collapse is generally believed to be driven by hydrophobic forces imposed by the presence of nonpolar amino acid side chains.  Contributions from backbone hydrogen bonds to protein folding and stability, however, are controversial.  To date, the exptl. dissection of side-chain and backbone contributions has not yet been achieved because both types of interactions are integral parts of protein structure.  Here, we realized this goal by applying mutagenesis and chem. modification on a set of disordered peptides and proteins.  We measured the protein dimensions and kinetics of intra-chain diffusion of modified polypeptides at the level of individual mols. using fluorescence correlation spectroscopy (FCS), thereby avoiding artifacts commonly caused by aggregation of unfolded protein material in bulk.  We found no contributions from side chains to collapse, but instead, identified backbone interactions as a source sufficient to form globules of native-like dimensions.  The presence of backbone hydrogen bonds decreased polypeptide water soly. dramatically and accelerated the nanosecond kinetics of loop closure, in agreement with recent predictions from computer simulation.  The presence of side chains, instead, slowed loop closure and modulated the dimensions of intrinsically disordered domains.  It appeared that the transient formation of backbone interactions facilitates the diffusive search for productive conformations at the early stage of folding and within intrinsically disordered proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCa-Q7pukl7bVg90H21EOLACvtfcHk0lh1rPKPcJk7zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D&md5=c8bcdbf4dbc91f7afe960d2aa7cf6024</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2011.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2011.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DLum%26aufirst%3DJ.%2BK.%26aulast%3DNeuweiler%26aufirst%3DH.%26atitle%3DBackbone-Driven%2520Collapse%2520in%2520Unfolded%2520Protein%2520Chains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D409%26issue%3D2%26spage%3D250%26epage%3D262%26doi%3D10.1016%2Fj.jmb.2011.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bargh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidro-Llobet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cleavable Linkers in Antibody–Drug Conjugates</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4361</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/C8CS00676H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1039%2FC8CS00676H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=31294429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=4361-4374&issue=16&author=J.+D.+Barghauthor=A.+Isidro-Llobetauthor=J.+S.+Parkerauthor=D.+R.+Spring&title=Cleavable+Linkers+in+Antibody%E2%80%93Drug+Conjugates&doi=10.1039%2FC8CS00676H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cleavable linkers in antibody-drug conjugates</span></div><div class="casAuthors">Bargh, Jonathan D.; Isidro-Llobet, Albert; Parker, Jeremy S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4361-4374</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clin. treatment of cancer.  The properties of the linker between the antibody and the payload are proven to be crit. to the success of an ADC.  Although ADC linkers can be 'non-cleavable', the vast majority of ADCs in clin. development have specific release mechanisms to allow controlled linker cleavage at the target site and are thus termed 'cleavable'.  In recent years, the development of new methods of drug release from ADCs has continued in parallel to the deepening understanding of the biol. processes underlying the mechanisms of action of pre-existing technologies.  This review summarises the advances in the field of cleavable linker technologies for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG2Xk9IvLpLVg90H21EOLACvtfcHk0lhTA3YFWyeAnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M&md5=bc73619319b21c2b85e3d613ca72f778</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2FC8CS00676H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00676H%26sid%3Dliteratum%253Aachs%26aulast%3DBargh%26aufirst%3DJ.%2BD.%26aulast%3DIsidro-Llobet%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCleavable%2520Linkers%2520in%2520Antibody%25E2%2580%2593Drug%2520Conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26issue%3D16%26spage%3D4361%26epage%3D4374%26doi%3D10.1039%2FC8CS00676H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koshikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabeshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiki, M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3327</span>– <span class="NLM_lpage">3339</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F0008-5472.CAN-14-2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=26130649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlequ7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=3327-3339&issue=16&author=N.+Koshikawaauthor=D.+Hoshinoauthor=H.+Taniguchiauthor=T.+Minegishiauthor=T.+Tomariauthor=S.-O.+Namauthor=M.+Aokiauthor=T.+Suetaauthor=T.+Nakagawaauthor=S.+Miyamotoauthor=K.+Nabeshimaauthor=A.+M.+Weaverauthor=M.+Seiki&title=Proteolysis+of+EphA2+Converts+It+from+a+Tumor+Suppressor+to+an+Oncoprotein&doi=10.1158%2F0008-5472.CAN-14-2798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein</span></div><div class="casAuthors">Koshikawa, Naohiko; Hoshino, Daisuke; Taniguchi, Hiroaki; Minegishi, Tomoko; Tomari, Taizo; Nam, Sung-Ouk; Aoki, Mikiko; Sueta, Takayuki; Nakagawa, Takashi; Miyamoto, Shingo; Nabeshima, Kazuki; Weaver, Alissa M.; Seiki, Motoharu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3327-3339</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases are considered candidate therapeutic targets in cancer, but they can exert opposing effects on cell growth.  In the presence of its ligands, Eph receptor EphA2 suppresses signaling by other growth factor receptors, including ErbB, whereas ligand-independent activation of EphA2 augments ErbB signaling.  To deploy EphA2-targeting drugs effectively in tumors, the anti-oncogenic ligand-dependent activation state of EphA2 must be discriminated from its oncogenic ligand-independent state.  Because the mol. basis for the latter is little understood, we investigated how the activation state of EphA2 can be switched in tumor tissue.  We found that ligand-binding domain of EphA2 is cleaved frequently by the membrane metalloproteinase MT1-MMP, a powerful modulator of the pericellular environment in tumor cells.  EphA2 immunostaining revealed a significant loss of the N-terminal portion of EphA2 in areas of tumor tissue that expressed MT1-MMP.  Moreover, EphA2 phosphorylation patterns that signify ligand-independent activation were obsd. specifically in these areas of tumor tissue.  Mechanistic expts. revealed that processing of EphA2 by MT1-MMP promoted ErbB signaling, anchorage-independent growth, and cell migration.  Conversely, expression of a proteolysis-resistant mutant of EphA2 prevented tumorigenesis and metastasis of human tumor xenografts in mice.  Overall, our results showed how the proteolytic state of EphA2 in tumors dets. its effector function and influences its status as a candidate biomarker for targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZcTaPxJAfBLVg90H21EOLACvtfcHk0lhTA3YFWyeAnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlequ7rF&md5=01a18af9811bb8517a7242b3321c2b5b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2798%26sid%3Dliteratum%253Aachs%26aulast%3DKoshikawa%26aufirst%3DN.%26aulast%3DHoshino%26aufirst%3DD.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DMinegishi%26aufirst%3DT.%26aulast%3DTomari%26aufirst%3DT.%26aulast%3DNam%26aufirst%3DS.-O.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DSueta%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DNabeshima%26aufirst%3DK.%26aulast%3DWeaver%26aufirst%3DA.%2BM.%26aulast%3DSeiki%26aufirst%3DM.%26atitle%3DProteolysis%2520of%2520EphA2%2520Converts%2520It%2520from%2520a%2520Tumor%2520Suppressor%2520to%2520an%2520Oncoprotein%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D16%26spage%3D3327%26epage%3D3339%26doi%3D10.1158%2F0008-5472.CAN-14-2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabuka, D.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1007/s40259-017-0254-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1007%2Fs40259-017-0254-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=29119409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ptlyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=521-531&issue=6&author=P.+M.+Drakeauthor=D.+Rabuka&title=Recent+Developments+in+ADC+Technology%3A+Preclinical+Studies+Signal+Future+Clinical+Trends&doi=10.1007%2Fs40259-017-0254-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends</span></div><div class="casAuthors">Drake Penelope M; Rabuka David</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">521-531</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The antibody-drug conjugate (ADC) field is in a transitional period.  Older approaches to conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but preclinical work is driving a rapid evolution in how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes.  These advances are largely based upon a body of investigational studies that together offer a deeper understanding of the absorption, distribution, metabolism, and excretion (ADME) and drug metabolism and pharmacokinetics (DMPK) fates of both the intact conjugate and its small-molecule component.  Knowing where the drug goes and how it is processed allows mechanistic connections to be drawn with commonly observed clinical toxicities.  The field is also starting to consider ADC interactions with the immune system and potential synergistic therapeutic opportunities therein.  In an indication of future directions for the field, antibody conjugates bearing non-cytotoxic small-molecule payloads are being developed to reduce side effects associated with treatment of chronic diseases.  ADCs are not a magic bullet to cure disease.  However, they will increasingly become valuable therapeutic tools to improve patient outcomes across a variety of indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS62B7fDJCL1bjnyZkbE8yXfW6udTcc2eZhTiljjo3dabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ptlyksg%253D%253D&md5=7f4cb76c7c59c0524a2511c72cf82cc4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs40259-017-0254-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-017-0254-1%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DP.%2BM.%26aulast%3DRabuka%26aufirst%3DD.%26atitle%3DRecent%2520Developments%2520in%2520ADC%2520Technology%253A%2520Preclinical%2520Studies%2520Signal%2520Future%2520Clinical%2520Trends%26jtitle%3DBioDrugs%26date%3D2017%26volume%3D31%26issue%3D6%26spage%3D521%26epage%3D531%26doi%3D10.1007%2Fs40259-017-0254-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Peptide Ligands Stabilized by Small Molecules</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1602</span>– <span class="NLM_lpage">1606</span>, <span class="refDoi"> DOI: 10.1002/anie.201309459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fanie.201309459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1602-1606&issue=6&author=S.+Chenauthor=D.+Bertoldoauthor=A.+Angeliniauthor=F.+Pojerauthor=C.+Heinis&title=Peptide+Ligands+Stabilized+by+Small+Molecules&doi=10.1002%2Fanie.201309459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Ligands Stabilized by Small Molecules</span></div><div class="casAuthors">Chen, Shiyu; Bertoldo, Davide; Angelini, Alessandro; Pojer, Florence; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1602-1606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicyclic peptides generated through directed evolution by using phage display offer an attractive ligand format for the development of therapeutics.  Being nearly 100-fold smaller than antibodies, they promise advantages such as access to chem. synthesis, efficient diffusion into tissues, and needle-free application.  However, unlike antibodies, they do not have a folded structure in soln. and thus do not bind as well as antibodies.  We developed bicyclic peptides with hydrophilic chem. structures at their center to promote noncovalent intramol. interactions, thereby stabilizing the peptide conformation.  The sequences of the peptides isolated by phage display from large combinatorial libraries were strongly influenced by the type of small mol. used in the screen, thus suggesting that the peptides fold around the small mols.  X-ray structure anal. revealed that the small mols. indeed formed hydrogen bonds with the peptides.  These noncovalent interactions stabilize the peptide-protein complexes and contribute to the high binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-9uyjWceNrVg90H21EOLACvtfcHk0lhAaRF1y1EnDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D&md5=4bc852345c54171bd8c7143a563bba2b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fanie.201309459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201309459%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DAngelini%26aufirst%3DA.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520Ligands%2520Stabilized%2520by%2520Small%2520Molecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26issue%3D6%26spage%3D1602%26epage%3D1606%26doi%3D10.1002%2Fanie.201309459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seiradake, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aricescu, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span> <span> </span><span class="NLM_article-title">An Extracellular Steric Seeding Mechanism for Eph-Ephrin Signaling Platform Assembly</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">398</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1038%2Fnsmb.1782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20228801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFynurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=398&author=E.+Seiradakeauthor=K.+Harlosauthor=G.+Suttonauthor=A.+R.+Aricescuauthor=E.+Y.+Jones&title=An+Extracellular+Steric+Seeding+Mechanism+for+Eph-Ephrin+Signaling+Platform+Assembly&doi=10.1038%2Fnsmb.1782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly</span></div><div class="casAuthors">Seiradake, Elena; Harlos, Karl; Sutton, Geoff; Aricescu, A. Radu; Jones, E. Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-402</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Erythropoetin-producing hepatoma (Eph) receptors are cell-surface protein tyrosine kinases mediating cell-cell communication.  Upon activation, they form signaling clusters.  We report crystal structures of the full ectodomain of human EphA2 (eEphA2) both alone and in complex with the receptor-binding domain of the ligand ephrinA5 (ephrinA5 RBD).  Unliganded eEphA2 forms linear arrays of staggered parallel receptors involving two patches of residues conserved across A-class Ephs.  EEphA2-ephrinA5 RBD forms a more elaborate assembly, whose interfaces include the same conserved regions on eEphA2, but rearranged to accommodate ephrinA5 RBD.  Cell-surface expression of mutant EphA2s showed that these interfaces are crit. for localization at cell-cell contacts and activation-dependent degrdn.  Our results suggest a 'nucleation' mechanism whereby a limited no. of ligand-receptor interactions 'seed' an arrangement of receptors which can propagate into extended signaling arrays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ4pkdiRR_hrVg90H21EOLACvtfcHk0lhAaRF1y1EnDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFynurY%253D&md5=8a52fc59122e9974ad56665dc98f6ff6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1782%26sid%3Dliteratum%253Aachs%26aulast%3DSeiradake%26aufirst%3DE.%26aulast%3DHarlos%26aufirst%3DK.%26aulast%3DSutton%26aufirst%3DG.%26aulast%3DAricescu%26aufirst%3DA.%2BR.%26aulast%3DJones%26aufirst%3DE.%2BY.%26atitle%3DAn%2520Extracellular%2520Steric%2520Seeding%2520Mechanism%2520for%2520Eph-Ephrin%2520Signaling%2520Platform%2520Assembly%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D398%26doi%3D10.1038%2Fnsmb.1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Himanen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yermekbayeva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atapattu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajashankar, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensinga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolov, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span> <span> </span><span class="NLM_article-title">Architecture of Eph Receptor Clusters</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10860</span>– <span class="NLM_lpage">10865</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004148107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1073%2Fpnas.1004148107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20505120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVKqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=10860-10865&issue=24&author=J.+P.+Himanenauthor=L.+Yermekbayevaauthor=P.+W.+Janesauthor=J.+R.+Walkerauthor=K.+Xuauthor=L.+Atapattuauthor=K.+R.+Rajashankarauthor=A.+Mensingaauthor=M.+Lackmannauthor=D.+B.+Nikolovauthor=S.+Dhe-Paganon&title=Architecture+of+Eph+Receptor+Clusters&doi=10.1073%2Fpnas.1004148107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Architecture of Eph receptor clusters</span></div><div class="casAuthors">Himanen, Juha R.; Yermekbayeva, Laila; Janes, Peter W.; Walker, John R.; Xu, Kai; Atapattu, Lakmali; Rajashankar, Kanagalaghatta R.; Mensinga, Anneloes; Lackmann, Martin; Nikolov, Dimitar B.; Dhe-Paganon, Sirano</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10860-10865, S10860/1-S10860/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases and their ephrin ligands regulate cell navigation during normal and oncogenic development.  Signaling of Ephs is initiated in a multistep process leading to the assembly of higher-order signaling clusters that set off bidirectional signaling in interacting cells.  However, the structural and mechanistic details of this assembly remained undefined.  Here the authors present high-resoln. structures of the complete EphA2 ectodomain and complexes with ephrin-A1 and A5 as the base unit of an Eph cluster.  The structures reveal an elongated architecture with novel Eph/Eph interactions, both within and outside of the Eph ligand-binding domain, that suggest the mol. mechanism underlying Eph/ephrin clustering.  Structure-function anal., by using site-directed mutagenesis and cell-based signaling assays, confirms the importance of the identified oligomerization interfaces for Eph clustering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCSVR5p8gBeLVg90H21EOLACvtfcHk0lhAaRF1y1EnDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVKqurs%253D&md5=d978be292357c62bffe2794822ef03d9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004148107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004148107%26sid%3Dliteratum%253Aachs%26aulast%3DHimanen%26aufirst%3DJ.%2BP.%26aulast%3DYermekbayeva%26aufirst%3DL.%26aulast%3DJanes%26aufirst%3DP.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DAtapattu%26aufirst%3DL.%26aulast%3DRajashankar%26aufirst%3DK.%2BR.%26aulast%3DMensinga%26aufirst%3DA.%26aulast%3DLackmann%26aufirst%3DM.%26aulast%3DNikolov%26aufirst%3DD.%2BB.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DArchitecture%2520of%2520Eph%2520Receptor%2520Clusters%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D24%26spage%3D10860%26epage%3D10865%26doi%3D10.1073%2Fpnas.1004148107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova-Berndt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, D.</span></span> <span> </span><span class="NLM_article-title">Application of Biomimetic HPLC to Estimate Lipophilicity, Protein and Phospholipid Binding of Potential Peptide Therapeutics</span>. <i>ADMET DMPK</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.5599/admet.544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.5599%2Fadmet.544" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=162-175&issue=2&author=K.+Valkoauthor=G.+Ivanova-Berndtauthor=P.+Beswickauthor=M.+Kindeyauthor=D.+Ko&title=Application+of+Biomimetic+HPLC+to+Estimate+Lipophilicity%2C+Protein+and+Phospholipid+Binding+of+Potential+Peptide+Therapeutics&doi=10.5599%2Fadmet.544"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.5599%2Fadmet.544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5599%252Fadmet.544%26sid%3Dliteratum%253Aachs%26aulast%3DValko%26aufirst%3DK.%26aulast%3DIvanova-Berndt%26aufirst%3DG.%26aulast%3DBeswick%26aufirst%3DP.%26aulast%3DKindey%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DD.%26atitle%3DApplication%2520of%2520Biomimetic%2520HPLC%2520to%2520Estimate%2520Lipophilicity%252C%2520Protein%2520and%2520Phospholipid%2520Binding%2520of%2520Potential%2520Peptide%2520Therapeutics%26jtitle%3DADMET%2520DMPK%26date%3D2018%26volume%3D6%26issue%3D2%26spage%3D162%26epage%3D175%26doi%3D10.5599%2Fadmet.544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gfeller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buth, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiman, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1322</span>, <span class="refDoi"> DOI: 10.1002/cbic.201300228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fcbic.201300228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=23828687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1316-1322&issue=11&author=S.+Chenauthor=D.+Gfellerauthor=S.+A.+Buthauthor=O.+Michielinauthor=P.+G.+Leimanauthor=C.+Heinis&title=Improving+Binding+Affinity+and+Stability+of+Peptide+Ligands+by+Substituting+Glycines+with+D-Amino+Acids&doi=10.1002%2Fcbic.201300228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span></div><div class="casAuthors">Chen, Shiyu; Gfeller, David; Buth, Sergey A.; Michielin, Olivier; Leiman, Petr G.; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1316-1322</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Improving the binding affinity and/or stability of peptide ligands often requires testing of large nos. of variants to identify beneficial mutations.  Herein we propose a type of mutation that promises a high success rate.  In a bicyclic peptide inhibitor of the cancer-related protease urokinase-type plasminogen activator (uPA), we obsd. a glycine residue that has a pos. .vphi. dihedral angle when bound to the target.  We hypothesized that replacing it with a D-amino acid, which favors pos. .vphi. angles, could enhance the binding affinity and/or proteolytic resistance.  Mutation of this specific glycine to D-serine in the bicyclic peptide indeed improved inhibitory activity (1.75-fold) and stability (fourfold).  X-ray-structure anal. of the inhibitors in complex with uPA showed that the peptide backbone conformation was conserved.  Anal. of known cyclic peptide ligands showed that glycine is one of the most frequent amino acids, and that glycines with pos. .vphi. angles are found in many protein-bound peptides.  These results suggest that the glycine-to-D-amino acid mutagenesis strategy could be broadly applied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSvU_PyOWh77Vg90H21EOLACvtfcHk0ljfCJAXzTECWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL&md5=e9ddaa6e0dfe2004d2ed52805ad18835</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201300228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201300228%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGfeller%26aufirst%3DD.%26aulast%3DButh%26aufirst%3DS.%2BA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DLeiman%26aufirst%3DP.%2BG.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DImproving%2520Binding%2520Affinity%2520and%2520Stability%2520of%2520Peptide%2520Ligands%2520by%2520Substituting%2520Glycines%2520with%2520D-Amino%2520Acids%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26issue%3D11%26spage%3D1316%26epage%3D1322%26doi%3D10.1002%2Fcbic.201300228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tugyi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iván, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecz, F.</span></span> <span> </span><span class="NLM_article-title">Partial D-Amino Acid Substitution: Improved Enzymatic Stability and Preserved Ab Recognition of a MUC2 Epitope Peptide</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1073/pnas.0407677102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1073%2Fpnas.0407677102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=15630090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=413-418&issue=2&author=R.+Tugyiauthor=K.+Urayauthor=D.+Iv%C3%A1nauthor=E.+Fellingerauthor=A.+Perkinsauthor=F.+Hudecz&title=Partial+D-Amino+Acid+Substitution%3A+Improved+Enzymatic+Stability+and+Preserved+Ab+Recognition+of+a+MUC2+Epitope+Peptide&doi=10.1073%2Fpnas.0407677102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide</span></div><div class="casAuthors">Tugyi, Regina; Uray, Katalin; Ivan, Dora; Fellinger, Erzsebet; Perkins, Alan; Hudecz, Ferenc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-418</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The stability of an immunogen against enzymic degrdn. is considered an important factor for the design of synthetic vaccines.  For our studies, we have selected an epitope from the tandem-repeat unit of the high-mol.-wt. MUC2 mucin glycoprotein, which can be underglycosylated in case of colon cancer.  In this study, we prepd. a MUC2 peptide contg. the PTGTQ epitope of a MUC2 protein backbone-specific mAb 996 and its derivs.  In these peptides, the N- and C-terminal flanking regions were systematically substituted by up to three D-amino acids.  Peptides prepd. by solid-phase synthesis were tested for their mAb 996 binding in competitive ELISA expts., and their stability was studied in serum and lysosomal prepn.  Our data show that the epitope function of peptide 15TPTPTGTQTPT25 is retained even in the presence of two D-amino acid residues at its N-terminal flanking region and up to three at its C-terminal flanking region (tpTPTGTQtpt).  Also, this partly D peptide shows high resistance against proteolytic degrdn. in dild. human serum and in lysosomal prepn.  These findings suggest that, by appropriate combination of structural modifications (namely, D-amino acid substitution) in the flanks of an Ab epitope, it is feasible to construct a synthetic antigen with preserved recognition properties and high stability against enzymic degrdn.  Peptides tPTPTGTQTpt and tpTPTGTQTpt derived from this study can be used for immunization expts. and as potential components of synthetic vaccines for tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1MtlZFnf6a7Vg90H21EOLACvtfcHk0ljfCJAXzTECWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D&md5=aa80020d0dcf9d18d18775fcf77b050a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0407677102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0407677102%26sid%3Dliteratum%253Aachs%26aulast%3DTugyi%26aufirst%3DR.%26aulast%3DUray%26aufirst%3DK.%26aulast%3DIv%25C3%25A1n%26aufirst%3DD.%26aulast%3DFellinger%26aufirst%3DE.%26aulast%3DPerkins%26aufirst%3DA.%26aulast%3DHudecz%26aufirst%3DF.%26atitle%3DPartial%2520D-Amino%2520Acid%2520Substitution%253A%2520Improved%2520Enzymatic%2520Stability%2520and%2520Preserved%2520Ab%2520Recognition%2520of%2520a%2520MUC2%2520Epitope%2520Peptide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26issue%3D2%26spage%3D413%26epage%3D418%26doi%3D10.1073%2Fpnas.0407677102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Cera, E.</span></span> <span> </span><span class="NLM_article-title">Serine Proteases</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1002/iub.186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fiub.186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19180666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=510-515&issue=5&author=E.+Di%0ACera&title=Serine+Proteases&doi=10.1002%2Fiub.186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Serine proteases</span></div><div class="casAuthors">Di Cera, Enrico</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  Over 1/3 of all known proteolytic enzymes are serine proteases.  Among these, the trypsins have undergone the most predominant genetic expansion to become the most abundant and functionally diverse group, yielding enzymes responsible for digestion, blood coagulation, fibrinolysis, development, fertilization, apoptosis, and immunity.  The success of this expansion resides in a highly efficient fold that couples catalysis and regulatory interactions.  An added complexity comes from the recent observation of a significant conformational plasticity of the trypsin fold.  A new paradigm emerges where 2 forms of the protease, E* and E, are in allosteric equil. and det. biol. activity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdrCeiq9KP_LVg90H21EOLACvtfcHk0ljfCJAXzTECWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLg%253D&md5=b3ef95563019933864656a763c944bed</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fiub.186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.186%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCera%26aufirst%3DE.%26atitle%3DSerine%2520Proteases%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26issue%3D5%26spage%3D510%26epage%3D515%26doi%3D10.1002%2Fiub.186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentilucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerisoli, L.</span></span> <span> </span><span class="NLM_article-title">Chemical Modifications Designed to Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">3185</span>– <span class="NLM_lpage">3203</span>, <span class="refDoi"> DOI: 10.2174/138161210793292555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.2174%2F138161210793292555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20687878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKlurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3185-3203&issue=28&author=L.+Gentilucciauthor=R.+De+Marcoauthor=L.+Cerisoli&title=Chemical+Modifications+Designed+to+Improve+Peptide+Stability%3A+Incorporation+of+Non-Natural+Amino+Acids%2C+Pseudo-Peptide+Bonds%2C+and+Cyclization&doi=10.2174%2F138161210793292555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization</span></div><div class="casAuthors">Gentilucci, Luca; De Marco, Rossella; Cerisoli, Lucia</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3185-3203</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Functions and properties of native peptides vary from highly specific antibiotics or cytotoxic antitumor drugs, to hormones, neurotransmitters, immunomodulators, etc.  Despite their potential utility as therapeutic agents, there are problems connected with the use of natural peptides, due to the low stability against proteolysis, resulting in a short duration of in vivo activity, and in a low bioavailability.  One way to overcome these disadvantages is the use of modified peptides, the so called peptidomimetics.  Overall, the less peptide character in a drug candidate, the more stable it is towards protease cleavage.  A huge no. of non-peptidic scaffolds have been reported in the literature; nevertheless, several cases have failed to reproduce the activity of the precursor peptide when the scaffold itself contains relevant pharmacophore elements.  Therefore, quasi-peptides still maintain their appeal for applications in medicinal chem.  For the large no. of different unnatural amino acids and peptidomimetics, the overview cannot be all-inclusive.  This review focuses on modified peptides in which the peptide character is still preponderant, with particular emphasis on the chem. methodologies utilized to introduce the modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKqrcss8C63rVg90H21EOLACvtfcHk0lhu61BDmvd-qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKlurvN&md5=415952939a1fad8af38d117812205853</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F138161210793292555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210793292555%26sid%3Dliteratum%253Aachs%26aulast%3DGentilucci%26aufirst%3DL.%26aulast%3DDe%2BMarco%26aufirst%3DR.%26aulast%3DCerisoli%26aufirst%3DL.%26atitle%3DChemical%2520Modifications%2520Designed%2520to%2520Improve%2520Peptide%2520Stability%253A%2520Incorporation%2520of%2520Non-Natural%2520Amino%2520Acids%252C%2520Pseudo-Peptide%2520Bonds%252C%2520and%2520Cyclization%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26issue%3D28%26spage%3D3185%26epage%3D3203%26doi%3D10.2174%2F138161210793292555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Takenori Furukawa, Hiroyuki Kimura, Hanae Torimoto, Yusuke Yagi, Hidekazu Kawashima, Kenji Arimitsu, <span class="NLM_string-name hlFld-ContribAuthor">Hiroyuki Yasui</span>. </span><span class="cited-content_cbyCitation_article-title">A Putative Single-Photon Emission CT Imaging Tracer for Erythropoietin-Producing Hepatocellular A2 Receptor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00030%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252BPutative%252BSingle-Photon%252BEmission%252BCT%252BImaging%252BTracer%252Bfor%252BErythropoietin-Producing%252BHepatocellular%252BA2%252BReceptor%26aulast%3DFurukawa%26aufirst%3DTakenori%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D17012021%26date%3D09072021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mona Alas, Azam Saghaeidehkordi, <span class="NLM_string-name hlFld-ContribAuthor">Kamaljit Kaur</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide–Drug Conjugates with Different Linkers for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 216-232. <a href="https://doi.org/10.1021/acs.jmedchem.0c01530" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01530%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPeptide%2525E2%252580%252593Drug%252BConjugates%252Bwith%252BDifferent%252BLinkers%252Bfor%252BCancer%252BTherapy%26aulast%3DAlas%26aufirst%3DMona%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D01092020%26date%3D31122020%26volume%3D64%26issue%3D1%26spage%3D216%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sabrina E. Iskandar, Victoria A. Haberman, <span class="NLM_string-name hlFld-ContribAuthor">Albert A. Bowers</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the Chemical Diversity of Genetically Encoded Libraries. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2020,</strong> <em>22 </em>
                                    (12)
                                     , 712-733. <a href="https://doi.org/10.1021/acscombsci.0c00179" title="DOI URL">https://doi.org/10.1021/acscombsci.0c00179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.0c00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.0c00179%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DExpanding%252Bthe%252BChemical%252BDiversity%252Bof%252BGenetically%252BEncoded%252BLibraries%26aulast%3DIskandar%26aufirst%3DSabrina%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08092020%26date%3D20102020%26date%3D09112020%26volume%3D22%26issue%3D12%26spage%3D712%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parisa  Hosseinzadeh</span>, <span class="hlFld-ContribAuthor ">Paris R.  Watson</span>, <span class="hlFld-ContribAuthor ">Timothy W.  Craven</span>, <span class="hlFld-ContribAuthor ">Xinting  Li</span>, <span class="hlFld-ContribAuthor ">Stephen  Rettie</span>, <span class="hlFld-ContribAuthor ">Fátima  Pardo-Avila</span>, <span class="hlFld-ContribAuthor ">Asim K.  Bera</span>, <span class="hlFld-ContribAuthor ">Vikram Khipple  Mulligan</span>, <span class="hlFld-ContribAuthor ">Peilong  Lu</span>, <span class="hlFld-ContribAuthor ">Alexander S.  Ford</span>, <span class="hlFld-ContribAuthor ">Brian D.  Weitzner</span>, <span class="hlFld-ContribAuthor ">Lance J.  Stewart</span>, <span class="hlFld-ContribAuthor ">Adam P.  Moyer</span>, <span class="hlFld-ContribAuthor ">Maddalena  Di Piazza</span>, <span class="hlFld-ContribAuthor ">Joshua G.  Whalen</span>, <span class="hlFld-ContribAuthor ">Per  Greisen</span>, <span class="hlFld-ContribAuthor ">David W.  Christianson</span>, <span class="hlFld-ContribAuthor ">David  Baker</span>. </span><span class="cited-content_cbyCitation_article-title">Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-23609-8" title="DOI URL">https://doi.org/10.1038/s41467-021-23609-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-23609-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-23609-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DAnchor%252Bextension%25253A%252Ba%252Bstructure-guided%252Bapproach%252Bto%252Bdesign%252Bcyclic%252Bpeptides%252Btargeting%252Benzyme%252Bactive%252Bsites%26aulast%3DHosseinzadeh%26aufirst%3DParisa%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey Y.-K.  Wong</span>, <span class="hlFld-ContribAuthor ">Raja  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Jiayuan  Miao</span>, <span class="hlFld-ContribAuthor ">Olena  Bilyk</span>, <span class="hlFld-ContribAuthor ">Vivian  Triana</span>, <span class="hlFld-ContribAuthor ">Mark  Miskolzie</span>, <span class="hlFld-ContribAuthor ">Antoine  Henninot</span>, <span class="hlFld-ContribAuthor ">John J.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Serhii  Kharchenko</span>, <span class="hlFld-ContribAuthor ">Anna  Iampolska</span>, <span class="hlFld-ContribAuthor ">Dmitriy M.  Volochnyuk</span>, <span class="hlFld-ContribAuthor ">Yu-Shan  Lin</span>, <span class="hlFld-ContribAuthor ">Lynne-Marie  Postovit</span>, <span class="hlFld-ContribAuthor ">Ratmir  Derda</span>. </span><span class="cited-content_cbyCitation_article-title">Genetically-encoded discovery of proteolytically stable bicyclic inhibitors for morphogen NODAL. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (28)
                                     , 9694-9703. <a href="https://doi.org/10.1039/D1SC01916C" title="DOI URL">https://doi.org/10.1039/D1SC01916C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC01916C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC01916C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DGenetically-encoded%252Bdiscovery%252Bof%252Bproteolytically%252Bstable%252Bbicyclic%252Binhibitors%252Bfor%252Bmorphogen%252BNODAL%26aulast%3DWong%26aufirst%3DJeffrey%2BY.-K.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D28%26spage%3D9694%26epage%3D9703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junxia  Wang</span>, <span class="hlFld-ContribAuthor ">Jingjing  Guo</span>, <span class="hlFld-ContribAuthor ">Kaifeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Weidong  Ruan</span>, <span class="hlFld-ContribAuthor ">Liang  Li</span>, <span class="hlFld-ContribAuthor ">Jiajun  Ling</span>, <span class="hlFld-ContribAuthor ">Ruixiao  Peng</span>, <span class="hlFld-ContribAuthor ">Huimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Chaoyong  Yang</span>, <span class="hlFld-ContribAuthor ">Zhi  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Auto-Panning: a highly integrated and automated biopanning platform for peptide screening. </span><span class="cited-content_cbyCitation_journal-name">Lab on a Chip</span><span> <strong>2021,</strong> <em>21 </em>
                                    (14)
                                     , 2702-2710. <a href="https://doi.org/10.1039/D1LC00129A" title="DOI URL">https://doi.org/10.1039/D1LC00129A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1LC00129A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1LC00129A%26sid%3Dliteratum%253Aachs%26jtitle%3DLab%2520on%2520a%2520Chip%26atitle%3DAuto-Panning%25253A%252Ba%252Bhighly%252Bintegrated%252Band%252Bautomated%252Bbiopanning%252Bplatform%252Bfor%252Bpeptide%252Bscreening%26aulast%3DWang%26aufirst%3DJunxia%26date%3D2021%26date%3D2021%26volume%3D21%26issue%3D14%26spage%3D2702%26epage%3D2710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Shen  Zhu</span>, <span class="hlFld-ContribAuthor ">Kexing  Tang</span>, <span class="hlFld-ContribAuthor ">Jiayi  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide–drug conjugate-based novel molecular drug delivery system in cancer. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2021,</strong> <em>70 </em><a href="https://doi.org/10.1016/j.tips.2021.07.001" title="DOI URL">https://doi.org/10.1016/j.tips.2021.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2021.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2021.07.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DPeptide%2525E2%252580%252593drug%252Bconjugate-based%252Bnovel%252Bmolecular%252Bdrug%252Bdelivery%252Bsystem%252Bin%252Bcancer%26aulast%3DZhu%26aufirst%3DYi-Shen%26date%3D2021%26volume%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Dian  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Biosynthetic Strategies for Macrocyclic Peptides. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (11)
                                     , 3338. <a href="https://doi.org/10.3390/molecules26113338" title="DOI URL">https://doi.org/10.3390/molecules26113338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26113338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26113338%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBiosynthetic%252BStrategies%252Bfor%252BMacrocyclic%252BPeptides%26aulast%3DWang%26aufirst%3DWei%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D11%26spage%3D3338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azam  Saghaeidehkordi</span>, <span class="hlFld-ContribAuthor ">Shiuan  Chen</span>, <span class="hlFld-ContribAuthor ">Sun  Yang</span>, <span class="hlFld-ContribAuthor ">Kamaljit  Kaur</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 661. <a href="https://doi.org/10.3390/pharmaceutics13050661" title="DOI URL">https://doi.org/10.3390/pharmaceutics13050661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13050661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13050661%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DEvaluation%252Bof%252Ba%252BKeratin%252B1%252BTargeting%252BPeptide-Doxorubicin%252BConjugate%252Bin%252Ba%252BMouse%252BModel%252Bof%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DSaghaeidehkordi%26aufirst%3DAzam%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marco  Catalano</span>, <span class="hlFld-ContribAuthor ">Gabriele  Bassi</span>, <span class="hlFld-ContribAuthor ">Giulia  Rotondi</span>, <span class="hlFld-ContribAuthor ">Lyna  Khettabi</span>, <span class="hlFld-ContribAuthor ">Maria  Dichiara</span>, <span class="hlFld-ContribAuthor ">Patrizia  Murer</span>, <span class="hlFld-ContribAuthor ">Jörg  Scheuermann</span>, <span class="hlFld-ContribAuthor ">Montserrat  Soler-Lopez</span>, <span class="hlFld-ContribAuthor ">Dario  Neri</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, affinity maturation and multimerization of small molecule ligands against human tyrosinase and tyrosinase-related protein 1. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 363-369. <a href="https://doi.org/10.1039/D0MD00310G" title="DOI URL">https://doi.org/10.1039/D0MD00310G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00310G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00310G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252Baffinity%252Bmaturation%252Band%252Bmultimerization%252Bof%252Bsmall%252Bmolecule%252Bligands%252Bagainst%252Bhuman%252Btyrosinase%252Band%252Btyrosinase-related%252Bprotein%252B1%26aulast%3DCatalano%26aufirst%3DMarco%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D3%26spage%3D363%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanna  Dotter</span>, <span class="hlFld-ContribAuthor ">Melanie  Boll</span>, <span class="hlFld-ContribAuthor ">Matthias  Eder</span>, <span class="hlFld-ContribAuthor ">Ann-Christin  Eder</span>. </span><span class="cited-content_cbyCitation_article-title">Library and post-translational modifications of peptide-based display systems. </span><span class="cited-content_cbyCitation_journal-name">Biotechnology Advances</span><span> <strong>2021,</strong> <em>47 </em>, 107699. <a href="https://doi.org/10.1016/j.biotechadv.2021.107699" title="DOI URL">https://doi.org/10.1016/j.biotechadv.2021.107699</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biotechadv.2021.107699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biotechadv.2021.107699%26sid%3Dliteratum%253Aachs%26jtitle%3DBiotechnology%2520Advances%26atitle%3DLibrary%252Band%252Bpost-translational%252Bmodifications%252Bof%252Bpeptide-based%252Bdisplay%252Bsystems%26aulast%3DDotter%26aufirst%3DHanna%26date%3D2021%26volume%3D47%26spage%3D107699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bethany M.  Cooper</span>, <span class="hlFld-ContribAuthor ">Jessica  Iegre</span>, <span class="hlFld-ContribAuthor ">Daniel H.  O' Donovan</span>, <span class="hlFld-ContribAuthor ">Maria  Ölwegård Halvarsson</span>, <span class="hlFld-ContribAuthor ">David R.  Spring</span>. </span><span class="cited-content_cbyCitation_article-title">Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs). </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>50 </em>
                                    (3)
                                     , 1480-1494. <a href="https://doi.org/10.1039/D0CS00556H" title="DOI URL">https://doi.org/10.1039/D0CS00556H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS00556H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS00556H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DPeptides%252Bas%252Ba%252Bplatform%252Bfor%252Btargeted%252Btherapeutics%252Bfor%252Bcancer%25253A%252Bpeptide%2525E2%252580%252593drug%252Bconjugates%252B%252528PDCs%252529%26aulast%3DCooper%26aufirst%3DBethany%2BM.%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D3%26spage%3D1480%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Anselmi</span>, <span class="hlFld-ContribAuthor ">Adina  Borbély</span>, <span class="hlFld-ContribAuthor ">Eduard  Figueras</span>, <span class="hlFld-ContribAuthor ">Carmela  Michalek</span>, <span class="hlFld-ContribAuthor ">Isabell  Kemker</span>, <span class="hlFld-ContribAuthor ">Luca  Gentilucci</span>, <span class="hlFld-ContribAuthor ">Norbert  Sewald</span>. </span><span class="cited-content_cbyCitation_article-title">Linker Hydrophilicity Modulates the Anticancer Activity of RGD–Cryptophycin Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>27 </em>
                                    (3)
                                     , 1015-1022. <a href="https://doi.org/10.1002/chem.202003471" title="DOI URL">https://doi.org/10.1002/chem.202003471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202003471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202003471%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DLinker%252BHydrophilicity%252BModulates%252Bthe%252BAnticancer%252BActivity%252Bof%252BRGD%2525E2%252580%252593Cryptophycin%252BConjugates%26aulast%3DAnselmi%26aufirst%3DMichele%26date%3D2021%26date%3D2020%26volume%3D27%26issue%3D3%26spage%3D1015%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Punit  Upadhyaya</span>, <span class="hlFld-ContribAuthor ">Johanna  Lahdenranta</span>, <span class="hlFld-ContribAuthor ">Kristen  Hurov</span>, <span class="hlFld-ContribAuthor ">Sailaja  Battula</span>, <span class="hlFld-ContribAuthor ">Rachel  Dods</span>, <span class="hlFld-ContribAuthor ">Eric  Haines</span>, <span class="hlFld-ContribAuthor ">Marianna  Kleyman</span>, <span class="hlFld-ContribAuthor ">Julia  Kristensson</span>, <span class="hlFld-ContribAuthor ">Jessica  Kublin</span>, <span class="hlFld-ContribAuthor ">Rachid  Lani</span>, <span class="hlFld-ContribAuthor ">Jun  Ma</span>, <span class="hlFld-ContribAuthor ">Gemma  Mudd</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Repash</span>, <span class="hlFld-ContribAuthor ">Katerine  Van Rietschoten</span>, <span class="hlFld-ContribAuthor ">Tom  Stephen</span>, <span class="hlFld-ContribAuthor ">Fanglei  You</span>, <span class="hlFld-ContribAuthor ">Helen  Harrison</span>, <span class="hlFld-ContribAuthor ">Liuhong  Chen</span>, <span class="hlFld-ContribAuthor ">Kevin  McDonnell</span>, <span class="hlFld-ContribAuthor ">Philip  Brandish</span>, <span class="hlFld-ContribAuthor ">Nicholas  Keen</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist. </span><span class="cited-content_cbyCitation_journal-name">Journal for ImmunoTherapy of Cancer</span><span> <strong>2021,</strong> <em>9 </em>
                                    (1)
                                     , e001762. <a href="https://doi.org/10.1136/jitc-2020-001762" title="DOI URL">https://doi.org/10.1136/jitc-2020-001762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/jitc-2020-001762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fjitc-2020-001762%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520for%2520ImmunoTherapy%2520of%2520Cancer%26atitle%3DAnticancer%252Bimmunity%252Binduced%252Bby%252Ba%252Bsynthetic%252Btumor-targeted%252BCD137%252Bagonist%26aulast%3DUpadhyaya%26aufirst%3DPunit%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D1%26spage%3De001762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Max  London</span>, <span class="hlFld-ContribAuthor ">Eugenio  Gallo</span>. </span><span class="cited-content_cbyCitation_article-title">The EphA2 and cancer connection: potential for immune-based interventions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Biology Reports</span><span> <strong>2020,</strong> <em>47 </em>
                                    (10)
                                     , 8037-8048. <a href="https://doi.org/10.1007/s11033-020-05767-y" title="DOI URL">https://doi.org/10.1007/s11033-020-05767-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11033-020-05767-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11033-020-05767-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Biology%2520Reports%26atitle%3DThe%252BEphA2%252Band%252Bcancer%252Bconnection%25253A%252Bpotential%252Bfor%252Bimmune-based%252Binterventions%26aulast%3DLondon%26aufirst%3DMax%26date%3D2020%26date%3D2020%26volume%3D47%26issue%3D10%26spage%3D8037%26epage%3D8048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gavin  Bennett</span>, <span class="hlFld-ContribAuthor ">Amy  Brown</span>, <span class="hlFld-ContribAuthor ">Gemma  Mudd</span>, <span class="hlFld-ContribAuthor ">Philip  Huxley</span>, <span class="hlFld-ContribAuthor ">Katerine  Van Rietschoten</span>, <span class="hlFld-ContribAuthor ">Silvia  Pavan</span>, <span class="hlFld-ContribAuthor ">Liuhong  Chen</span>, <span class="hlFld-ContribAuthor ">Sophie  Watcham</span>, <span class="hlFld-ContribAuthor ">Johanna  Lahdenranta</span>, <span class="hlFld-ContribAuthor ">Nicholas  Keen</span>. </span><span class="cited-content_cbyCitation_article-title">MMAE Delivery Using the
              Bicycle
              Toxin Conjugate BT5528. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (7)
                                     , 1385-1394. <a href="https://doi.org/10.1158/1535-7163.MCT-19-1092" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-1092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-1092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-1092%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DMMAE%252BDelivery%252BUsing%252Bthe%252BBicycle%252BToxin%252BConjugate%252BBT5528%26aulast%3DBennett%26aufirst%3DGavin%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D7%26spage%3D1385%26epage%3D1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Schematic representation of a Bicycle with a generic small-molecule scaffold linked via three cysteine residues (orange). N- and C-terminal extensions outside the Bicycle loops can be incorporated (gray). (b) Examples of scaffolds that can be used to generate Bicycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Bicycles have a tolerance to conjugation as they are identified while attached to a large phage particle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of the chemically stabilized, TBMB cyclized EphA2 binding Bicycle BCY6044 and prototype Bicycle toxin conjugate BCY6046.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Efficacy study using Bicycle toxin conjugate BCY6046. Full regression of the CDX tumor (HT-1080 cells) was observed within 14 days when BCY6046 was dosed at 3 mg/kg qw. (b) BCY6046 toxicology responses were evaluated in a single ascending dose study via IV bolus injection to eight female rats at 1, 2, and 3 mg/kg. ALT and AST levels were measured on day 5. Elevated levels were observed at 2 mg/kg and at the minimum efficacious dose, 3 mg/kg. (c) Bicycle toxin conjugate BCY6135 shows good efficacy in a CDX model using HT-1080 cells when dosed at 3 mg/kg qw, leading to full regression of the tumor. (d) BCY6135 toxicology responses were monitored in a 14 day repeat dose study following IV bolus injection to six female rats at 3, 5, and 7.5 mg/kg on days 1 and 8, with ALT and AST levels measured on day 15. ALT and AST levels were low at the efficacious dose (3 mg/kg) and close to levels recorded for reference laboratory animals at 5 mg/kg. ALT and AST levels exceeded the normal range at 2.5 times the efficacious dose (7.5 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) EphA2 (gray ribbon) interacts with its cognate ligands via the ligand-binding domain (LBD); ephrin A5 (blue ribbon) inserts a large unstructured loop into a hydrophobic channel on EphA2 (PDB accession number <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X11">2X11</a><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>). (b) BCY6065 (orange sticks and surface) binds EphA2 LBD (gray ribbon). The Bicycle backbone forms an open turn structure with a central short 3<sub>10</sub> helix stabilized by the TATA scaffold (PDB accession number <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RW2">6RW2</a>). (c) BCY6065 (orange sticks) sits closely over the surface of EphA2 (gray ribbon and surface), burying around 1650 Å<sup>2</sup>; two conformers were observed for His8 of the Bicycle (alternate conformer shown in purple).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of TATA-cyclized BTC precursor BCY6099, DOTA conjugate BCY6164, and Bicycle toxin conjugates BCY6135.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/medium/jm9b02129_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. μPET image of an HT-1080 tumor-bearing mouse 60 min after dosing Ga<sup>68</sup>-BCY6164 (scaled at 4–20% ID/g). High levels of Bicycle can be seen in the tumor. A high signal in the kidneys and bladder show this to be the main route of elimination, whereas the signal in the liver is minimal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02129/20200416/images/large/jm9b02129_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02129&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01248" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01248" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">Phage-Encoded Combinatorial Chemical Libraries Based on Bicyclic Peptides</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">502</span>, <span class="refDoi"> DOI: 10.1038/nchembio.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-Encoded+Combinatorial+Chemical+Libraries+Based+on+Bicyclic+Peptides&doi=10.1038%2Fnchembio.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0lixi6Ra1cfGQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-Encoded%2520Combinatorial%2520Chemical%2520Libraries%2520Based%2520on%2520Bicyclic%2520Peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26doi%3D10.1038%2Fnchembio.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeriswyl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stace, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tite, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and Its Orthologues While Sparing Paralogous Proteases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fcmdc.201200071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=22492508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1173-1176&issue=7&author=V.+Baeriswylauthor=H.+Rapleyauthor=L.+Pollaroauthor=C.+Staceauthor=D.+Teufelauthor=E.+Walkerauthor=S.+Chenauthor=G.+Winterauthor=J.+Titeauthor=C.+Heinis&title=Bicyclic+Peptides+with+Optimized+Ring+Size+Inhibit+Human+Plasma+Kallikrein+and+Its+Orthologues+While+Sparing+Paralogous+Proteases&doi=10.1002%2Fcmdc.201200071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases</span></div><div class="casAuthors">Baeriswyl, Vanessa; Rapley, Helen; Pollaro, Lisa; Stace, Catherine; Teufel, Dan; Walker, Edward; Chen, Shiyu; Winter, Greg; Tite, John; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1173-1176, S1173/1-S1173/5</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In this work, we aimed at generating bicyclic peptides inhibiting both human and murine plasma kallikrein (PK) but not any paralogous proteases.  We speculated that inhibitors with the desired specificity profile could be obtained by generating binders to a surface region that is identical in PK orthologues but different in paralogues.  By comparing structural models of target and related nontarget proteases to identify conserved regions in the vicinity of the active site and by modulating the loop size of our libraries of peptide macrocycles accordingly, we succeeded in identifying potent inhibitors of human, rat and monkey plasma kallikrein that do not also inhibit related human serum proteases.  Our strategy should facilitate the evaluation of this type of peptide macrocycles in animal models, and furthermore, avoid unwanted off-target activities that would be detrimental to their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTYMUG-b7ubVg90H21EOLACvtfcHk0lixi6Ra1cfGQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Kksbk%253D&md5=5a3177403617ce635c46b0a759a110ab</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200071%26sid%3Dliteratum%253Aachs%26aulast%3DBaeriswyl%26aufirst%3DV.%26aulast%3DRapley%26aufirst%3DH.%26aulast%3DPollaro%26aufirst%3DL.%26aulast%3DStace%26aufirst%3DC.%26aulast%3DTeufel%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DTite%26aufirst%3DJ.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DBicyclic%2520Peptides%2520with%2520Optimized%2520Ring%2520Size%2520Inhibit%2520Human%2520Plasma%2520Kallikrein%2520and%2520Its%2520Orthologues%2520While%2520Sparing%2520Paralogous%2520Proteases%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D7%26spage%3D1173%26epage%3D1176%26doi%3D10.1002%2Fcmdc.201200071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittrup, K. D.</span></span> <span> </span><span class="NLM_article-title">A Modeling Analysis of the Effects of Molecular Size and Binding Affinity on Tumor Targeting</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2861</span>– <span class="NLM_lpage">2871</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1535-7163.MCT-09-0195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19825804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2861-2871&issue=10&author=M.+M.+Schmidtauthor=K.+D.+Wittrup&title=A+Modeling+Analysis+of+the+Effects+of+Molecular+Size+and+Binding+Affinity+on+Tumor+Targeting&doi=10.1158%2F1535-7163.MCT-09-0195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A modeling analysis of the effects of molecular size and binding affinity on tumor targeting</span></div><div class="casAuthors">Schmidt, Michael M.; Wittrup, K. Dane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2861-2871</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and therapy.  However, it remains largely unclear how size differences among these mols. influence their targeting properties.  Here, we develop a simple, mechanistic model that can be used to understand and predict the complex interplay between mol. size, affinity, and tumor uptake.  Empirical relationships between mol. radius and capillary permeability, interstitial diffusivity, available vol. fraction, and plasma clearance were obtained using data in the literature.  These relationships were incorporated into a compartmental model of tumor targeting using MATLAB to predict the magnitude, specificity, time dependence, and affinity dependence of tumor uptake for mols. across a broad size spectrum.  In the typical size range for proteins, the model uncovers a complex trend in which intermediate-sized targeting agents (MW, ∼25 kDa) have the lowest tumor uptake, whereas higher tumor uptake levels are achieved by smaller and larger agents.  Small peptides accumulate rapidly in the tumor but require high affinity to be retained, whereas larger proteins can achieve similar retention with >100-fold weaker binding.  For mols. in the size range of liposomes, the model predicts that antigen targeting will not significantly increase tumor uptake relative to untargeted mols.  All model predictions are shown to be consistent with exptl. observations from published targeting studies.  The results and techniques have implications for drug development, imaging, and therapeutic dosing. [Mol Cancer Ther 2009;8(10):2861-71].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIy-sqAvgserVg90H21EOLACvtfcHk0lgz5Df_X3_eJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7K&md5=da1ea6be17fad4873d808e883eacbf78</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0195%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DM.%2BM.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DA%2520Modeling%2520Analysis%2520of%2520the%2520Effects%2520of%2520Molecular%2520Size%2520and%2520Binding%2520Affinity%2520on%2520Tumor%2520Targeting%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26issue%3D10%26spage%3D2861%26epage%3D2871%26doi%3D10.1158%2F1535-7163.MCT-09-0195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wüst, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rietschoten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranski, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stace, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schierbaum, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F0008-5472.CAN-18-0238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=30606721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFCns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=841-852&issue=4&author=M.+Ederauthor=S.+Pavanauthor=U.+Bauder-W%C3%BCstauthor=K.+van+Rietschotenauthor=A.-C.+Baranskiauthor=H.+Harrisonauthor=S.+Campbellauthor=C.+L.+Staceauthor=E.+H.+Walkerauthor=L.+Chenauthor=G.+Bennettauthor=G.+Muddauthor=U.+Schierbaumauthor=K.+Leottaauthor=U.+Haberkornauthor=K.+Kopkaauthor=D.+P.+Teufel&title=Bicyclic+Peptides+as+a+New+Modality+for+Imaging+and+Targeting+of+Proteins+Overexpressed+by+Tumors&doi=10.1158%2F0008-5472.CAN-18-0238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic peptides as a new modality for imaging and targeting of proteins overexpressed by tumors</span></div><div class="casAuthors">Eder, Matthias; Pavan, Silvia; Bauder-Wuest, Ulrike; Van Rietschoten, Katerine; Baranski, Ann-Christin; Harrison, Helen; Campbell, Spencer; Stace, Catherine L.; Walker, Edward H.; Chen, Liuhong; Bennett, Gavin; Mudd, Gemma; Schierbaum, Ursula; Leotta, Karin; Haberkorn, Uwe; Kopka, Klaus; Teufel, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">841-852</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. imaging of cancers using probes specific for tumor-assocd. target proteins offers a powerful soln. for providing information regarding selection of targeted therapy, patient stratification, and response to therapy.  Here we demonstrate the power of bicyclic peptides as targeting probes, exemplified with the tumor-overexpressed matrix metalloproteinase MT1-MMP as a target.  A bicyclic peptide with subnanomolar affinity towards MT1-MMP was identified, and its radioconjugate showed selective tumor uptake in an HT1080 xenograft mouse model.  Proteolytic stabilization of the peptide by chem. modification significantly enhanced the in vivo tumor signal [from 2.5%ID/g to 12%ID/g at 1 h post injection (p.i.)].  Studies using mouse xenograft models with different cell lines show a robust correlation between tumor signals and in vivo MT1-MMP expression levels.  Fatty acid modification of the bicyclic peptide extended its circulating half-life, resulting in increased tumor signals (36%ID/g at 6 h p.i.).  Comparative work with an equipotent radiolabeled MT1-MMP targeting antibody demonstrated starkly differential biodistribution and tumor accumulation properties, with the tumor signal slowly increasing to 6.2%ID/g within 48 h.  The rapid tumor penetration characteristics of bicyclic peptides, coupled with high potency and chem. versatility, thus offer high-contrast imaging probes for clin. diagnostics with compelling addnl. potential in targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxf56_J7cP7bVg90H21EOLACvtfcHk0lgz5Df_X3_eJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFCns7Y%253D&md5=a9b2d0b6494baa6bd8da2acccd4435b9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0238%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DM.%26aulast%3DPavan%26aufirst%3DS.%26aulast%3DBauder-W%25C3%25BCst%26aufirst%3DU.%26aulast%3Dvan%2BRietschoten%26aufirst%3DK.%26aulast%3DBaranski%26aufirst%3DA.-C.%26aulast%3DHarrison%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DStace%26aufirst%3DC.%2BL.%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DSchierbaum%26aufirst%3DU.%26aulast%3DLeotta%26aufirst%3DK.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26atitle%3DBicyclic%2520Peptides%2520as%2520a%2520New%2520Modality%2520for%2520Imaging%2520and%2520Targeting%2520of%2520Proteins%2520Overexpressed%2520by%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D4%26spage%3D841%26epage%3D852%26doi%3D10.1158%2F0008-5472.CAN-18-0238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno
Candilejo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roxburgh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabaratnam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katugampola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremayne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langford, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symeonides, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, M.</span></span> <span> </span><span class="NLM_article-title">A Cancer Research UK Phase I/IIa Trial of BT1718 (a First in Class Bicycle Drug Conjugate) given Intravenously in Patients with Advanced Solid Tumours</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2610</span>– <span class="NLM_lpage">2610</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.TPS2610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1200%2FJCO.2018.36.15_suppl.TPS2610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2610-2610&issue=15&author=U.+Banerjiauthor=N.+Cookauthor=T.+R.+J.+Evansauthor=I.+Moreno%0ACandilejoauthor=P.+Roxburghauthor=C.+L.+S.+Kellyauthor=N.+Sabaratnamauthor=R.+Passiauthor=S.+Leslieauthor=S.+Katugampolaauthor=L.+Godfreyauthor=N.+Tremayneauthor=G.+Bennettauthor=M.+Koehlerauthor=G.+Langfordauthor=S.+N.+Symeonidesauthor=M.+Pittman&title=A+Cancer+Research+UK+Phase+I%2FIIa+Trial+of+BT1718+%28a+First+in+Class+Bicycle+Drug+Conjugate%29+given+Intravenously+in+Patients+with+Advanced+Solid+Tumours&doi=10.1200%2FJCO.2018.36.15_suppl.TPS2610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.TPS2610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.TPS2610%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DCook%26aufirst%3DN.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DMoreno%2BCandilejo%26aufirst%3DI.%26aulast%3DRoxburgh%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DC.%2BL.%2BS.%26aulast%3DSabaratnam%26aufirst%3DN.%26aulast%3DPassi%26aufirst%3DR.%26aulast%3DLeslie%26aufirst%3DS.%26aulast%3DKatugampola%26aufirst%3DS.%26aulast%3DGodfrey%26aufirst%3DL.%26aulast%3DTremayne%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DLangford%26aufirst%3DG.%26aulast%3DSymeonides%26aufirst%3DS.%2BN.%26aulast%3DPittman%26aufirst%3DM.%26atitle%3DA%2520Cancer%2520Research%2520UK%2520Phase%2520I%252FIIa%2520Trial%2520of%2520BT1718%2520%2528a%2520First%2520in%2520Class%2520Bicycle%2520Drug%2520Conjugate%2529%2520given%2520Intravenously%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumours%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15%26spage%3D2610%26epage%3D2610%26doi%3D10.1200%2FJCO.2018.36.15_suppl.TPS2610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span>; <span class="NLM_string-name">Bennett, G. S.</span>; <span class="NLM_string-name">Brown, A.</span>; <span class="NLM_string-name">Mudd, G.</span>; <span class="NLM_string-name">Van Reitschoten, K.</span>; <span class="NLM_string-name">Pavan, S.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Watcham, S.</span>; <span class="NLM_string-name">Lahdenranta, J.</span>; <span class="NLM_string-name">Keen, N.</span></span> <i>Unpubl. Results</i>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Huxley%2C+P.%3B+Bennett%2C+G.+S.%3B+Brown%2C+A.%3B+Mudd%2C+G.%3B+Van+Reitschoten%2C+K.%3B+Pavan%2C+S.%3B+Chen%2C+L.%3B+Watcham%2C+S.%3B+Lahdenranta%2C+J.%3B+Keen%2C+N.+Unpubl.+Results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuxley%26aufirst%3DP.%26jtitle%3DUnpubl.%2520Results" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">Eph-Ephrin Bidirectional Signaling in Physiology and Disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2008.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1016%2Fj.cell.2008.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=18394988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=38-52&issue=1&author=E.+B.+Pasquale&title=Eph-Ephrin+Bidirectional+Signaling+in+Physiology+and+Disease&doi=10.1016%2Fj.cell.2008.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Eph-ephrin bidirectional signaling in physiology and disease</span></div><div class="casAuthors">Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-52</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases of the Eph family bind to cell surface-assocd. ephrin ligands on neighboring cells.  The ensuing bidirectional signals have emerged as a major form of contact-dependent communication between cells.  New findings reveal that Eph receptors and ephrins coordinate not only developmental processes but also the normal physiol. and homeostasis of many adult organs.  Imbalance of Eph/ephrin function may therefore contribute to a variety of diseases.  The challenge now is to better understand the complex and seemingly paradoxical signaling mechanisms of Eph receptors and ephrins, which will enable effective strategies to target these proteins in the treatment of diseases such as diabetes and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwi9x94COQ7Vg90H21EOLACvtfcHk0lib3YRju9eDqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslOlu7o%253D&md5=67d6b24808f5d0672aad39dca99d3c8f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DEph-Ephrin%2520Bidirectional%2520Signaling%2520in%2520Physiology%2520and%2520Disease%26jtitle%3DCell%26date%3D2008%26volume%3D133%26issue%3D1%26spage%3D38%26epage%3D52%26doi%3D10.1016%2Fj.cell.2008.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">CDNA Cloning and Characterization of Eck, an Epithelial Cell Receptor Protein-Tyrosine Kinase in the Eph/Elk Family of Protein Kinases</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">6316</span>– <span class="NLM_lpage">6324</span>, <span class="refDoi"> DOI: 10.1128/MCB.10.12.6316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1128%2FMCB.10.12.6316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=2174105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADyaK3MXisVWmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=6316-6324&issue=12&author=R.+A.+Lindbergauthor=T.+Hunter&title=CDNA+Cloning+and+Characterization+of+Eck%2C+an+Epithelial+Cell+Receptor+Protein-Tyrosine+Kinase+in+the+Eph%2FElk+Family+of+Protein+Kinases&doi=10.1128%2FMCB.10.12.6316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases</span></div><div class="casAuthors">Lindberg, Richard A.; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6316-24</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A human epithelial (HeLa) cDNA library was screened with degenerate oligonucleotides designed to hybridize to highly conserved regions of protein-tyrosine kinases.  One cDNA from this screen was shown to contain a putative protein-tyrosine kinase catalytic domain and subsequently used to isolate another cDNA from a human keratinocyte library that encompasses the entire coding region of a 976-amino-acid polypeptide.  The predicted protein has an external domain of 534 amino acids with a presumptive N-terminal signal peptide, a transmembrane domain, and a cytoplasmic domain of 418 amino acids that includes a canonical protein-tyrosine kinase catalytic domain.  Mol. phylogeny indicates that this protein kinase is closely related to eph and elk and that this receptor family is more closely related to the non-receptor protein-tyrosine kinase families than to other receptor protein-tyrosine kinases.  Antibodies raised against a TrpE fusion protein immunopptd. a 130-kDa protein that became phosphorylated on tyrosine in immune complex kinase assays, indicating that this protein is a bona fide protein-tyrosine kinase.  Anal. of RNA from 13 adult rat organs showed that the eck gene is expressed most highly in tissues that contain a high proportion of epithelial cells, e.g., skin, intestine, lung, and ovary.  Several cell lines of epithelial origin were found to express the eck protein kinase at the protein and RNA levels.  Immunohistochem. anal. of several rat organs also showed staining in epithelial cells.  These observations lead to the naming of this protein kinase eck, for epithelial cell kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqPiqFHu0RxrVg90H21EOLACvtfcHk0lib3YRju9eDqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXisVWmu7c%253D&md5=75d34ab8db9b752fbf1888ac5e58663a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FMCB.10.12.6316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.10.12.6316%26sid%3Dliteratum%253Aachs%26aulast%3DLindberg%26aufirst%3DR.%2BA.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DCDNA%2520Cloning%2520and%2520Characterization%2520of%2520Eck%252C%2520an%2520Epithelial%2520Cell%2520Receptor%2520Protein-Tyrosine%2520Kinase%2520in%2520the%2520Eph%252FElk%2520Family%2520of%2520Protein%2520Kinases%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1990%26volume%3D10%26issue%3D12%26spage%3D6316%26epage%3D6324%26doi%3D10.1128%2FMCB.10.12.6316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker-Daniels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Differential Regulation of EphA2 in Normal and Malignant Cells</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)63899-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1016%2FS0002-9440%2810%2963899-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=12651595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2003&pages=1037-1042&issue=4&author=J.+Walker-Danielsauthor=A.+R.+Hessauthor=M.+J.+C.+Hendrixauthor=M.+S.+Kinch&title=Differential+Regulation+of+EphA2+in+Normal+and+Malignant+Cells&doi=10.1016%2FS0002-9440%2810%2963899-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of EphA2 in normal and malignant cells</span></div><div class="casAuthors">Walker-Daniels, Jennifer; Hess, Angela R.; Hendrix, Mary J. C.; Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1042</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">A review on the biochem. and cellular consequences of EphA2 stimulation, esp. in malignant cells.  The mechanisms that may explain the overexpression and functional alterations of EphA2 in cancer are discussed.  A hypothetical model representing a potential signaling pathway initiated by EphA2 and crit. for vasculogenic mimicry is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOCiDKgpnOxrVg90H21EOLACvtfcHk0lib3YRju9eDqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVemt70%253D&md5=e6298e47af35ad4815d6ba053df0931c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963899-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963899-0%26sid%3Dliteratum%253Aachs%26aulast%3DWalker-Daniels%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DA.%2BR.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520Regulation%2520of%2520EphA2%2520in%2520Normal%2520and%2520Malignant%2520Cells%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2003%26volume%3D162%26issue%3D4%26spage%3D1037%26epage%3D1042%26doi%3D10.1016%2FS0002-9440%2810%2963899-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ireton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.2174/1568009053765780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&issue=3&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+Receptor+Tyrosine+Kinase+as+a+Promising+Target+for+Cancer+Therapeutics&doi=10.2174%2F1568009053765780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0liOFv9ofkIdJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520Receptor%2520Tyrosine%2520Kinase%2520as%2520a%2520Promising%2520Target%2520for%2520Cancer%2520Therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D157%26doi%3D10.2174%2F1568009053765780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1078-0432.CCR-12-2654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=23155185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=128-137&issue=1&author=S.+Wangauthor=R.+Noberiniauthor=J.+L.+Stebbinsauthor=S.+Dasauthor=Z.+Zhangauthor=B.+Wuauthor=S.+Mitraauthor=S.+Billetauthor=A.+Fernandezauthor=N.+A.+Bhowmickauthor=S.+Kitadaauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Targeted+Delivery+of+Paclitaxel+to+EphA2-Expressing+Cancer+Cells&doi=10.1158%2F1078-0432.CCR-12-2654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Noberini, Roberta; Stebbins, John L.; Das, Swadesh; Zhang, Ziming; Wu, Bainan; Mitra, Sayantan; Billet, Sandrine; Fernandez, Ana; Bhowmick, Neil A.; Kitada, Shinichi; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: YSA is an EphA2-targeting peptide that effectively delivers anticancer agents to prostate cancer tumors.  Here, we report on how we increased the drug-like properties of this delivery system.  Exptl. Design: By introducing non-natural amino acids, we have designed two new EphA2 targeting peptides: YNH, where norleucine and homoserine replace the two methionine residues of YSA, and dYNH, where a D-tyrosine replaces the L-tyrosine at the first position of the YNH peptide.  We describe the details of the synthesis of YNH and dYNH paclitaxel conjugates (YNH-PTX and dYNH-PTX) and their characterization in cells and in vivo.  Results: dYNH-PTX showed improved stability in mouse serum and significantly reduced tumor size in a prostate cancer xenograft model and also reduced tumor vasculature in a syngeneic orthotopic allograft mouse model of renal cancer compared with vehicle or paclitaxel treatments.  Conclusion: This study reveals that targeting EphA2 with dYNH drug conjugates could represent an effective way to deliver anticancer agents to a variety of tumor types.  Clin Cancer Res; 19(1); 128-37. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM9wK1ey90VLVg90H21EOLACvtfcHk0liOFv9ofkIdJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D&md5=9d11d8f57028d5245b0d344652ef311e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2654%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTargeted%2520Delivery%2520of%2520Paclitaxel%2520to%2520EphA2-Expressing%2520Cancer%2520Cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D1%26spage%3D128%26epage%3D137%26doi%3D10.1158%2F1078-0432.CCR-12-2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzad, M. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangala, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2562</span>– <span class="NLM_lpage">2570</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1078-0432.CCR-10-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20388851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlegtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2562-2570&issue=9&author=J.-W.+Leeauthor=R.+L.+Stoneauthor=S.+J.+Leeauthor=E.+J.+Namauthor=J.-W.+Rohauthor=A.+M.+Nickauthor=H.-D.+Hanauthor=M.+M.+K.+Shahzadauthor=H.-S.+Kimauthor=L.+S.+Mangalaauthor=N.+B.+Jenningsauthor=S.+Maoauthor=J.+Gooyaauthor=D.+Jacksonauthor=R.+L.+Colemanauthor=A.+K.+Sood&title=EphA2+Targeted+Chemotherapy+Using+an+Antibody+Drug+Conjugate+in+Endometrial+Carcinoma&doi=10.1158%2F1078-0432.CCR-10-0017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma</span></div><div class="casAuthors">Lee, Jeong-Won; Stone, Rebecca L.; Lee, Sun Joo; Nam, Eun Ji; Roh, Ju-Won; Nick, Alpa M.; Han, Hee-Dong; Shahzad, Mian M. K.; Kim, Hye-Sun; Mangala, Lingegowda S.; Jennings, Nicholas B.; Mao, Shenlan; Gooya, John; Jackson, Dowdy; Coleman, Robert L.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2562-2570</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: EphA2 overexpression is frequently obsd. in endometrial cancers and is predictive of poor clin. outcome.  Here, we use an antibody drug conjugate (MEDI-547) composed of a fully human monoclonal antibody against both human and murine EphA2 (1C1) and the tubulin polymn. inhibitor monomethylauristatin F. Exptl. Design: EphA2 expression was examd. in endometrial cancer cell lines by Western blot.  Specificity of MEDI-547 was examd. by antibody degrdn. and internalization assays.  Viability and apoptosis were investigated in endometrial cancer cell lines and orthotopic tumor models.  RESULTS: EphA2 was expressed in the Hec-1A and Ishikawa cells but was absent in the SPEC-2 cells.  Antibody degrdn. and internalization assays showed that the antibody drug conjugate decreased EphA2 protein levels and was internalized in EphA2-pos. cells (Hec-1A and Ishikawa).  Moreover, in vitro cytotoxicity and apoptosis assays showed that the antibody drug conjugate decreased viability and increased apoptosis of Hec-1A and Ishikawa cells.  In vivo therapy expts. in mouse orthotopic models with this antibody drug conjugate resulted in 86% to 88% growth inhibition (P < 0.001) in the orthotopic Hec-1A and Ishikawa models compared with controls.  Moreover, the mice treated with this antibody drug conjugate had a lower incidence of distant metastasis compared with controls.  The antitumor effects of the therapy were related to decreased proliferation and increased apoptosis of tumor and assocd. endothelial cells.  CONCLUSIONS: The preclin. data for endometrial cancer treatment using MEDI-547 show substantial antitumor activity.  Clin Cancer Res; 16(9); 2562-70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7BtEP1K3EebVg90H21EOLACvtfcHk0liOFv9ofkIdJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlegtrY%253D&md5=3c104d9d0abbcc1240ea66eeb08bf558</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0017%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.-W.%26aulast%3DStone%26aufirst%3DR.%2BL.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DNam%26aufirst%3DE.%2BJ.%26aulast%3DRoh%26aufirst%3DJ.-W.%26aulast%3DNick%26aufirst%3DA.%2BM.%26aulast%3DHan%26aufirst%3DH.-D.%26aulast%3DShahzad%26aufirst%3DM.%2BM.%2BK.%26aulast%3DKim%26aufirst%3DH.-S.%26aulast%3DMangala%26aufirst%3DL.%2BS.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DEphA2%2520Targeted%2520Chemotherapy%2520Using%2520an%2520Antibody%2520Drug%2520Conjugate%2520in%2520Endometrial%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D9%26spage%3D2562%26epage%3D2570%26doi%3D10.1158%2F1078-0432.CCR-10-0017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1403</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fcmdc.201400067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=24677792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1403-1412&issue=7&author=E.+Barileauthor=S.+Wangauthor=S.+K.+Dasauthor=R.+Noberiniauthor=R.+Dahlauthor=J.+L.+Stebbinsauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design%2C+Synthesis+and+Bioevaluation+of+an+EphA2+Receptor-Based+Targeted+Delivery+System&doi=10.1002%2Fcmdc.201400067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System</span></div><div class="casAuthors">Barile, Elisa; Wang, Si; Das, Swadesh K.; Noberini, Roberta; Dahl, Russell; Stebbins, John L.; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1403-1412</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Because of its overexpression in a range of solid tumors, the EphA2 receptor is a validated target for cancer therapeutics.  The authors recently described a new targeted delivery system based on specific EphA2-targeting peptides conjugated with the chemotherapeutic agent paclitaxel.  Here, the chem. determinants responsible for the stability and degrdn. of these agents in plasma were investigated.  Introducing modifications in both the peptide and the linker between the peptide and paclitaxel resulted in drug conjugates that are both long-lived in rat plasma and that markedly decrease tumor size in a prostate cancer xenograft model compared with paclitaxel alone treatment.  These studies identify crit. rate-limiting degrdn. sites on the peptide-drug conjugates, enabling the design of agents with increased stability and efficacy.  These results provide support for the central hypothesis that peptide-drug conjugates targeting EphA2 represent an innovative and potentially effective strategy to selectively deliver cytotoxic drugs to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0PtVZMIpXmrVg90H21EOLACvtfcHk0li7Mxzn7exU3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D&md5=4b83eea1d0ea2ee884f003e7565eb65f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400067%26sid%3Dliteratum%253Aachs%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Bioevaluation%2520of%2520an%2520EphA2%2520Receptor-Based%2520Targeted%2520Delivery%2520System%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D7%26spage%3D1403%26epage%3D1412%26doi%3D10.1002%2Fcmdc.201400067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morvaridi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Therapy of Pancreatic Cancer via an EphA2 Receptor-Targeted Delivery of Gemcitabine</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">17103</span>– <span class="NLM_lpage">17110</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.18632%2Foncotarget.7931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=26959746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17103-17110&issue=13&author=B.+A.+Quinnauthor=S.+Wangauthor=E.+Barileauthor=S.+K.+Dasauthor=L.+Emdadauthor=D.+Sarkarauthor=S.+K.+Deauthor=S.+K.+Morvaridiauthor=J.+L.+Stebbinsauthor=S.+J.+Pandolauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Therapy+of+Pancreatic+Cancer+via+an+EphA2+Receptor-Targeted+Delivery+of+Gemcitabine&doi=10.18632%2Foncotarget.7931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span></div><div class="casAuthors">Quinn Bridget A; Das Swadesh K; Emdad Luni; Sarkar Devanand; Fisher Paul B; Wang Si; Barile Elisa; De Surya K; Stebbins John L; Fisher Paul B; Pellecchia Maurizio; Barile Elisa; De Surya K; Pellecchia Maurizio; Morvaridi Susan Kharagh; Pandol Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">17103-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.  In some patients, an active transport mechanism allows gemcitabine to enter efficiently into the tumor cells, resulting in a significant clinical benefit.  However, in most patients, low expression of gemcitabine transporters limits the efficacy of the drug to marginal levels, and patients need frequent administration of the drug at high doses, significantly increasing systemic drug toxicity.  In this article we focus on a novel targeted delivery approach for gemcitabine consisting of conjugating the drug with an EphA2 targeting agent.  We show that the EphA2 receptor is highly expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective than gemcitabine alone in targeting pancreatic tumors.  Our preliminary observations suggest that this approach may provide a general benefit to pancreatic cancer patients and offers a comprehensive strategy for enhancing delivery of diverse therapeutic agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing toxicity while enhancing therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkle74R4yp-ekdrW1FkXG-fW6udTcc2ebQBLFZ_2d0E7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D&md5=0b5e311729fc3517d90882844ab3d3f2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7931%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMorvaridi%26aufirst%3DS.%2BK.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTherapy%2520of%2520Pancreatic%2520Cancer%2520via%2520an%2520EphA2%2520Receptor-Targeted%2520Delivery%2520of%2520Gemcitabine%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D13%26spage%3D17103%26epage%3D17110%26doi%3D10.18632%2Foncotarget.7931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salem, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udompholkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2061</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2052-2061&issue=5&author=A.+F.+Salemauthor=S.+Wangauthor=S.+Billetauthor=J.-F.+Chenauthor=P.+Udompholkulauthor=L.+Gambiniauthor=C.+Baggioauthor=H.-R.+Tsengauthor=E.+M.+Posadasauthor=N.+A.+Bhowmickauthor=M.+Pellecchia&title=Reduction+of+Circulating+Cancer+Cells+and+Metastases+in+Breast-Cancer+Models+by+a+Potent+EphA2-Agonistic+Peptide%E2%80%93Drug+Conjugate&doi=10.1021%2Facs.jmedchem.7b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate</span></div><div class="casAuthors">Salem, Ahmed F.; Wang, Si; Billet, Sandrine; Chen, Jie-Fu; Udompholkul, Parima; Gambini, Luca; Baggio, Carlo; Tseng, Hsian-Rong; Posadas, Edwin M.; Bhowmick, Neil A.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EphA2 overexpression has been assocd. with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers.  We have recently proposed the development of peptide-drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YSA peptide or its optimized version, 123B9.  Although our studies indicated that YSA- and 123B9-drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concns. required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic.  Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concns.  Furthermore, we demonstrated that the conjugation of dimeric 123B9 with paclitaxel is very effective at targeting circulating tumor cells and inhibiting lung metastasis in breast-cancer models.  These studies represent an important step toward the development of effective EphA2-targeting PDCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBQLb1QD1aSrVg90H21EOLACvtfcHk0li7Mxzn7exU3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1ylt7o%253D&md5=a03f5dbbc9030174487353d42332b3ab</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01837%26sid%3Dliteratum%253Aachs%26aulast%3DSalem%26aufirst%3DA.%2BF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DUdompholkul%26aufirst%3DP.%26aulast%3DGambini%26aufirst%3DL.%26aulast%3DBaggio%26aufirst%3DC.%26aulast%3DTseng%26aufirst%3DH.-R.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DReduction%2520of%2520Circulating%2520Cancer%2520Cells%2520and%2520Metastases%2520in%2520Breast-Cancer%2520Models%2520by%2520a%2520Potent%2520EphA2-Agonistic%2520Peptide%25E2%2580%2593Drug%2520Conjugate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2052%26epage%3D2061%26doi%3D10.1021%2Facs.jmedchem.7b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1021/jm201743s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201743s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2427-2436&issue=5&author=S.+Wangauthor=W.+J.+Placzekauthor=J.+L.+Stebbinsauthor=S.+Mitraauthor=R.+Noberiniauthor=M.+Koolpeauthor=Z.+Zhangauthor=R.+Dahlauthor=E.+B.+Pasqualeauthor=M.+Pellecchia&title=Novel+Targeted+System+To+Deliver+Chemotherapeutic+Drugs+to+EphA2-Expressing+Cancer+Cells&doi=10.1021%2Fjm201743s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Placzek, William J.; Stebbins, John L.; Mitra, Sayantan; Noberini, Roberta; Koolpe, Mitchell; Zhang, Ziming; Dahl, Russell; Pasquale, Elena B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2427-2436</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects.  We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors.  Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel.  We found that the peptide-drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site.  We believe these studies open the way to the development of a new class of therapeutic compds. that exploit the EphA2 receptor for drug delivery to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pu5ES26uUrVg90H21EOLACvtfcHk0liwYIfOBBCzGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D&md5=3835d4051c60b26e126da69b9b7510ca</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201743s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201743s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPlaczek%26aufirst%3DW.%2BJ.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DNovel%2520Targeted%2520System%2520To%2520Deliver%2520Chemotherapeutic%2520Drugs%2520to%2520EphA2-Expressing%2520Cancer%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D5%26spage%3D2427%26epage%3D2436%26doi%3D10.1021%2Fjm201743s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazenbaker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamynathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiener, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">A Human Antibody–Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In Vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9367</span>– <span class="NLM_lpage">9374</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F0008-5472.CAN-08-1933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19010911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9367-9374&issue=22&author=D.+Jacksonauthor=J.+Gooyaauthor=S.+Maoauthor=K.+Kinneerauthor=L.+Xuauthor=M.+Camaraauthor=C.+Fazenbakerauthor=R.+Flemingauthor=S.+Swamynathanauthor=D.+Meyerauthor=P.+D.+Senterauthor=C.+Gaoauthor=H.+Wuauthor=M.+Kinchauthor=S.+Coatsauthor=P.+A.+Kienerauthor=D.+A.+Tice&title=A+Human+Antibody%E2%80%93Drug+Conjugate+Targeting+EphA2+Inhibits+Tumor+Growth+In+Vivo&doi=10.1158%2F0008-5472.CAN-08-1933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo</span></div><div class="casAuthors">Jackson, Dowdy; Gooya, John; Mao, Shenlan; Kinneer, Krista; Xu, Linda; Camara, Margarita; Fazenbaker, Christine; Fleming, Ryan; Swamynathan, Sudha; Meyer, Damon; Senter, Peter D.; Gao, Changshou; Wu, Herren; Kinch, Michael; Coats, Steven; Kiener, Peter A.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9367-9374</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase is selectively expressed on the surface of many different human tumors.  We have previously shown that tumor cells can be targeted by EphA2 monoclonal antibodies and that these antibodies function, in part, by inducing EphA2 internalization and degrdn.  In this report, we describe the isolation and characterization of a fully human monoclonal antibody (1C1) that selectively binds both the human and rodent EphA2 receptor.  After cell binding, the antibody induces rapid tyrosine phosphorylation, internalization, and degrdn. of the EphA2 receptor.  Because monoclonal antibodies that selectively bind tumor cells and internalize provide a vehicle for targeted delivery of cytotoxics, 1C1 was conjugated to the microtubule inhibitor monomethylauristatin phenylalanine using a stable maleimidocaproyl linker.  The anti-EphA2 antibody-drug conjugate [1C1-maleimidocaproyl-MMAF (mcMMAF)] stimulated the activation of caspase-3/caspase-7 and the death of EphA2-expressing cells with IC50 values as low as 3 ng/mL.  Similarly, the conjugate induced degrdn. of the EphA2 receptor and inhibited tumor growth in vivo.  Administration of 1C1-mcMMAF at doses as low as 1 mg/kg once weekly resulted in significant growth inhibition of EphA2-expressing tumors without any observable adverse effects in mouse xenograft and rat syngeneic tumor models.  Our data support the use of an antibody-drug conjugate approach to selectively target and inhibit the growth of EphA2-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC1fbfPqDzS7Vg90H21EOLACvtfcHk0liwYIfOBBCzGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK&md5=1e17e48422e5fc318773fd1de578ac16</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1933%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCamara%26aufirst%3DM.%26aulast%3DFazenbaker%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DR.%26aulast%3DSwamynathan%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DCoats%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DA%2520Human%2520Antibody%25E2%2580%2593Drug%2520Conjugate%2520Targeting%2520EphA2%2520Inhibits%2520Tumor%2520Growth%2520In%2520Vivo%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9367%26epage%3D9374%26doi%3D10.1158%2F0008-5472.CAN-08-1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziata, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzoianu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechleider, R.</span></span> <span> </span><span class="NLM_article-title">Phase 1, Open-Label Study of MEDI-547 in Patients with Relapsed or Refractory Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9801-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1007%2Fs10637-012-9801-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=22370972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=77-84&issue=1&author=C.+M.+Annunziataauthor=E.+C.+Kohnauthor=P.+LoRussoauthor=N.+D.+Houstonauthor=R.+L.+Colemanauthor=M.+Buzoianuauthor=G.+Robbieauthor=R.+Lechleider&title=Phase+1%2C+Open-Label+Study+of+MEDI-547+in+Patients+with+Relapsed+or+Refractory+Solid+Tumors&doi=10.1007%2Fs10637-012-9801-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors</span></div><div class="casAuthors">Annunziata, Christina M.; Kohn, Elise C.; LoRusso, Patricia; Houston, Nicole D.; Coleman, Robert L.; Buzoianu, Manuela; Robbie, Gabriel; Lechleider, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy.  We aimed to evaluate the safety profile, max. tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate composed of the cytotoxic drug auristatin (toxin) linked to a human anti-EphA2 monoclonal antibody (1C1), in patients with solid tumors relapsed/refractory to std. therapy.  Methods: In this phase 1, open-label study with planned dose-escalation and dose-expansion cohorts, patients received a 1-h i.v. infusion of MEDI-547 (0.08 mg/kg) every 3 wk.  Results: Six patients received 0.08 mg/kg; all discontinued treatment.  Dose escalation was not pursued.  The study was stopped before cohort 2 enrollment due to treatment-related bleeding and coagulation events (hemorrhage-related, n = 3; epistaxis, n = 2).  Therefore, lower doses were not explored and an MTD could not be selected.  The most frequently reported treatment-related adverse events (AEs) were increased liver enzymes, decreased Hb, decreased appetite, and epistaxis.  Three patients (50%) experienced treatment-related serious AEs, including conjunctival hemorrhage, pain (led to study drug discontinuation), liver disorder, and hemorrhage.  Best response included progressive disease (n = 5; 83.3%) and stable disease (n = 1; 16.7%).  Minimal or no dissocn. of toxin from 1C1 conjugate occurred in the blood.  Serum MEDI-547 concns. decreased rapidly, ∼70% by 3 days post-dose.  No accumulation of MEDI-547 was obsd. at 0.08 mg/kg upon administration of a second dose 3 wk following dose 1.  Conclusions: The safety profile of MEDI-547 does not support further clin. investigation in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRCw89EUGfabVg90H21EOLACvtfcHk0liwYIfOBBCzGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D&md5=9af486f7c7287d8c150dade6baaf45b6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9801-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9801-2%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziata%26aufirst%3DC.%2BM.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DHouston%26aufirst%3DN.%2BD.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DBuzoianu%26aufirst%3DM.%26aulast%3DRobbie%26aufirst%3DG.%26aulast%3DLechleider%26aufirst%3DR.%26atitle%3DPhase%25201%252C%2520Open-Label%2520Study%2520of%2520MEDI-547%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26issue%3D1%26spage%3D77%26epage%3D84%26doi%3D10.1007%2Fs10637-012-9801-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span> <span> </span><span class="NLM_article-title">Abstract 5854: BT5528, a Bicycle Toxin Conjugate Targeting EphA2 Has Potent Anti-Tumor Activity without Bleeding or Coagulation Abnormalities in Preclinical Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">13 Supplement</span>),  <span class="NLM_fpage">5854</span>– <span class="NLM_lpage">5854</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-5854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1538-7445.AM2018-5854" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5854-5854&issue=13+Supplement&author=G.+Bennettauthor=P.+Huxleyauthor=A.+Brownauthor=G.+Muddauthor=P.+U.+Parkauthor=N.+Keen&title=Abstract+5854%3A+BT5528%2C+a+Bicycle+Toxin+Conjugate+Targeting+EphA2+Has+Potent+Anti-Tumor+Activity+without+Bleeding+or+Coagulation+Abnormalities+in+Preclinical+Models&doi=10.1158%2F1538-7445.AM2018-5854"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-5854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-5854%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DKeen%26aufirst%3DN.%26atitle%3DAbstract%25205854%253A%2520BT5528%252C%2520a%2520Bicycle%2520Toxin%2520Conjugate%2520Targeting%2520EphA2%2520Has%2520Potent%2520Anti-Tumor%2520Activity%2520without%2520Bleeding%2520or%2520Coagulation%2520Abnormalities%2520in%2520Preclinical%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D13%2520Supplement%26spage%3D5854%26epage%3D5854%26doi%3D10.1158%2F1538-7445.AM2018-5854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahdenranta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span> <span> </span><span class="NLM_article-title">Abstract 4481: BT5528, an EphA2-Targeting Bicycle Toxin Conjugate (BTC): Profound Efficacy without Bleeding and Coagulation Abnormalities in Animal Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13 Supplement</span>),  <span class="NLM_fpage">4481</span>– <span class="NLM_lpage">4481</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1538-7445.AM2019-4481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=4481-4481&issue=13+Supplement&author=G.+S.+Bennettauthor=A.+Brownauthor=G.+Muddauthor=J.+Lahdenrantaauthor=N.+Keen&title=Abstract+4481%3A+BT5528%2C+an+EphA2-Targeting+Bicycle+Toxin+Conjugate+%28BTC%29%3A+Profound+Efficacy+without+Bleeding+and+Coagulation+Abnormalities+in+Animal+Models&doi=10.1158%2F1538-7445.AM2019-4481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4481%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%2BS.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DLahdenranta%26aufirst%3DJ.%26aulast%3DKeen%26aufirst%3DN.%26atitle%3DAbstract%25204481%253A%2520BT5528%252C%2520an%2520EphA2-Targeting%2520Bicycle%2520Toxin%2520Conjugate%2520%2528BTC%2529%253A%2520Profound%2520Efficacy%2520without%2520Bleeding%2520and%2520Coagulation%2520Abnormalities%2520in%2520Animal%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%2520Supplement%26spage%3D4481%26epage%3D4481%26doi%3D10.1158%2F1538-7445.AM2019-4481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahdenranta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span> <span> </span><span class="NLM_article-title">Abstract C066: BT5528, a Bicycle Toxin Conjugate Targeting EphA2: Mechanism of Action and Clinical Translation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12 Supplement</span>),  <span class="NLM_fpage">C066</span>– <span class="NLM_lpage">C066</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2019-4481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F1538-7445.AM2019-4481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=C066-C066&issue=12+Supplement&author=G.+Bennettauthor=A.+Brownauthor=G.+Muddauthor=J.+Lahdenrantaauthor=N.+Keen&title=Abstract+C066%3A+BT5528%2C+a+Bicycle+Toxin+Conjugate+Targeting+EphA2%3A+Mechanism+of+Action+and+Clinical+Translation&doi=10.1158%2F1538-7445.AM2019-4481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2019-4481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2019-4481%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DMudd%26aufirst%3DG.%26aulast%3DLahdenranta%26aufirst%3DJ.%26aulast%3DKeen%26aufirst%3DN.%26atitle%3DAbstract%2520C066%253A%2520BT5528%252C%2520a%2520Bicycle%2520Toxin%2520Conjugate%2520Targeting%2520EphA2%253A%2520Mechanism%2520of%2520Action%2520and%2520Clinical%2520Translation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26issue%3D12%2520Supplement%26spage%3DC066%26epage%3DC066%26doi%3D10.1158%2F1538-7445.AM2019-4481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dail, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">46974</span>– <span class="NLM_lpage">46979</span>, <span class="refDoi"> DOI: 10.1074/jbc.M208495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1074%2Fjbc.M208495200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=12351647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFSksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46974-46979&issue=49&author=M.+Koolpeauthor=M.+Dailauthor=E.+B.+Pasquale&title=An+Ephrin+Mimetic+Peptide+That+Selectively+Targets+the+EphA2+Receptor&doi=10.1074%2Fjbc.M208495200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor</span></div><div class="casAuthors">Koolpe, Mitchell; Dail, Monique; Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">46974-46979</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases represent promising disease targets because they are differentially expressed in pathol. vs. normal tissues.  The EphA2 receptor is up-regulated in transformed cells and tumor vasculature where it likely contributes to cancer pathogenesis.  To exploit EphA2 as a therapeutic target, the authors used phage display to identify two related peptides that bind selectively to EphA2 with high affinity (submicromolar KD values).  The peptides target the ligand-binding domain of EphA2 and compete with ephrin ligands for binding.  Remarkably, one of the peptides has ephrin-like activity in that it stimulates EphA2 tyrosine phosphorylation and signaling.  Furthermore, this peptide can deliver phage particles to endothelial and tumor cells expressing EphA2.  In contrast, peptides corresponding to receptor-interacting portions of ephrin ligands bind weakly and promiscuously to many Eph receptors.  Bioactive ephrin mimetic peptides could be used to selectively deliver agents to Eph receptor-expressing tissues and modify Eph signaling in therapies for cancer, pathol. angiogenesis, and nerve regeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7htYrrvzjzbVg90H21EOLACvtfcHk0lhK4XkQw7TWMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFSksLc%253D&md5=edc49f9be61235b27420735e3697f5d7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M208495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M208495200%26sid%3Dliteratum%253Aachs%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DDail%26aufirst%3DM.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DAn%2520Ephrin%2520Mimetic%2520Peptide%2520That%2520Selectively%2520Targets%2520the%2520EphA2%2520Receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D49%26spage%3D46974%26epage%3D46979%26doi%3D10.1074%2Fjbc.M208495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuweiler, H.</span></span> <span> </span><span class="NLM_article-title">Backbone-Driven Collapse in Unfolded Protein Chains</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>409</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2011.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1016%2Fj.jmb.2011.03.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=21497607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2011&pages=250-262&issue=2&author=D.+P.+Teufelauthor=C.+M.+Johnsonauthor=J.+K.+Lumauthor=H.+Neuweiler&title=Backbone-Driven+Collapse+in+Unfolded+Protein+Chains&doi=10.1016%2Fj.jmb.2011.03.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Backbone-Driven Collapse in Unfolded Protein Chains</span></div><div class="casAuthors">Teufel, Daniel P.; Johnson, Christopher M.; Lum, Jenifer K.; Neuweiler, Hannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-262</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Collapse of unfolded protein chains is an early event in folding.  It affects structural properties of intrinsically disordered proteins (IDPs), which take up a considerable fraction of the human proteome.  Collapse is generally believed to be driven by hydrophobic forces imposed by the presence of nonpolar amino acid side chains.  Contributions from backbone hydrogen bonds to protein folding and stability, however, are controversial.  To date, the exptl. dissection of side-chain and backbone contributions has not yet been achieved because both types of interactions are integral parts of protein structure.  Here, we realized this goal by applying mutagenesis and chem. modification on a set of disordered peptides and proteins.  We measured the protein dimensions and kinetics of intra-chain diffusion of modified polypeptides at the level of individual mols. using fluorescence correlation spectroscopy (FCS), thereby avoiding artifacts commonly caused by aggregation of unfolded protein material in bulk.  We found no contributions from side chains to collapse, but instead, identified backbone interactions as a source sufficient to form globules of native-like dimensions.  The presence of backbone hydrogen bonds decreased polypeptide water soly. dramatically and accelerated the nanosecond kinetics of loop closure, in agreement with recent predictions from computer simulation.  The presence of side chains, instead, slowed loop closure and modulated the dimensions of intrinsically disordered domains.  It appeared that the transient formation of backbone interactions facilitates the diffusive search for productive conformations at the early stage of folding and within intrinsically disordered proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCa-Q7pukl7bVg90H21EOLACvtfcHk0lhK4XkQw7TWMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFeit7k%253D&md5=c8bcdbf4dbc91f7afe960d2aa7cf6024</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2011.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2011.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DTeufel%26aufirst%3DD.%2BP.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DLum%26aufirst%3DJ.%2BK.%26aulast%3DNeuweiler%26aufirst%3DH.%26atitle%3DBackbone-Driven%2520Collapse%2520in%2520Unfolded%2520Protein%2520Chains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D409%26issue%3D2%26spage%3D250%26epage%3D262%26doi%3D10.1016%2Fj.jmb.2011.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bargh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidro-Llobet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cleavable Linkers in Antibody–Drug Conjugates</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4361</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/C8CS00676H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1039%2FC8CS00676H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=31294429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=4361-4374&issue=16&author=J.+D.+Barghauthor=A.+Isidro-Llobetauthor=J.+S.+Parkerauthor=D.+R.+Spring&title=Cleavable+Linkers+in+Antibody%E2%80%93Drug+Conjugates&doi=10.1039%2FC8CS00676H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cleavable linkers in antibody-drug conjugates</span></div><div class="casAuthors">Bargh, Jonathan D.; Isidro-Llobet, Albert; Parker, Jeremy S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4361-4374</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clin. treatment of cancer.  The properties of the linker between the antibody and the payload are proven to be crit. to the success of an ADC.  Although ADC linkers can be 'non-cleavable', the vast majority of ADCs in clin. development have specific release mechanisms to allow controlled linker cleavage at the target site and are thus termed 'cleavable'.  In recent years, the development of new methods of drug release from ADCs has continued in parallel to the deepening understanding of the biol. processes underlying the mechanisms of action of pre-existing technologies.  This review summarises the advances in the field of cleavable linker technologies for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG2Xk9IvLpLVg90H21EOLACvtfcHk0lhK4XkQw7TWMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M&md5=bc73619319b21c2b85e3d613ca72f778</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2FC8CS00676H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00676H%26sid%3Dliteratum%253Aachs%26aulast%3DBargh%26aufirst%3DJ.%2BD.%26aulast%3DIsidro-Llobet%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCleavable%2520Linkers%2520in%2520Antibody%25E2%2580%2593Drug%2520Conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26issue%3D16%26spage%3D4361%26epage%3D4374%26doi%3D10.1039%2FC8CS00676H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koshikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sueta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabeshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiki, M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3327</span>– <span class="NLM_lpage">3339</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1158%2F0008-5472.CAN-14-2798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=26130649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlequ7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=3327-3339&issue=16&author=N.+Koshikawaauthor=D.+Hoshinoauthor=H.+Taniguchiauthor=T.+Minegishiauthor=T.+Tomariauthor=S.-O.+Namauthor=M.+Aokiauthor=T.+Suetaauthor=T.+Nakagawaauthor=S.+Miyamotoauthor=K.+Nabeshimaauthor=A.+M.+Weaverauthor=M.+Seiki&title=Proteolysis+of+EphA2+Converts+It+from+a+Tumor+Suppressor+to+an+Oncoprotein&doi=10.1158%2F0008-5472.CAN-14-2798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein</span></div><div class="casAuthors">Koshikawa, Naohiko; Hoshino, Daisuke; Taniguchi, Hiroaki; Minegishi, Tomoko; Tomari, Taizo; Nam, Sung-Ouk; Aoki, Mikiko; Sueta, Takayuki; Nakagawa, Takashi; Miyamoto, Shingo; Nabeshima, Kazuki; Weaver, Alissa M.; Seiki, Motoharu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3327-3339</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases are considered candidate therapeutic targets in cancer, but they can exert opposing effects on cell growth.  In the presence of its ligands, Eph receptor EphA2 suppresses signaling by other growth factor receptors, including ErbB, whereas ligand-independent activation of EphA2 augments ErbB signaling.  To deploy EphA2-targeting drugs effectively in tumors, the anti-oncogenic ligand-dependent activation state of EphA2 must be discriminated from its oncogenic ligand-independent state.  Because the mol. basis for the latter is little understood, we investigated how the activation state of EphA2 can be switched in tumor tissue.  We found that ligand-binding domain of EphA2 is cleaved frequently by the membrane metalloproteinase MT1-MMP, a powerful modulator of the pericellular environment in tumor cells.  EphA2 immunostaining revealed a significant loss of the N-terminal portion of EphA2 in areas of tumor tissue that expressed MT1-MMP.  Moreover, EphA2 phosphorylation patterns that signify ligand-independent activation were obsd. specifically in these areas of tumor tissue.  Mechanistic expts. revealed that processing of EphA2 by MT1-MMP promoted ErbB signaling, anchorage-independent growth, and cell migration.  Conversely, expression of a proteolysis-resistant mutant of EphA2 prevented tumorigenesis and metastasis of human tumor xenografts in mice.  Overall, our results showed how the proteolytic state of EphA2 in tumors dets. its effector function and influences its status as a candidate biomarker for targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZcTaPxJAfBLVg90H21EOLACvtfcHk0ljGtBP7i1X-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlequ7rF&md5=01a18af9811bb8517a7242b3321c2b5b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2798%26sid%3Dliteratum%253Aachs%26aulast%3DKoshikawa%26aufirst%3DN.%26aulast%3DHoshino%26aufirst%3DD.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DMinegishi%26aufirst%3DT.%26aulast%3DTomari%26aufirst%3DT.%26aulast%3DNam%26aufirst%3DS.-O.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DSueta%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DNabeshima%26aufirst%3DK.%26aulast%3DWeaver%26aufirst%3DA.%2BM.%26aulast%3DSeiki%26aufirst%3DM.%26atitle%3DProteolysis%2520of%2520EphA2%2520Converts%2520It%2520from%2520a%2520Tumor%2520Suppressor%2520to%2520an%2520Oncoprotein%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D16%26spage%3D3327%26epage%3D3339%26doi%3D10.1158%2F0008-5472.CAN-14-2798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabuka, D.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1007/s40259-017-0254-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1007%2Fs40259-017-0254-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=29119409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ptlyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=521-531&issue=6&author=P.+M.+Drakeauthor=D.+Rabuka&title=Recent+Developments+in+ADC+Technology%3A+Preclinical+Studies+Signal+Future+Clinical+Trends&doi=10.1007%2Fs40259-017-0254-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends</span></div><div class="casAuthors">Drake Penelope M; Rabuka David</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">521-531</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The antibody-drug conjugate (ADC) field is in a transitional period.  Older approaches to conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but preclinical work is driving a rapid evolution in how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes.  These advances are largely based upon a body of investigational studies that together offer a deeper understanding of the absorption, distribution, metabolism, and excretion (ADME) and drug metabolism and pharmacokinetics (DMPK) fates of both the intact conjugate and its small-molecule component.  Knowing where the drug goes and how it is processed allows mechanistic connections to be drawn with commonly observed clinical toxicities.  The field is also starting to consider ADC interactions with the immune system and potential synergistic therapeutic opportunities therein.  In an indication of future directions for the field, antibody conjugates bearing non-cytotoxic small-molecule payloads are being developed to reduce side effects associated with treatment of chronic diseases.  ADCs are not a magic bullet to cure disease.  However, they will increasingly become valuable therapeutic tools to improve patient outcomes across a variety of indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS62B7fDJCL1bjnyZkbE8yXfW6udTcc2eZDe_KjUZwWPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ptlyksg%253D%253D&md5=7f4cb76c7c59c0524a2511c72cf82cc4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs40259-017-0254-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-017-0254-1%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DP.%2BM.%26aulast%3DRabuka%26aufirst%3DD.%26atitle%3DRecent%2520Developments%2520in%2520ADC%2520Technology%253A%2520Preclinical%2520Studies%2520Signal%2520Future%2520Clinical%2520Trends%26jtitle%3DBioDrugs%26date%3D2017%26volume%3D31%26issue%3D6%26spage%3D521%26epage%3D531%26doi%3D10.1007%2Fs40259-017-0254-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Peptide Ligands Stabilized by Small Molecules</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1602</span>– <span class="NLM_lpage">1606</span>, <span class="refDoi"> DOI: 10.1002/anie.201309459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fanie.201309459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1602-1606&issue=6&author=S.+Chenauthor=D.+Bertoldoauthor=A.+Angeliniauthor=F.+Pojerauthor=C.+Heinis&title=Peptide+Ligands+Stabilized+by+Small+Molecules&doi=10.1002%2Fanie.201309459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Ligands Stabilized by Small Molecules</span></div><div class="casAuthors">Chen, Shiyu; Bertoldo, Davide; Angelini, Alessandro; Pojer, Florence; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1602-1606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicyclic peptides generated through directed evolution by using phage display offer an attractive ligand format for the development of therapeutics.  Being nearly 100-fold smaller than antibodies, they promise advantages such as access to chem. synthesis, efficient diffusion into tissues, and needle-free application.  However, unlike antibodies, they do not have a folded structure in soln. and thus do not bind as well as antibodies.  We developed bicyclic peptides with hydrophilic chem. structures at their center to promote noncovalent intramol. interactions, thereby stabilizing the peptide conformation.  The sequences of the peptides isolated by phage display from large combinatorial libraries were strongly influenced by the type of small mol. used in the screen, thus suggesting that the peptides fold around the small mols.  X-ray structure anal. revealed that the small mols. indeed formed hydrogen bonds with the peptides.  These noncovalent interactions stabilize the peptide-protein complexes and contribute to the high binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-9uyjWceNrVg90H21EOLACvtfcHk0ljGtBP7i1X-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D&md5=4bc852345c54171bd8c7143a563bba2b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fanie.201309459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201309459%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DAngelini%26aufirst%3DA.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520Ligands%2520Stabilized%2520by%2520Small%2520Molecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26issue%3D6%26spage%3D1602%26epage%3D1606%26doi%3D10.1002%2Fanie.201309459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seiradake, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aricescu, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span> <span> </span><span class="NLM_article-title">An Extracellular Steric Seeding Mechanism for Eph-Ephrin Signaling Platform Assembly</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">398</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1038%2Fnsmb.1782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20228801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFynurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=398&author=E.+Seiradakeauthor=K.+Harlosauthor=G.+Suttonauthor=A.+R.+Aricescuauthor=E.+Y.+Jones&title=An+Extracellular+Steric+Seeding+Mechanism+for+Eph-Ephrin+Signaling+Platform+Assembly&doi=10.1038%2Fnsmb.1782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly</span></div><div class="casAuthors">Seiradake, Elena; Harlos, Karl; Sutton, Geoff; Aricescu, A. Radu; Jones, E. Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-402</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Erythropoetin-producing hepatoma (Eph) receptors are cell-surface protein tyrosine kinases mediating cell-cell communication.  Upon activation, they form signaling clusters.  We report crystal structures of the full ectodomain of human EphA2 (eEphA2) both alone and in complex with the receptor-binding domain of the ligand ephrinA5 (ephrinA5 RBD).  Unliganded eEphA2 forms linear arrays of staggered parallel receptors involving two patches of residues conserved across A-class Ephs.  EEphA2-ephrinA5 RBD forms a more elaborate assembly, whose interfaces include the same conserved regions on eEphA2, but rearranged to accommodate ephrinA5 RBD.  Cell-surface expression of mutant EphA2s showed that these interfaces are crit. for localization at cell-cell contacts and activation-dependent degrdn.  Our results suggest a 'nucleation' mechanism whereby a limited no. of ligand-receptor interactions 'seed' an arrangement of receptors which can propagate into extended signaling arrays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ4pkdiRR_hrVg90H21EOLACvtfcHk0ljqAfjx5aEeRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFynurY%253D&md5=8a52fc59122e9974ad56665dc98f6ff6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1782%26sid%3Dliteratum%253Aachs%26aulast%3DSeiradake%26aufirst%3DE.%26aulast%3DHarlos%26aufirst%3DK.%26aulast%3DSutton%26aufirst%3DG.%26aulast%3DAricescu%26aufirst%3DA.%2BR.%26aulast%3DJones%26aufirst%3DE.%2BY.%26atitle%3DAn%2520Extracellular%2520Steric%2520Seeding%2520Mechanism%2520for%2520Eph-Ephrin%2520Signaling%2520Platform%2520Assembly%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D398%26doi%3D10.1038%2Fnsmb.1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Himanen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yermekbayeva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atapattu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajashankar, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensinga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolov, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span> <span> </span><span class="NLM_article-title">Architecture of Eph Receptor Clusters</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10860</span>– <span class="NLM_lpage">10865</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004148107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1073%2Fpnas.1004148107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20505120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVKqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=10860-10865&issue=24&author=J.+P.+Himanenauthor=L.+Yermekbayevaauthor=P.+W.+Janesauthor=J.+R.+Walkerauthor=K.+Xuauthor=L.+Atapattuauthor=K.+R.+Rajashankarauthor=A.+Mensingaauthor=M.+Lackmannauthor=D.+B.+Nikolovauthor=S.+Dhe-Paganon&title=Architecture+of+Eph+Receptor+Clusters&doi=10.1073%2Fpnas.1004148107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Architecture of Eph receptor clusters</span></div><div class="casAuthors">Himanen, Juha R.; Yermekbayeva, Laila; Janes, Peter W.; Walker, John R.; Xu, Kai; Atapattu, Lakmali; Rajashankar, Kanagalaghatta R.; Mensinga, Anneloes; Lackmann, Martin; Nikolov, Dimitar B.; Dhe-Paganon, Sirano</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10860-10865, S10860/1-S10860/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases and their ephrin ligands regulate cell navigation during normal and oncogenic development.  Signaling of Ephs is initiated in a multistep process leading to the assembly of higher-order signaling clusters that set off bidirectional signaling in interacting cells.  However, the structural and mechanistic details of this assembly remained undefined.  Here the authors present high-resoln. structures of the complete EphA2 ectodomain and complexes with ephrin-A1 and A5 as the base unit of an Eph cluster.  The structures reveal an elongated architecture with novel Eph/Eph interactions, both within and outside of the Eph ligand-binding domain, that suggest the mol. mechanism underlying Eph/ephrin clustering.  Structure-function anal., by using site-directed mutagenesis and cell-based signaling assays, confirms the importance of the identified oligomerization interfaces for Eph clustering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCSVR5p8gBeLVg90H21EOLACvtfcHk0ljqAfjx5aEeRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVKqurs%253D&md5=d978be292357c62bffe2794822ef03d9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004148107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004148107%26sid%3Dliteratum%253Aachs%26aulast%3DHimanen%26aufirst%3DJ.%2BP.%26aulast%3DYermekbayeva%26aufirst%3DL.%26aulast%3DJanes%26aufirst%3DP.%2BW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DAtapattu%26aufirst%3DL.%26aulast%3DRajashankar%26aufirst%3DK.%2BR.%26aulast%3DMensinga%26aufirst%3DA.%26aulast%3DLackmann%26aufirst%3DM.%26aulast%3DNikolov%26aufirst%3DD.%2BB.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DArchitecture%2520of%2520Eph%2520Receptor%2520Clusters%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D24%26spage%3D10860%26epage%3D10865%26doi%3D10.1073%2Fpnas.1004148107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova-Berndt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, D.</span></span> <span> </span><span class="NLM_article-title">Application of Biomimetic HPLC to Estimate Lipophilicity, Protein and Phospholipid Binding of Potential Peptide Therapeutics</span>. <i>ADMET DMPK</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.5599/admet.544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.5599%2Fadmet.544" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=162-175&issue=2&author=K.+Valkoauthor=G.+Ivanova-Berndtauthor=P.+Beswickauthor=M.+Kindeyauthor=D.+Ko&title=Application+of+Biomimetic+HPLC+to+Estimate+Lipophilicity%2C+Protein+and+Phospholipid+Binding+of+Potential+Peptide+Therapeutics&doi=10.5599%2Fadmet.544"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.5599%2Fadmet.544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5599%252Fadmet.544%26sid%3Dliteratum%253Aachs%26aulast%3DValko%26aufirst%3DK.%26aulast%3DIvanova-Berndt%26aufirst%3DG.%26aulast%3DBeswick%26aufirst%3DP.%26aulast%3DKindey%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DD.%26atitle%3DApplication%2520of%2520Biomimetic%2520HPLC%2520to%2520Estimate%2520Lipophilicity%252C%2520Protein%2520and%2520Phospholipid%2520Binding%2520of%2520Potential%2520Peptide%2520Therapeutics%26jtitle%3DADMET%2520DMPK%26date%3D2018%26volume%3D6%26issue%3D2%26spage%3D162%26epage%3D175%26doi%3D10.5599%2Fadmet.544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gfeller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buth, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiman, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1322</span>, <span class="refDoi"> DOI: 10.1002/cbic.201300228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fcbic.201300228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=23828687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1316-1322&issue=11&author=S.+Chenauthor=D.+Gfellerauthor=S.+A.+Buthauthor=O.+Michielinauthor=P.+G.+Leimanauthor=C.+Heinis&title=Improving+Binding+Affinity+and+Stability+of+Peptide+Ligands+by+Substituting+Glycines+with+D-Amino+Acids&doi=10.1002%2Fcbic.201300228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D-Amino Acids</span></div><div class="casAuthors">Chen, Shiyu; Gfeller, David; Buth, Sergey A.; Michielin, Olivier; Leiman, Petr G.; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1316-1322</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Improving the binding affinity and/or stability of peptide ligands often requires testing of large nos. of variants to identify beneficial mutations.  Herein we propose a type of mutation that promises a high success rate.  In a bicyclic peptide inhibitor of the cancer-related protease urokinase-type plasminogen activator (uPA), we obsd. a glycine residue that has a pos. .vphi. dihedral angle when bound to the target.  We hypothesized that replacing it with a D-amino acid, which favors pos. .vphi. angles, could enhance the binding affinity and/or proteolytic resistance.  Mutation of this specific glycine to D-serine in the bicyclic peptide indeed improved inhibitory activity (1.75-fold) and stability (fourfold).  X-ray-structure anal. of the inhibitors in complex with uPA showed that the peptide backbone conformation was conserved.  Anal. of known cyclic peptide ligands showed that glycine is one of the most frequent amino acids, and that glycines with pos. .vphi. angles are found in many protein-bound peptides.  These results suggest that the glycine-to-D-amino acid mutagenesis strategy could be broadly applied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSvU_PyOWh77Vg90H21EOLACvtfcHk0ljqAfjx5aEeRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGku7vL&md5=e9ddaa6e0dfe2004d2ed52805ad18835</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201300228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201300228%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGfeller%26aufirst%3DD.%26aulast%3DButh%26aufirst%3DS.%2BA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DLeiman%26aufirst%3DP.%2BG.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DImproving%2520Binding%2520Affinity%2520and%2520Stability%2520of%2520Peptide%2520Ligands%2520by%2520Substituting%2520Glycines%2520with%2520D-Amino%2520Acids%26jtitle%3DChemBioChem%26date%3D2013%26volume%3D14%26issue%3D11%26spage%3D1316%26epage%3D1322%26doi%3D10.1002%2Fcbic.201300228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tugyi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iván, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecz, F.</span></span> <span> </span><span class="NLM_article-title">Partial D-Amino Acid Substitution: Improved Enzymatic Stability and Preserved Ab Recognition of a MUC2 Epitope Peptide</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1073/pnas.0407677102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1073%2Fpnas.0407677102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=15630090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=413-418&issue=2&author=R.+Tugyiauthor=K.+Urayauthor=D.+Iv%C3%A1nauthor=E.+Fellingerauthor=A.+Perkinsauthor=F.+Hudecz&title=Partial+D-Amino+Acid+Substitution%3A+Improved+Enzymatic+Stability+and+Preserved+Ab+Recognition+of+a+MUC2+Epitope+Peptide&doi=10.1073%2Fpnas.0407677102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide</span></div><div class="casAuthors">Tugyi, Regina; Uray, Katalin; Ivan, Dora; Fellinger, Erzsebet; Perkins, Alan; Hudecz, Ferenc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-418</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The stability of an immunogen against enzymic degrdn. is considered an important factor for the design of synthetic vaccines.  For our studies, we have selected an epitope from the tandem-repeat unit of the high-mol.-wt. MUC2 mucin glycoprotein, which can be underglycosylated in case of colon cancer.  In this study, we prepd. a MUC2 peptide contg. the PTGTQ epitope of a MUC2 protein backbone-specific mAb 996 and its derivs.  In these peptides, the N- and C-terminal flanking regions were systematically substituted by up to three D-amino acids.  Peptides prepd. by solid-phase synthesis were tested for their mAb 996 binding in competitive ELISA expts., and their stability was studied in serum and lysosomal prepn.  Our data show that the epitope function of peptide 15TPTPTGTQTPT25 is retained even in the presence of two D-amino acid residues at its N-terminal flanking region and up to three at its C-terminal flanking region (tpTPTGTQtpt).  Also, this partly D peptide shows high resistance against proteolytic degrdn. in dild. human serum and in lysosomal prepn.  These findings suggest that, by appropriate combination of structural modifications (namely, D-amino acid substitution) in the flanks of an Ab epitope, it is feasible to construct a synthetic antigen with preserved recognition properties and high stability against enzymic degrdn.  Peptides tPTPTGTQTpt and tpTPTGTQTpt derived from this study can be used for immunization expts. and as potential components of synthetic vaccines for tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1MtlZFnf6a7Vg90H21EOLACvtfcHk0lh0R7ZlRB_lzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXptFSkuw%253D%253D&md5=aa80020d0dcf9d18d18775fcf77b050a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0407677102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0407677102%26sid%3Dliteratum%253Aachs%26aulast%3DTugyi%26aufirst%3DR.%26aulast%3DUray%26aufirst%3DK.%26aulast%3DIv%25C3%25A1n%26aufirst%3DD.%26aulast%3DFellinger%26aufirst%3DE.%26aulast%3DPerkins%26aufirst%3DA.%26aulast%3DHudecz%26aufirst%3DF.%26atitle%3DPartial%2520D-Amino%2520Acid%2520Substitution%253A%2520Improved%2520Enzymatic%2520Stability%2520and%2520Preserved%2520Ab%2520Recognition%2520of%2520a%2520MUC2%2520Epitope%2520Peptide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26issue%3D2%26spage%3D413%26epage%3D418%26doi%3D10.1073%2Fpnas.0407677102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Cera, E.</span></span> <span> </span><span class="NLM_article-title">Serine Proteases</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1002/iub.186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.1002%2Fiub.186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=19180666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=510-515&issue=5&author=E.+Di%0ACera&title=Serine+Proteases&doi=10.1002%2Fiub.186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Serine proteases</span></div><div class="casAuthors">Di Cera, Enrico</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Inc.</span>)
        </div><div class="casAbstract">A review.  Over 1/3 of all known proteolytic enzymes are serine proteases.  Among these, the trypsins have undergone the most predominant genetic expansion to become the most abundant and functionally diverse group, yielding enzymes responsible for digestion, blood coagulation, fibrinolysis, development, fertilization, apoptosis, and immunity.  The success of this expansion resides in a highly efficient fold that couples catalysis and regulatory interactions.  An added complexity comes from the recent observation of a significant conformational plasticity of the trypsin fold.  A new paradigm emerges where 2 forms of the protease, E* and E, are in allosteric equil. and det. biol. activity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdrCeiq9KP_LVg90H21EOLACvtfcHk0lh0R7ZlRB_lzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCgsLg%253D&md5=b3ef95563019933864656a763c944bed</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fiub.186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fiub.186%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCera%26aufirst%3DE.%26atitle%3DSerine%2520Proteases%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26issue%3D5%26spage%3D510%26epage%3D515%26doi%3D10.1002%2Fiub.186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentilucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerisoli, L.</span></span> <span> </span><span class="NLM_article-title">Chemical Modifications Designed to Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">3185</span>– <span class="NLM_lpage">3203</span>, <span class="refDoi"> DOI: 10.2174/138161210793292555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=10.2174%2F138161210793292555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=20687878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKlurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3185-3203&issue=28&author=L.+Gentilucciauthor=R.+De+Marcoauthor=L.+Cerisoli&title=Chemical+Modifications+Designed+to+Improve+Peptide+Stability%3A+Incorporation+of+Non-Natural+Amino+Acids%2C+Pseudo-Peptide+Bonds%2C+and+Cyclization&doi=10.2174%2F138161210793292555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization</span></div><div class="casAuthors">Gentilucci, Luca; De Marco, Rossella; Cerisoli, Lucia</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3185-3203</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Functions and properties of native peptides vary from highly specific antibiotics or cytotoxic antitumor drugs, to hormones, neurotransmitters, immunomodulators, etc.  Despite their potential utility as therapeutic agents, there are problems connected with the use of natural peptides, due to the low stability against proteolysis, resulting in a short duration of in vivo activity, and in a low bioavailability.  One way to overcome these disadvantages is the use of modified peptides, the so called peptidomimetics.  Overall, the less peptide character in a drug candidate, the more stable it is towards protease cleavage.  A huge no. of non-peptidic scaffolds have been reported in the literature; nevertheless, several cases have failed to reproduce the activity of the precursor peptide when the scaffold itself contains relevant pharmacophore elements.  Therefore, quasi-peptides still maintain their appeal for applications in medicinal chem.  For the large no. of different unnatural amino acids and peptidomimetics, the overview cannot be all-inclusive.  This review focuses on modified peptides in which the peptide character is still preponderant, with particular emphasis on the chem. methodologies utilized to introduce the modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKqrcss8C63rVg90H21EOLACvtfcHk0lh0R7ZlRB_lzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKlurvN&md5=415952939a1fad8af38d117812205853</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F138161210793292555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210793292555%26sid%3Dliteratum%253Aachs%26aulast%3DGentilucci%26aufirst%3DL.%26aulast%3DDe%2BMarco%26aufirst%3DR.%26aulast%3DCerisoli%26aufirst%3DL.%26atitle%3DChemical%2520Modifications%2520Designed%2520to%2520Improve%2520Peptide%2520Stability%253A%2520Incorporation%2520of%2520Non-Natural%2520Amino%2520Acids%252C%2520Pseudo-Peptide%2520Bonds%252C%2520and%2520Cyclization%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26issue%3D28%26spage%3D3185%26epage%3D3203%26doi%3D10.2174%2F138161210793292555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X11" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X11','PDB','2X11'); return false;">PDB: 2X11</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RW2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RW2','PDB','6RW2'); return false;">PDB: 6RW2</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i26"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02129">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_78304"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02129?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02129</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">General procedures; compound analytics; sequences of representative EphA2 binding Bicycles from phage screens, human Ephrin-A1 to -A5 G-H loop sequence alignment; additional PET images; additional toxicology data; body weights of CDX animals (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_001.pdf">jm9b02129_si_001.pdf (1.3 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02129/suppl_file/jm9b02129_si_002.csv">jm9b02129_si_002.csv (17.16 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the EphA2 LBD-BCY6065 cocrystal structure have been deposited in the Protein Data Bank under accession number <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RW2">6RW2</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02129&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-8%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02129%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02129" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679961c46ee63d94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
